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Chapter 1 
Introduction 
 
1.1. Importance and use of chiral 1,2 diamines. 
 
The 1,2-diamino moiety is present in many chiral natural products with valuable biological 
properties and in drugs where the pharmacological activity is related to their absolute 
configuration. Moreover, enantiopure 1,2-diamines are widely used as chiral auxiliaries and 
ligands in asymmetric synthesis and catalysis, especially the C2-symmetric trans-1,2-
diaminocyclohexane 1 and syn-1,2-diphenyl-1,2-diaminoethane 2 and their N,N’-
disubstituted derivatives1.  
 
Ph
NH2H2NNH2H2N
1 2
Ph
 
 
For example the titanium complex 3 can promote the addition of diethylzinc to aromatic 
aldehydes with high control of enantioselectivity. The same reaction protocol has been 
extended further to aliphatic aldehydes2. 
 
NTfTfN
3,5 mol%
hexane/toluene
ee=99%
Ti
Oi-Pri-PrOO
H
OH
Et2Zn+
 
 
Moreover, trans-1,2-diaminocyclohexane is the source of chirality in metal-salen complexes 
which are a class of “privileged” ligands that are able to catalize in an enantioselective 
fashion a great variety of reaction like, for example the epoxidation of olefins3 or the 
reduction of prochiral chetones4. 
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N
O O
t-Bu
t-But-Bu
t-Bu
N
Mn
Cl
Ph
Ph
O
5 mol%
aq NaOCl, DCM
81%, ee=92%
R Ar
O
R Ar
OH
iPrOH o HCOOH
base
M-L*
N
P P
N
Cl
ee% = 58-99%
Cl
Ru
PhPh
N
R R
N
Ar
O
Ar
O
R' R'
ee% = 28-80%  
 
These compounds have been used also as chiral auxiliaries for the synthesis of enantiopure 
compounds; for example Hanessian employed trans-1,2-diaminocyclohexane to prepare 
chiral α-alchil-substituted phosfonic acids5. 
 
MeHN NHMe MeHN
P
NHMe
OY
MeHN
P
NHMe
OY
R
P
OH
O
Y
R
HO
P
O
Y
Cl
Cl
Base, RX
 
 
Alexakis and Mangeney studied cyclic aminals derived from N,N’-dimethyl-1,2-diphenyl-1,2-
diaminoethane as chiral auxiliaries in the addition of organometallic reagents to hydrazone 
4. Very good control of diastereoselectivity was generally obtained, but the addition of 
Grignard reagents followed the opposite sense of asymmetric induction with respect to 
organolithium reagents6. 
N
NMe2
O
MeHN
Ph
NHMe
Ph
NMe2N N
N
Me
Me
Ph
Ph
_______
________
___
____
NHMe2N N
N
Me
Me
Ph
Ph
NHMe2N N
N
Me
Me
Ph
Ph
R
R
RLi, -70 °C
THF or Et2O
RMgX, rt
Et2O or Toluene
67-99%
d.r. 67-94%
68-92%
d.r. 99%4
 
 
These compounds are also very important for their pharmacological properties. In fact, a 
large set of biologically active compounds feature the 1,2-diamino moiety. For example, 
the cis-platinum complex 5 and its derivatives 6 and 7 are active as anticancer agents7a. 
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Pt
Cl
NH3
Cl NH3
NH2H2N
Pt
O O
O O
NHH2N
Pt
O O
CR3
O
R3C
O
Cis-Platinum Oxalyl-Platinum NDDP
5 6 7  
 
Compounds 8 and 9 showed a powerful agonist effect for the κ−opioid receptor and show 
low effects of dependency and other collateral effects7b. 
 
 
Cl
ClO
NMe
N
Ph
Cl
ClO
NMe
N
8 9  
 
TamifluTM is an anti-influenza drug developed by Roche and has recently received attention 
as a possible defence against the outbreak of the avian flu.8 
 
CO2EtO
NH2.H3PO4
AcHN
TamifluTM  
 
1.2. Asymmetric synthesis of 1,2 diamines from chiral imines. 
 
For the above reported reasons, the synthesis and chemistry of 1,2-diamines[9,10] attracted 
very much interest in the past and many synthetic routes to these compounds from 
different functional groups have been described. On the other hand, many optically pure 
compounds are available from the “chiral pool” and can be used as starting materials for 
the preparation of properly designed, optically pure 1,2-diamines. Im this case, the 
existing stereocenter(s) can be maintained, or a new stereocenter(s) can be created 
exploiting the asymmetric induction of the already present one(s). Such asymmetric 
transformations have been increasingly employed in the last few decades, as an alternative 
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to optical resolution[9,11,12] and enzyme-catalyzed kinetic resolution[13–15], which are 
principally based on the use of optically pure monocarboxylic and dicarboxylic acids.  
1,2-Diamines with general structure 10 can be synthesized from precursors containing one 
or two prochiral azomethine functions (C=N), involving in the first step the stereoselective 
formation of one or two stereocentres in the ethylene tether linking the two nitrogen 
atoms (Scheme). To obtain the primary 1,2-diamines, the nitrogen substituent Z has to be 
removed in a subsequent step by using methodologies which must not affect the 
stereochemical integrity of the intermediate compounds. For example, route A involves the 
stereoselective formation of the C1–C2 bond by the reductive coupling of monofunctional 
compounds 11. This occurs by a preliminary single electron transfer from an electrode or a 
chemical reductant species, and is generally suited to the preparation of symmetrically 
1,2-disubstituted 1,2-diamines 10 (R1 = R2). Also, the addition of an α-aminoalkyl metal 
reagent to monoazomethine compounds 11 leads to the same target 10 (route B). On the 
other hand, routes C–F exploit transformations of unsaturated compounds already 
possessing the N–C–C–N skeleton. In fact, in routes C and D the chiral α-amino azomethine 
compounds 12 and 13, arbitrarily depicted with the R configuration, undergo addition by 
an organometallic reagent and a reducing agent (hydrogen, hydride), respectively. Finally, 
symmetrically or unsymmetrically 1,2-disubstituted 1,2-diamines 10 can be obtained by the 
analogous reactions of 1,2-bis(azomethine) compounds, like 1,4-diazadienes 14 and 15 
(routes E and F). The reactivity of the azomethine compound and consequently the 
applicability of a given methodology and/or the choice of the reagent are dependent on 
the nature of both the C- and the N-substituents (imine, oxime, hydrazone, nitrone). These 
methods are complementary to other ones which exploit the addition of nitrogen 
compounds to C=C bonds[9,16].  
R1
H2N R1(2)
NH2
R1
N
Z
YXN
H
M
RR1
N
Z
R1(2)
NR1
YXN
Z
R1(2)
NR1
N
Z
Z
N
N
Z
Z
NR1
YXN
Z
RM
C
[H]
D
RM        E F        [H]
e-        A B
11
13
1415
12
11
10
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For example, Kise described the reductive coupling (route A) of aromatic imines derived 
from valine esters, but good diastereoselectivity was obtained only when a tether between 
the two imine functionalities was present like in 1617. 
 
Ar N
O
O
O
NAr
O
NH O
NH O
Ar
O
O
Ar
R
R
R
R
Zn, MsOH
THF, O °C
Ar
Ar
NHCbz
NHCbz
Ar= Ph, R=H, 68%
(R,R)/(R,S)/(S,S)= 91:9:0
Ar= 4-MeOPh, R=H, 68%
(R,R)/(R,S)/(S,S)= 97:3:0
Ar= 2-OHPh, R=Me, 39%
(R,R)/(R,S)/(S,S)= 99:1:0
16  
Boys proposed a synthesis of the chiral cyclic urea 17 that features the addition of chiral α-
amino carbanions, obtained by asymmetric hydrogen abstraction (metallation) of N-
benzylic amides by the BuLi-(-)-sparteine complex to imines (route B)18.  
 
Ph
N
BocPMP
1) BuLi-(-)Sparteine
   Toluene, -78 °C
   
2)
Ph N
Ph
NN
Ph Ph
O
PhPMP
78%, trans/cis 20:1
ee% 73%
17  
 
The addition of organometallic reagents to  α−amino imines is a widely exploited route 
since these compounds are widely available from the corresponding α−aminoacids (Route 
C). Kobayashi studied the addition of allyltrichlorosilane to the chiral α-amino-hydrazone 
18, which proceeded with high yield and good control of diastereoselctivity19.   
 
Bn
N
NHBz
NHCbz
SiCl3
DMF, 0 °C
Bn
HN
NHBz
NHCbz
92%, d.r. 98:2
18  
 
The reduction of  α−amino ketimines is complementary to the organometallic addition to 
aldimines. As described by Reetz, the chiral 1,2 diamine 20 was synthesised by reductive 
amination of the chiral α−amino-ketone 19 (Route D)20.  
 
O
R
NBn2
Me
NH4OAc, NaBH3CN, MgSO4
MeOH, Reflux
NH2
R
NBn2
Me
R=i-Bu, Bn
76-83%; d.r.95:5
19 20  
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Our research group has been very active in the enantioselective synthesis of this class of 
compounds by addition of organometallic reagents to the chiral 1,2-bis-imine derived from 
glyoxal and 1-phenylethylamine as chiral auxiliary 21 (route E). For example, allylzinc 
bromide reacted at low temperature with very high control of diastereoselectivity. The 
main diastereoisomer was obtained pure by crystallization from MeOH with 76% yield21.  
 
NN
PhPh
HNNH
PhPh
ZnBr
THF, -78 °C
76%, d.r. 93:4:3
21  
 
The reduction of chiral 1,2-bis-imines has been also exploited (Route F), e.g. the reduction 
of the chiral dihydropyrazine 22 is the key step of the asymmetric synthesis of  2322. 
 
N
NMe
Me
Ph
Ph
NaBH3CN, PPTS
MeOH, -30 to -20 °C N
H
H
NMe
Me
Ph
Ph
d.r 15:1
1) AcCl, Py
2) Li-NH3
NHAc
NHAc
Me
Me
23, 80%22  
 
1.3. Homoallylic amines as precursors of cyclic amines 
 
Enantiopure homoallylic amines are valuable intermediates for the synthesis of highly 
functionalized cyclic compounds. These compounds, whivh can be easily synthesized by 
diastereo-or enantio-selective addition of allylic organometallic reagents to (chiral) imines, 
can undergo different types of functionalization of the two C=C double bonds, for example 
epoxidation, dihydroxylation and transition metal catalyzed ring closure reactions such as 
metathesis reactions. 
Alexakis synthesized the chiral bis-piperazine 24 starting from the diaminodiene 21 by 
preliminary hydroboration/oxidation step and subsequent ring closure through the di-
tosylate intermediate 23. 
 
HNNH
PhPh
HO OH 1) TsCl
2) Pd(OH)2, HCOONH4
N
H
N
H
H H
21
24, 65%
1) 9BBN
2) H2O2/ NaOH
97%  
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Our research group has been very active in this field of research, for example we 
deswcribed the cycization of the diaminodiene 21 to 4,5-diaminodimethylcyclohexanes by 
reductive cyclozirconation, that proceed with good yield and fair stereoselectivity. 
Particularly, using preformed dibutylzirconocene Cp2ZrBu2 (4eq.), the 4(R),5(S)-diamino-
4(S),5(S)-dimethylcyclohexane was the major stereoisomer, whereas using the Cp2ZrCl2 
(10%)/BuMgCl (5 eq) system the preferential formation of the 1(R),2(R)-diamino-4(S),5(S)-
dimethylcyclohexane was observed24. This reaction protocol was then extended to 3,6-
disubstituted diamonodienes25. 
NH HN
PhPh
NH HN
PhPh
NH HN
PhPh
NH HN
PhPh
A:
A:  92% a:b:c= 82:5:13
B:  97% a:b:c= 6:16:78
_______________________________________________
_______
+ +
BuMgCl 5eq.
Cp2ZrCl2 0.1 eq
B: Cp2ZrBu2 4 eq.
Et2O, 0 ° a 25 °C, 18hr THF, -78 a 0 °C
21
25a 25b 26c
 
 
The reaction of aminoalkene moieties with electophiles, mainly halogens, mercury salts 
and selenium derivatives, has been widely exploited for the synthesis of azaheterocycles. 
Davies studied the iodine mediated cyclization of some substitutued homoallylic 
sulphonamides, which gave trans-2,5-disubstituted-iodopirrolidines as the major products. 
In this case the 5-endo cyclization is favored over the 4-exo as stated by the Baldwin’s 
rules26. 
 
NPh Ph
Ts
I
Ph
Ph
NH
Ts
I2 / K2CO3
80%, d.r. 88:12 
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Chapter 2  
Stereoselective Synthesis of 3,6-Disubstituted 1,2-Diaminocyclohexanes 
by Ring Closing Metathesis of 4,5-Diamino-1,7-octadiene derivatives 
 
NH HN
Ph Ph
R R
N N
Ph Ph
R R
P
O H
NH HN
Ph Ph
R R
ClH3N NH3Cl
R R. 2HCl
 
 
2.1 Introduction 
 
The ring closing metathesis (RCM) of 1,n-dienes has been widely applied for the 
construction of nitrogen containing compounds, for example natural alkaloids containing 
the pyrrolidine or piperidine ring1 and amino-cycloalkenes.2 A number of molybdenum- and 
especially ruthenium-carbene complexes are now available for the metathesis reaction.  
 
Ru
PCy
3
Cl
PCy
3
Ph
Cl
Ru
Cl
PCy
3
Ph
NN
Mes Mes
Cl
Mo
N
(CF
3
)
2
CH
3
CO
(CF
3
)
2
CH
3
CO
Ph
iPrPri
O Ru PCy
3
Cl
Cl
Ru
P
Cl
P Ph
Cy
Cy
N
Cy
Cy
N
Cl
Ru
P
Cl
P Ph
Cy Cy
Cy Cy
N
N
Cl
. .
2 Cl-
2 Cl-
+
+
+
+
Water soluble catalysts
Hoveyda's recyclable
catalyst
4
Schrock's catalyst 
1
1st gen. Grubbs' 
catalyst
2
2nd gen. Grubbs' 
catalyst
3
5 6
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The Schrock’s molybdenum-based catalyst 1, was the first structurally defined catalyst, 
but despite its superior reactivity, especially for hindered olefins, its instability and low 
tolerance to many functional groups limited its use. The ruthenium-based Grubbs' catalyst 
2 is stable to air and easier to handle, but less reactive, and has become the most popular 
reagent for the metathesis reaction. The increasing interest to the RCM reaction led to the 
development of a variety of new reagents, like the 2nd generation Grubbs’ catalyst 3, 
where the substitution of a phosphine ligand with an heterocyclic carbene increased both 
its termal stability and reactivity, particularly in the reaction of electron-poor olefins. 
Moreover, the reagent 4, synthesized by Hoveyda, is stable enough to be recovered at the 
end of the reaction and reused several times. Also water-soluble compounds like 5 e 6 
have been studied. 
The mechanism of the RCM reaction has been studied in detail, but can be easily 
summarized by a series of [2+2] reversible cycloaddition steps between a metal-alkylidene 
complex and an alkene, leading to metallacyclobutanes3. The equilibria are shifted towards 
the formation of the cycloalkene, as ethylene is evolved, and the catalytically active 
species is regenerated. The RCM reaction is usually exploited for the construction of five- 
or six- membered rings but has been also successful employed for macrocyclization 
reactions. 
 
 
 
Configurationally pure 4,5-diamino-1,7-octadienes and 3,6-disubstituted-derivatives c-e 1 
are available by the double addition of γ-substituted allylzinc reagents to the optically pure 
1,2-bis-imine derived from glyoxal and (S)-1-phenylethylamine.4 In the reactions of γ-
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substituted allylzinc compounds four stereocenters are newly created in the products 1: 
the configuration of the α-amino stereocenters (C4,C5) is controlled by the chiral auxiliary, 
whereas the configuration of the stereocenters C3,C6 depends on the E/Z configuration of 
the C=C bond in the allylic zinc reagent. 
 
NH HN
Ph Ph
Ph Ph
NN
PhPh
R ZnX-MX
NH HN
Ph Ph
NH HN
Ph Ph
HO OH
NH HN
Ph Ph
PhO OPh
NH HN
Ph Ph
EtO OEt
NH HN
Ph Ph
NH HN
Ph Ph
RO ZnX-MX
Or
73% 70% 60% 87%
48% 31% 45%
 
 
It is known that both 1st and 2nd gen. Grubbs’ catalysts are sensible to the amine moiety so 
a protection step is usually required. Our research group had previously reported5 that the 
dihydrochloride of the (4R,5R)-4,5-diamino-1,7-octadiene derivative 7 can be converted to 
the N,N’-disubstituted-1,2-diaminocyclohex-4-ene 8 using the first generation Grubbs 
complex 2 as the catalyst.  
 
N N
Ph Ph
NH HN
Ph Ph
NH HN
Ph Ph
NH HN
Ph Ph
1) HCl/MeOH quant.
2) 2 (3 mol%), DCM, 40°C
3) NaOH aq.
CF3COOH (2.5 eq)
2 (10 mol%), PhMe 110 °C
8, 73 %
10, 48 %
7
9
 
 
On the other hand, the cyclization of the vinyl-substituted diaminodiene could be achieved 
with moderate diastereoselectivity through formation of the formaldehyde aminal 9, which 
was then converted to the diaminocyclohexene 10 in the presence of trifluoroacetic acid in 
refluxing toluene. In these conditions, the hydrolysis of the imidazolidine ring was due, 
probably to the presence of traces of water in the solvent or reagents.5b  
The interest in 1,2-diaminocyclohexenes stems from their potential as intermediates for 
the construction of more functionalized compounds, owing to the possible transformation 
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of the alkene function, for example epoxidation and dihydroxylation. Moreover, 
hydrogenation of the 3,6-disubsstituted derivatives provides access to saturated 
compounds which can act as novel chiral N,N-ligands of metal species. As a matter of fact, 
the effect of substituents on the activity and enatiooselectivity of salen complexes 
featuring a substituted cyclohexane ring has become an important field of investigation.6 
Moreover, polyhydroxylated diaminocyclohexenes (diaminoconduritols) and –cyclohexanes 
are potentially active as glycosidase inhibitors and can form cytostatic platinum 
complexes.7  
Since it was apparent from the previous results that the RCM reaction of these class of 
compounds was strongly affected by the steric effects of the allylic substituents R, we 
continued the investigation on several 3,6-disubstituted compounds, aiming to find out 
suitable protocols for their cyclization.  
 
2.2. RCM of substituted 4,5-diamino-1,7-octadienes dihydrochlorides 
 
The dihydrochlorides of all diaminodienes were obtained in quantitative yields by reaction 
with anhydrous HCl in MeOH for 10 min, followed by removal of the solvent. All the results 
of the RCM reactions carried out on these salts are summarized in Table 1. 
At first, we examined the RCM reaction of the dimethyl substituted diaminodiene 11 which 
was easily obtained as a 55:45 mixture of epimers by the addition of crotylzinc bromide to 
the glyoxal diimine, and were very difficultly separated by column chromatography. We 
observed that the ruthenium catalysts 2 and 3 displayed different activity in the reaction 
of 11-2HCl. Working with catalyst 2 in refluxing CH2Cl2 no reaction was observed after 6 h. 
Instead, catalyst 3 (5 mol%) in the same conditions was able to discriminate at a high 
degree the two epimers: the C1-symmetric diastereomer C1-11 was quickly consumed and 
converted to cis-12, while the C2-symmetric isomer C2-11 did not react, as determined by 
GC/MS analysis of the reaction mixture. The diaminocyclohexene cis-12 and unreacted C2-
11 were separated by SiO2 column chromatography and isolated with 35 and 37% yields, 
respectively. Hence, the preliminary separation of the two diastereomers of 11, which is 
tedious and incomplete on a large scale, is unnecessary. 
 
 - 14 - 
NH HN
Ph Ph2HCl
NH HN
Ph Ph
NH HN
Ph Ph
1) 3 (4 mol%), 
    DCM 40°C
2) NaOH aq.
3) SiO2
Cis-12, 35% C2-11, 37%11  
 
Applying the same reaction condition to the dihydroxy-substituted compound, we observed 
almost complete conversion using 7 mol% of catalyst 3, and obtained the desired diamino-
diol with good yield (70%) after purification. Even in this case, the 1st generation Grubbs’ 
catalyst 2 was ineffective. With this regard, it should be underlined that previously 
described syntheses of oxygen-substituted cyclohexenes by RCM reactions were generally 
achieved through protection of the hydroxy functions in the starting 1,7-dienes, and 
required high loadings of the catalyst 2 (up to 30 mol%), high temperatures and long 
reaction times.8 Moreover, the isomerization of the allylic secondary alcohol moiety to 
ethyl ketone was a competitive side reaction.8c, 9  
Unluckily, this reaction protocol proved to be unsuccessful with the ethoxy- and phenoxy-
substituted substrates and no improvement was observed raising the reaction temperature 
or using higher catalyst loadings. In all cases, we recovered the starting material 
unchanged , with no detectable contamination by cross-metathesis products. This led us to 
think that bulky R substituents prevent the formation of the metallacyclobutane in the first 
step of the catalytic cycle. It should be also pointed out that the 1st generation Grubbs’ 
catalyst was again ineffective.  
 
NH HN
Ph Ph
R R
NH HN
Ph Ph
R R
.2 HCl
HCl/Dioxane
MeOH
NH HN
Ph Ph
R R
1) 2 or 3
2) NaOH
 
 
R Solvent Temp (°C) Cat % Time (h) Yield % 
OH CH2Cl2 40 3, 7 4 70 
OH CH2Cl2 40       2, 5 3 No reaction 
Me (55:45 mixture) CH2Cl2 40 3, 5 6 35 (C1) 
Me (55:45 mixture) CH2Cl2 40 2, 4 6 No reaction 
OEt (75:25 mixture) CH2Cl2 40 3, 7 4 No reaction 
OPh CH2Cl2 40 3, 10 6 No reaction 
OPh toluene 110 3, 10 3 No reaction 
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2.2 RCM of 3,6-disubstituted 4,5-diamino-1,7-octadienes through 
formation of their phosphorous acid diamides. 
 
We have made some attempts to protect the amine moieties  to avoid the acidic conditions 
that can degrade the catalyst in the methatesis reaction, but with poor success. Reaction 
of 7 with carbonic acid derivatives like 1,1’-carbonyldiimidazole (Staab reagent), 
triphosgene or diethyl carbonate yielded cyclic ureas in low yields. On the other hand with 
acetyl chloride and trifluoroacetic anhydride the monoamide was the main product.  
 
HNNH
PhPh
N N
PhPh
O
a) CDI or
b) (EtO)2CO or
c) triphosgene
a) AcCl/TEA or
b) (CF3CO)2O/TEA
Low Yields
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_______
NH N
PhPh
Main Products
OX
 
Then we found that the diamine moiety could be easily protected as a cyclic phosphorous 
diamide by reaction with PCl3 then quenching with water. In addition, this protection can 
be simply removed by hydrolysis with a methanolic solution of HCl10. It should be noted 
that the quaternary phosphorous atom in a C1-symmetric diamide like 15 is a new 
stereocenter. In these case, a 1:1 mixture of epimers was observed by 1H-, 13C- and 31P-
NMR analyses. 
 
NH HN
Ph Ph
R R
N N
Ph Ph
R R
P
O H
1) PCl3/TEA/DMAP
    DCM, 40 °C
2) H2O
 
 
 
R Yield %  
Me (trans) 93 “C2”-13 
Me (55:45 mixture) 87 13 
Vinyl 92 14 
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OEt (75:25 mixture) 75 15 
Ph 94 16 
OPh 100 17 
 
The products were used in the RCM step without further purification, then the protection 
was immediately removed, because the free diamines were more easily purified by column 
chromatography. With the phosphorous diamide 13 we observed a quick cyclization in the 
presence of 4 mol% of catalyst 3 in CH2Cl2 at 40 °C. After acidic hydrolysis of the reaction 
mixture, the desired free diamine 18 was isolated with 92% yield. The trans-dimethyl-
substituted diastereomer “C2”-18 was similarly prepared with good yield starting from 
“C2”-11, which had been recovered from the previously described reaction. The 
phosphorous diamide 14 with pentadienyl-substituents was similarly prepared but we 
observed that it did not undergo cyclization in the presence of catalyst 2, but the ring 
closure was moderately successful in the presence of the catalyst 3 (7 mol%) in refluxing 
benzene for 3 h. Better reaction conditions were found using CH2Cl2 as the solvent at 40 
°C. By this way, cis-19 was isolated with 53% yield after chromatographic separation from 
minor amounts of the trans-diastereomer and unreacted 14. 
Either the dihydrochloride and the phosphorous diamide 15 of the diethoxy substituted 
substrate (75:25 mixture of diastereomers, the prevalent one had C1-symmetry) were 
submitted to RCM reactions in refluxing CH2Cl2 (entries 11, 12) but only the latter could be 
converted with moderate yield to the desired cyclohexene cis-20. Unfortunately, the 
phosphorous diamides 16 prepared from phenyl-substituted and the phenoxy-substituted 
17 diaminodienes did not undergo cyclization either in CH2Cl2 and in benzene or toluene at 
the reflux temperature even using 10 mmol% of catalyst 6. From these results, it is clear 
that the RCM reaction of 3,6-disubstituted-4,5-diamino-1,7-octadienes was best 
accomplished through the cyclic phosphorous diamides  by using the ruthenium catalyst 3 
in CH2Cl2 at 40 °C. The reaction was very sensitive to steric effects, being affected by the 
nature of the substituents and the configuration of the inherent stereocenters. 
Particularly, cyclohexenes were more easily formed when the allylic substituents could 
assume the relative cis-relationship in the six-membered ring. 
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N N
Ph Ph
R R
P
O H
NH HN
Ph Ph
R R
1) 2 or 3
2) HCl/MeOH
 
 
R Solvent Temp (°C) Cat % Time (h) Yield % 
Me (trans) DCM 40 3, 4 3 “C2”-12, 74 
Me (55:45 mixture) DCM 40 3, 4 3 12, 92 
Vinyl DCM 40 3, 7 3 cis-18, 53 
Vinyl PhMe 110 2, 7 6 No reaction 
OEt (75:25 mixture) DCM 40 3, 5 3 cis-19,38 
Ph DCM 40 3, 10 6 No reaction 
Ph C6H6 80 2, 10 6 No reaction 
OPh DCM 40 3, 10 6 No reaction 
OPh PhMe 110 3, 10 4 No reaction 
 
Finally, the N-unsubstituted diaminocyclohexanes (1R,2R,3R,6S)-20, (1R,2R,3S,6S)-20, 
(1S,2S,3R,6R)-21, (1R,2R,3R,6S)-22 and (1S,2S,3R,6S)-23 were prepared from 12-19 by 
palladium-catalyzed hydrogenation/hydrogenolysis in refluxing ethanol. Particularly, the 
diethyl-substituted compound 22 was obtained from the vinyl-substituted precursor cis-18.  
 
ClH3N NH3Cl
RR
1) HCO2NH4,
    20% Pd(OH)2/C
    EtOH, reflux, 3 h
2) HCl/dioxane
NH HN
RR
Ph Ph
Me Me
ClH3N NH3Cl
(1R,2R,3R,6S)-20
             90%
ClH3N NH3Cl ClH3N NH3Cl
(1S,2S,3R,6R)-21
             91%
Me Me Me Me HO OH
(1R,2R,3S,6S)-20
             91%
21
6 3
2
3
1 21
6 3 6
ClH3N NH3Cl
(1R,2R,3R,6S)-22,
            94%
Et Et
21
6 3
ClH3N NH3Cl
(1S,2S,3R,6S)-23,
            55%
EtO OEt
21
6 3
 
 
It should be observed that the RCM reactions allowed us to prepare new 1,2-
diaminocyclohexane derivatives, where both the amino groups are equatorially oriented 
and the C3,C6 substituents are in one of the three possible relative orientations: axial-
equatorial (21-23), equatorial-equatorial (21) and axial-axial (22). The effect of the 
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relative stereochemistry of the C3/C6 substituents, and their size should now be assessed 
in a number of asymmetric reactions, like those catalyzed by salen complexes. 
 
Experimental Section 
 
Melting points are uncorrected. Solvents were distilled over the appropriate drying agent in 
N2 atmosphere before use: THF (sodium benzophenone ketyl, then LiAlH4), CH2Cl2 (P2O5). 
Optical rotations were measured on a digital polarimeter in a 1-dm cell and [α]D-values are 
given in 101 deg cm3 g1. 1H NMR spectra were recorded on a Varian Gemini instrument at 
300 or 200 MHz for samples in CDCl3 which was stored over Mg: 
1H chemical shifts are 
reported in ppm relative to CHCl3 δH 7.27, δC 77.0) and J-values are given in Hz. 31P NMR 
spectra were recorded on a Varian Mercury 400 spectrometer at 161.90 MHz; chemical 
shifts are referenced to external standard 85% H3PO4. MS spectra were taken at an ionizing 
voltage of 70 eV on a Hewlett-Packard 5970 or 5890 spectrometer with GLC injection. 
Chromatographic separations were performed on columns of SiO2 (Merck, 230-400 mesh) at 
medium pressure. The ruthenium catalysts 5 and 6 were purchased from Aldrich. The 
metathesis reactions were carried in a flame-dried apparatus under a static atmosphere of 
dry Ar. 
 
General procedure for the RCM reactions of diaminodienes 1 through their 
dihydrochlorides 
To the stirred solution of diaminodiene (2 mmol) in MeOH (5 mL) was added HCl (4 M in 
dioxane, 1 mL), then the solvent was removed at reduced pressure to leave an off-white 
solid. This is dissolved in CH2Cl2 (6 mL), the complex 3 (5-7 mol%) was added while Ar was 
bubbled through the solution (0.5 min), and the solution was stirred at 40 °C until (almost) 
complete conversion (TLC analysis). The cooled reaction mixture was treated with 2 M 
NaOH (5 mL) and the organic phase was extracted with CH2Cl2 (3 × 5 mL). The collected 
organic layers were dried over CaCl2 and concentrated at reduced pressure to leave a 
greyish solid. Pure diaminocyclohexenes were obtained by column chromatography (SiO2, 
cyclohexane/ethyl acetate mixtures). 
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(1R,2R,3R,6S)-3,6-dimethyl-N,N'-bis[(1S)-1-phenylethyl]cyclohex-4-ene-1,2-diamine 
(cis-12) 
This compound was obtained as an oil starting from the (6R,6S)-mixture of 11-2HCl through 
chromatographic separation of unreacted (C2)-11.  
[α]D
25 −61.5 (c 0.22, CHCl3).  
IR (neat): 3340, 3295, 3062, 3023, 1602, 1370 cm-1.  
1H NMR (300 MHz, CDCl3): δ = 0.63 and 1.11 (6 H, 2 d, J = 6.9 Hz), 1.22 and 1.48 (6 H, 2 d, J 
= 6.6 Hz), 1.27 (1 H, s) 2.0 (2 H, m), 2.07 (1 H, dd, J = 9.9, 8.7 Hz), 2.36 (1 H, dd, J = 15.3, 
5.1 Hz), 2.40 (1 H, m), 3.68 and 3.81 (2 H, 2 q, J = 6.6 Hz), 5.21 (1 H, ddd, J = 9.9, 1.8, 1.5 
Hz), 5.46 (1 H, ddd, J = 9.9, 4.8, 2.4 Hz), 7.1-7.4 (m, 10 H).  
13C NMR (50 MHz, CDCl3): δ = 14.2, 20.2, 24.1, 25.6, 31.1, 41.0, 53.5, 55.7, 56.7, 58.4, 
126.7, 127.2, 128.1, 128.3, 130.3, 131.5. GC/MS m/z (relative intensity): 105 (100), 214 
(65), 110 (51), 120 (17), 348 (2, M+).  
Anal. Calcd for C24H32N2: C, 82.71; H, 9.25; N, 8.04. Found: C, 82.46; H, 9.29; N, 8.07.  
 
(1R,4R,5S,6S)-5,6-bis{[(1S)-1-phenylethyl]amino}cyclohex-2-ene-1,4-diol. 
White powder: mp 120-122 °C.  
[α]D
25 −11.4 (c 0.63, CHCl3).  
IR (KBr): 3318, 3027, 1600, 1324, 1259 cm-1.  
1H NMR (200 MHz, CDCl3): δ = 1.38 (6 H, d, J = 6.6 Hz), 1.9-2.9 (4 H, broad), 2.45 (2 H, m), 
3.81 (2 H, q, J = 6.6 Hz), 4.06 (2 H, m), 5.97 (2 H, dd, J = 1.4, 2.8), 7.2-7.4 (10 H, m).  
13C NMR (75 MHz, CDCl3): δ = 25.2, 52.5, 55.1, 62.3, 126.6, 127.2, 128.6, 130.5, 145.1.  
Anal. Calcd for C22H28N2O2: C, 74.97; H, 8.01; N, 7.95. Found: C, 74.67; H, 8.04; N, 7.92. 
 
Preparation of the phosphorous diamides. 
To the stirred solution of the diaminodiene (2 mmol) in DCM (10 mL) was added Et3N (2.02 
g, 20 mmol), DMAP (10 mg). Freshly distilled PCl3 (0.55 g, 4 mmol) was added at 0 °C and 
the mixture was stirred for 3 h at reflux temperature. After cooling at 0 °C, H2O (10 mL) 
was slowly added (care!), CH2Cl2 was removed at reduced pressure, and the organic 
materials were extracted with Et2O (3 × 10 mL). The ethereal layers were collected, then 
Na2SO4 and SiO2 (1 g) were added, the mixture was stirred for 30 min, then filtered through 
a small pad of Celite, and the organic solution was concentrated at reduced pressure. The 
products were used avoiding further purification. 
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(4R,5R)-1,3-bis[(1S)-1-phenylethyl]-4,5-bis(1-vinylprop-2-en-1-yl)-1,3,2-
diazaphospholidine 2-oxide (14) 
Whitish oil.  
[α]D
25 +21.6 (c 0.44, CHCl3). 
IR (neat): 3428, 3077, 2360 (P-H), 1635, 1226 (P=O), 1129, 1037, 998, 918, 773, 704 cm- 1. 
1H NMR (300 MHz, CDCl3): δ = 1.73 (d, J = 7.3 Hz, 3 H), 1.78 (d, J = 7.3 Hz, 3 H), 2.55-2.75 
(m, 3 H), 2.85-2.95 (m, 1 H), 4.10-4.20 (m, 1 H), 4.25-4.55 (m, 3 H), 4.75-5.25 (m, 7 H), 
5.30-5.50 (m, 1 H), 5.50-5.70 (m, 2 H), 7.25-7.45 (m, 8 H), 7.55-7.65 (m, 2 H), 8.04 (d, 
1JP,H = 609 Hz, 1 H, PH). 
13C NMR (75 MHz, CDCl3): δ = 21.42 (d, 3JC,P = 3.6 Hz, CH3), 21.4 (d, 3JC,P = 3.6 Hz, CH3), 
51.2 (CHCH=CH2), 51.6 (CHCH=CH2), 55.85 (d, 
2JC,P = 7.2 Hz, CHCH3), 56.2 (d, 
2JC,P = 6.1 Hz, 
CHCH3), 59.7 (d, 
2JC,P = 9.0 Hz, CHCHN), 62.6 (d, 
2JC,P = 7.8 Hz, CHCHN), 116.6 (CH2=), 
116.9 (CH2=), 117.6 (CH2=), 117.8 (CH2=), 127.4, 127.5, 127.85, 128.0, 128.35, 128.6 (6 
lines for arom. CH), 136.1 (CH=), 136.2 (CH=), 136.9 (CH=), 137.25 (CH=), 142.8 (arom.), 
143.1 (C arom.). 
31P NMR (162 MHz, CDCl3): δ = 8.9 (dm, 1JP,H = 609 Hz). 
 
(4R,5R)-4,5-bis[(1S)-1-methylprop-2-en-1-yl]-1,3-bis[(1S)-1-phenylethyl]-1,3,2-
diazaphospholidine-2-oxide (C2-13) 
Whitish oil. 
[α]D
25 −31.2 (c 0.73, CHCl3). 
IR (neat): 3445, 3065, 3035, 2346 (P-H), 1638, 1600, 1228 (P=O), 1130, 1033, 913, 802, 704 
cm-1. 
1H NMR (300 MHz, CDCl3): δ = 0.76 (d, J = 7.1 Hz, 3 H), 0.79 (d, J = 7.1 Hz, 3 H), 1.76 (d, J 
= 7.0 Hz, 3 H), 1.82 (d, J = 7.0 Hz, 3 H), 2.20-2.49 (m, 2 H), 2.58-2.90 (m, 2 H), 4.12-4.42 
(m, 2 H), 4.52-5.04 (m, 4 H), 5.15-5.34 (m, 1 H), 5.65-5.84 (m, 1 H), 7.23-7.43 (m, 8 H), 
7.52-7.60 (m, 2 H), 7.96 (d, 1JP,H = 609 Hz, 1 H, PH). 
13C NMR (75 MHz, CDCl3): δ = 15.4 (CH3CHCH=), 15.6 (CH3CHCH=), 21.6 (d, 3JC,P = 4.7 Hz, 
CH3CHN), 21.7 (d, 
3JC,P = 5.2 Hz, CH3CHN), 38.2 (CHCH=CH2), 38.7 (CHCH=CH2), 55.0 (d, 
2JC,P = 6.9 Hz, NCHCH3), 55.1 (d, 
2JC,P = 7.6 Hz, NCHCH3), 60.1 (d, 
2JC,P = 9.1 Hz, CHCHN), 
62.55 (d, 2JC,P = 8.2 Hz, CHCHN), 115.5 (CH2=), 116.0 (CH2=), 127.3, 127.4, 127.7, 127.9, 
128.2, 128.4 (6 lines for arom. CH), 138.3 (CH=), 139.3, (CH=), 142.35  (arom.), 142.8 
(arom.). 
31P NMR (162 MHz, CDCl3): δ = 9.9 (dm, 1JP,H = 609 Hz). 
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(4R,5R)-1,3-bis[(1S)-1-phenylethyl]-4,5-bis[(1R)-1-phenylprop-2-en-1-yl]-1,3,2-
diazaphospholidine 2-oxide (16) 
White solid: m.p. 210-215 °C (dec).  
[α]D
25 +19.2 (c 0.39, CHCl3). 
IR (KBr): 3429, 3026, 2329 (P-H), 1600, 1226 (P=O), 1128, 1035, 988, 933, 900, 770, 701, 
635, 542 cm -1. 
1H NMR (300 MHz, CDCl3): δ = 1.39 (d, J = 7.2 Hz, 3 H), 1.44 (d, J = 7.2 Hz, 3 H), 2.58-3.05 
(m, 5 H), 3.05-3.20 (m, 1 H), 3.80 (d, J = 17.3 Hz, 1 H), 3.95 (d, J = 17.3 Hz, 1 H), 4.69 
(dd, J = 10.4 Hz, J = 1.8 Hz, 1 H), 4.77 (dd, J = 10.4 Hz, J = 1.8 Hz, 1 H), 5.50-5.70 (m, 2 
H), 7.05-7.20 (m, 4 H), 7.20-7.45 (m, 14 H), 7.50-7.62 (m, 2 H), 8.30 (d, 1JP,H = 602 Hz, 1 
H, PH), 
13C NMR (75 MHz, CDCl3): δ = 21.2 (d, 3JC,P = 6.0 Hz, CH3), 21.3 (d, 3JC,P = 5.0 Hz, CH3), 53.8 
(CHCH=CH2), 54.8 (CHCH=CH2), 56.0 (d, 
2JC,P = 6.8 Hz, CHCH3), 57.0 (d, 
2JC,P = 5.0 Hz, 
CHCH3), 61.9 (d, 
2JC,P = 9.7 Hz, CHCHN), 65.6 (d, 
2JC,P = 7.7 Hz, CHCHN), 117.6 (CH2=), 
117.9 (CH2=), 126.75, 126.92, 127.2, 127.4, 127.7, 128.1, 128.35, 128.4, 128.4, 128.6 (10 
lines, 2 sign. overl. for arom. CH), 137.2 (CH=), 137.7 (CH=), 141.4 (arom.), 141.7 (C 
arom.), 143.9 (arom.), 143.95 (arom.). 
31P NMR (162 MHz, CDCl3): δ = 7.2 (dm, 1JP,H = 602 Hz). 
 
(4S,5S)-4-[(1R,S1-ethoxyprop-2-en-1-yl]-5-[(1S)-1-ethoxyprop-2-en-1-yl]-1,3-bis[(1S)-1-
phenylethyl]-1,3,2-diazaphospholidine 2-oxide and (4S,5S)-4,5-bis[(1S)-1-ethoxyprop-
2-en-1-yl]-1,3-bis[(1S)-1-phenylethyl]-1,3,2-diazaphospholidine 2-oxide (15, dr 70:30) 
Yellowish oil. 
[α]D
25
 −7.0 (c 0.68, CHCl3). 
IR (neat): 3433, 3062, 3028, 2346 (P-H), 1640, 1226 (P=O), 1131, 929, 772, 703 cm-1. 
1H NMR (300 MHz, CDCl3): δ = 0.87 (t, J = 7.0 Hz, 3 H), 0.95 (t, J = 7.0 Hz, 3 H), 1.01 (t, J = 
7.0 Hz, 3 H), 1.07 (t, J = 7.0 Hz, 3 H), 1.11 (t, J = 7.0 Hz, 3 H), 1.14 (t, J = 7.2 Hz, 3 H), 
1.69 (d, J = 7.3 Hz, 3 H) 1.70 (d, J = 7.0 Hz, 3 H), 1.71 (d, J = 7.1 Hz, 3 H), 1.72 (d, J = 7.2 
Hz, 3 H), 1.76 (d, J = 7.0 Hz, 3 H), 1.78 (d, J = 6.5 Hz, 3 H), 2.40-3.60 (m, 24 H), 4.10-5.90 
(m, 24 H), 7.20-7.50 (m, 24 H), 7.50-7.65 (m, 6 H), 7.96 (d, 1JP,H = 609 Hz, 2 H, PH), 8.07 
(d, 1JP,H = 604 Hz, 1 H, PH). 
13C NMR (75 MHz, CDCl3): δ = 14.9 (CH3CH2OCH=), 15.0 (CH3CH2OCH=), 15.1 (CH3CH2OCH=), 
15.2 (CH3CH2OCH=), 15.2 (CH3CH2OCH=), 15.3 (CH3CH2OCH=), 21.2 (d, 
3JC,P = 3.4 Hz, CH3), 
21.2 (d, 3JC,P = 3.2 Hz, CH3), 21.3 (d, 
3JC,P = 4.3 Hz, CH3), 21.4 (d, 
3JC,P = 3.7 Hz, CH3), 21.5 
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(d, 3JC,P = 5.5 Hz, CH3), 21.7 (d, 
3JC,P = 4.9 Hz, CH3), 55.2 (d, 
2JC,P = 6.0 Hz, CHCH3), 55.6 
(d, 2JC,P = 7.1 Hz, CHCH3), 55.8 (d, 
2JC,P = 7.5 Hz, CHCH3), 55.9 (d, 
2JC,P = 6.1 Hz, CHCH3), 
56.25 (d, 2JC,P = 7.0 Hz, CHCH3), 56.9 (d, 
2JC,P = 5.7 Hz, CHCH3), 57.3 (d, 
2JC,P = 8.7 Hz, 
CHCHN), 56.2 (d, 2JC,P = 9.6 Hz, CHCHN), 58.8 (d, 
2JC,P = 9.6 Hz, CHCHN), 60.8 (d, 
2JC,P = 
8.2 Hz, CHCHN), 61.35 (d, 2JC,P = 7.8 Hz, CHCHN), 61.6 (d, 
2JC,P = 8.4 Hz, CHCHN), 63.95 
(OCH2), 64.0 (OCH2), 64.15 (OCH2), 64.3 (OCH2), 64.5 (OCH2), 64.5 (OCH2), 81.1 
(CHCH=CH2), 81.6 (CHCH=CH2), 82.7 (CHCH=CH2), 82.9 (CHCH=CH2), 83.2 (CHCH=CH2), 83.5 
(CHCH=CH2), 117.9 (CH2=), 118.0 (CH2=), 118.9 (CH2= 3 sign. overl.), 119.7 (CH2=), 127.15, 
127.2, 127.27, 127.3, 127.3, 127.4, 127.5, 127.5, 127.6, 127.8, 127.9, 128.0, 128.2, 128.2, 
128.2, 128.3, 128.23 128.5 (18 lines for arom. CH), 134.6 (CH=), 135.0 (CH=), 135.1 (CH=), 
135.38 (CH=), 135.58 (CH=), 135.69 (CH=), 143.10 (arom.), 143.35 (arom.), 143.4 (arom.), 
143.4 (arom.), 143.55 (arom.), 143.8 (arom.). 
31P NMR (162 MHz, CDCl3): δ = 12.1 (dm, 1JP,H = 609 Hz),  = 11.1 (dm, 1JP,H = 609 Hz), and  
= 8.3 (dm, 1JP,H = 604 Hz). 
 
(4S,5S)-4,5-bis[(1S)-1-phenoxyprop-2-en-1-yl]-1,3-bis[(1S)-1-phenylethyl]-1,3,2-
diazaphospholidine 2-oxide (17) 
White solid: m.p. 125-134 (dec.). 
[α]D
25 +1.7 (c 1.8, CHCl3). 
IR (KBr): 3406, 3070, 3042, 2365 (PH), 1646, 1597, 1228 (P=O), 1118, 1031, 928, 803, 753, 
700, 692 cm- 1. 
1H NMR (300 MHz, CDCl3): δ = 1.72 (d, J = 7.0 Hz, 3 H), 1.79 (d, J = 7.0 Hz, 3 H), 3.28-3.41 
(m, 1 H), 3.41-3.55 (m,. 1 H), 4.16-4.34 (m, 2 H), 4.38-4.60 (m, 2 H), 4.98-5.30 (m, 4 H), 
5.40-5.57 (m, 1 H), 5.60-5.78 (m, 1 H), 6.65 (d, J = 8.1 Hz, 2 H), 6.74 (d, J = 8.1 Hz, 2 H), 
6.88-7.00 (m, 2 H), 7.10-7.30 (m, 10 H), 7.34-7.53 (m, 4 H), 8.06 (d, 1JP,H = 613 Hz, 1 H, 
PH). 
13C NMR (75 MHz, CDCl3): δ = 20.83 (d, 3JC,P = 4.2 Hz, CH3), 21.3 (d, 3JC,P = 4.2 Hz, CH3), 
54.6 (d, 2JC,P = 6.5 Hz, CHCH3), 55.0 (d, 
2JC,P = 8.0 Hz, CHCH3), 57.7 (d, 
2JC,P = 8.9 Hz, 
CHCHN), 60.14 (d, 2JC,P = 8.1 Hz, CHCHN), 78.4 (CHCH=CH2), 79.4 (CHCH=CH2), 115.7 
(arom. CH), 116.3 (arom. CH), 118.6 (CH2=), 119.0 (CH2=), 121.10, 121.15, 127.3, 127.4, 
127.5, 127.5, 128.4, 128.5, 129.2, 129.3 (10 lines for arom. CH), 133.65 (CH=), 134.5 
(CH=), 142.35 (arom.), 142.4 (arom.), 142.7 (arom.), 142.7 (arom.). 
31P NMR (162 MHz, CDCl3): δ = 13.4 (dm, 1JP,H = 613 Hz). 
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General procedure for the RCM reactions of phosphorous acid diamides.  
The complex 3 (43 mg, 0.05 mmol) was added to the stirred solution of the phosphorous 
diamide (2 mmol) in CH2Cl2 (6 mL) while Ar was bubbled through the solution (0.5 min), 
and the solution was stirred at 40 °C. An equal amount of complex 3 was added after 1.5 h 
and the mixture was further stirred at 40 °C for 1.5-2 h. Solvent was removed at reduced 
pressure and the residue was dissolved in MeOH (8 mL, then HCl (4 M in dioxane, 2 mL) was 
added  and the mixture was stirred overnight. The solvent was removed at reduced 
pressure and the residue was treated with Et2O (10 mL), H2O (10 mL) and solid NaOH until 
pH 11. The organic phase was separated and the aqueous layer was further extracted with 
Et2O (3 × 5 mL). The collected organic layers were dried over Na2SO4 and concentrated at 
reduced pressure to leave a yellowish oil. The pure diaminocyclohexene was obtained by 
column chromatography (SiO2, cyclohexane/ethyl acetate mixtures). 
 
Compound Cis-18 was previously described.3b 
 
(1R,2R,3S,6S)-3,6-dimethyl-N,N'-bis[(1S)-1-phenylethyl]cyclohex-4-ene-1,2-diamine 
(trans-12) 
Yellowish oil; [α]D
25 +64.2 (c 1.74, CHCl3).  
IR (neat): 3317, 3082, 3060, 3011, 1602, 1368 cm-1.  
1H NMR (300 MHz, CDCl3): δ = 1.09 (6 H, d, J = 5.7 Hz), 1.28 (6 H, d, J = 6.6 Hz), 1.68 (2 H, 
broad m), 2.04 (4 H, m), 3.89 (2 H, q, J = 6.6 Hz), 5.21 (2 H, s), 7.1-7.4 (10 H, m).  
13C NMR (50 MHz, CDCl3): δ = 20.5, 24.8, 40.6, 58.1, 62.3, 126.8, 127.1, 128.3, 131.4, 
145.8.  
GC/MS m/z (relative intensity): 105 (100), 214 (63), 110 (50), 120 (17), 348 (3, M+).  
Anal. Calcd for C24H32N2: C, 82.71; H, 9.25; N, 8.04. Found: C, 82.41; H, 9.29; N, 8.01. 
 
(1S,2S,3R,6S)-3,6-diethoxy-N,N'-bis[(1S)-1-phenylethyl]cyclohex-4-ene-1,2-diamine 
(Cis-19) 
Yellowish oil; [α]D
25
 −82.7 (c 0.7, CHCl3).  
IR (neat): 3301, 3027, 1602, 1369, 1326, 1270, 1088 cm- 1.  
1H NMR (200 MHz, CDCl3): δ = 1.09 and 1.26 (6 H, 2 t, J = 7.0 Hz), 1.32 and 1.44 (6 H, 2 d, J 
= 6.2 Hz), 2.24 (2 H, dd, J = 11.4, 3.2 Hz), 2.55 (2 H, dd, J = 11.4, 8.0 Hz), 3.43 (1 H, dq, J 
= 1.8, 8.0), 3.5-3.75 (4 H, m), 3.75-3.95 (2 H, m), 4.17 (1 H, q, J = 6.6 Hz), 5.79 (1H, dd, J 
=1.8, 10.4 Hz), 5.90 (1H, ddd, J =1.2, 4.8, 10.4 Hz), 7.1-7.5 (10 H, m).  
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13C NMR (50 MHz, CDCl3): δ = 15.55, 15.8, 24.9, 25.8, 26.9, 54.0, 54.2, 55.4, 57.1, 64.1, 
64.2, 68.5, 125.8, 126.3, 126.9, 127.0,127.0, 128.1, 128.5, 131.6, 145.3, 146.5.  
GC/MS m/z (relative intensity): 105 (100), 57 (33), 77 (22), 161 (20), 106 (12), 266 (10), 
120 (6).  
Anal. Calcd for C26H36N2O2: C, 76.43; H, 8.88; N, 6.86. Found: C, 76,74; H, 8.91; N, 6.84.  
 
General procedure for the preparation of 1,2-diaminocyclohexanes dihydrochlorides. 
The mixture of 1,2-diaminocyclohexene 2 (1 mmol), HCO2NH4 (0.800 g, 12.5 mmol), 20% 
Pd(OH)2/C (0.100 g) in EtOH (10 mL) was heated at reflux temperature for 3 h. The cooled 
mixture was filtered over a small pad of celite and the organic solution was treated with 
HCl (4 M in dioxane, 0.5 mL). Solvents were removed at reduced pressure to leave the 
diamine dihydrochloride as a white solid, >95% pure by 1H NMR.  
 
(1R,2R,3R,6S)-3,6-dimethylcyclohexane-1,2-diaminium dichloride (cis-20) 
M.p.: 200-210 °C (dec.).  
[α]D
25 
−8.4 (c 0.5, MeOH).  
IR (KBr): 3420, 2500-3500 (broad), 1594, 1566, 1498 cm-1.  
1H NMR (300 MHz, CD3OD): δ = 1.13 (3 H, d, J = 7.2 Hz), 1.20 (3 H, d, J = 6.6 Hz), 1.50 (1 H, 
dt, J =  2.7, 12.9 Hz), 1.60-1.90 (4 H, m), 2,50 (1 H, m), 3.39 (1 H, dd, J = 10.5, 11.1 Hz), 
3.66 (1 H, dd, J = 4.8, 10.5 Hz). 
13C NMR (75 MHz, CD3OD): δ = 12.9, 18.8, 28.3, 30.9, 33.1, 37.3, 56.2, 56.4.  
Anal. Calcd for C8H20Cl2N2: C, 44.66; H, 9.37; N, 13.02. Found: C, 44.47; H, 9.40; N, 12.97. 
 
(1R,2R,3S,6S)-3,6-dimethylcyclohexane-1,2-diaminium dichloride (trans-20) 
M.p.: 230-240 °C (dec.).  
[α]D
25 +7.2 (c 1.3, MeOH).  
IR (KBr): 3425, 2500-3400 (broad), 1594, 1520 cm -1.  
1H NMR (300 MHz, CD3OD): δ = 1.18 (6 H, d, J = 6.0 Hz), 1.34 (2 H, m), 1.82 (4 H, d, J = 7.5 
Hz), 3.2 (2 H, d, J = 7.8 Hz). 
13C NMR (75 MHz, CD3OD): δ = 19.0, 33.4, 37.1, 59.8.  
Anal. Calcd for C8H20Cl2N2: C, 44.66; H, 9.37; N, 13.02. Found: C, 44.48; H, 9.41; N, 12.98. 
 
(1S,2S,3R,6R)-3,6-dihydroxycyclohexane-1,2-diaminium dichloride (21) 
M.p.: 200-210 °C (dec.).  
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[α]D
25 - 73.2 (c 0.17, MeOH).  
IR (KBr): 3364, 2600-3200 (broad), 1549, 1205 cm- 1.  
1H NMR (300 MHz, CD3OD): δ = 1.60 (2 H, dd, J = 9.8, 4.2 Hz),1.89 (2 H, dd, J = 9.8, 1.2 Hz), 
3.53 (2 H, m), 4.07 (2 H, m).  
13C NMR (75 MHz, CD3OD): δ = 26.2, 53.3, 67.1.  
Anal. Calcd for C6H16Cl2N2O2: C, 32.89; H, 7.36; N, 12.79. Found: C, 32.75; H, 7.39; N, 
12.75. 
 
(1S,2S,3R,6S)-3,6-diethoxycyclohexane-1,2-diaminium dichloride (22) 
The crude compound was isolated as a yellowish solid with 87% yield, then was washed 
with 8:1 Et2O/MeOH mixture to leave a white solid with 55% yield. 
 M.p.: 175-185 °C (dec.).  
[α]D
25
 −14.1 (c 0.27, MeOH).  
IR (KBr): 3413, 3143, 2200-2500 (broad), 1626, 1107 cm-1.  
1H NMR (300 MHz, CD3OD): δ = 1.27 and 1.29 (6 H, 2 t, J = 6.9 Hz), 1.55 (2 H, m), 2.12 (1 H, 
m), 2.25 (1 H, m), 3.40-3.65 (4 H, m), 3.65-3.90 (3 H, m), 3.93 (1 H, s).  
13C NMR (50 MHz, CD3OD): δ = 15.85, 15.9, 23.7, 24.1, 54.7, 55.5, 65.6, 66.0, 74.4, 77.7.  
Anal. Calcd for C10H24Cl2N2O2: C, 43.64; H, 8.79; N, 10.00. Found: C, 43 51; H, 8.82; N, 
10.15. 
 
(1R,2R,3R,6S)-3,6-diethylcyclohexane-1,2-diaminium dichloride (23) 
M.p.: 170-180 °C (dec.).  
[α]D
25 −3.8 (c 0.44, MeOH).  
IR (KBr): 3436, 2500-3400 (broad), 1594, 1503 cm -1.  
1H NMR (300 MHz, CD3OD): δ = 0.88 (6 H, t, J = 7.0 Hz), 1.1-1.7 (8 H, m), 1.7-1.8 (1 H, m), 
1.9-2.1 (1 H, m), 3.26 (1 H, dd, J = 9.6, 8.0 Hz), 3.49 (1 H, dd, J = 9.6, 4.8).  
13C NMR (75 MHz, CD3OD): δ = 11.0, 11.9, 19.2, 23.6, 25.1, 25.3, 39.6, 42.6, 54.7, 56.6.  
Anal. Calcd for C10H24Cl2N2: C, 49.38; H, 9.95; N, 11.52. Found: C, 49.58; H, 9.99; N, 11.48. 
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Chapter 3  
Iodine-mediated cyclization of chiral 4,5-diamino-1,7-octadienes: 
A stereoselective route to 2,5-diazabicyclo[2.2.1]heptanes 
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3.1. Introduction 
 
The electophile–mediated cyclization of homoallylic amines is a powerful tool for the 
construction of aza-heterocycles, so we envisioned that the compound 1, featuring 
either the 4- and 5-aminoalkene moieties, could be usefully employed for the synthesis 
of byciclic aza-heterocycles.1 In principle, different pathways can be followed by 
reaction with an electrophile, however, the 5-exo cyclization of the two 5-aminoalkene 
moieties was expected to be preferred with respect to the 4-exo- and 6-endo 
cyclizations of the 4- and 5-aminoalkene moieties, respectively, according to the 
Baldwin's rules for ring closure 2 . 
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3.2. Iodine-mediated cyclization of (4R,5R)-4,5-di[(S)-1-
phenylethylamino]-1,7-octadiene 
 
By analogy with reported procedures for the cyclization of unsaturated primary, 
secondary and tertiary amines, involving treatment with iodine or N-iodosuccinimide,3 
we carried out the reaction of the prototypical diaminodiene 1 with two equivalents of 
iodine in the biphasic system dichloromethane/aqueous sodium hydrogencarbonate. A 
mixture of two polar products was observed by TLC. They partially decomposed during 
the GC-MS analysis. Moreover, concentration of the organic solution at reduced pressure 
led to the isolation of a dark and thick residue, unless the bath temperature was kept 
below 30 °C. By taking this precaution, a light yellow solid was obtained with almost 
quantitative yield. 1H NMR analysis of the crude product showed that it was mainly 
composed of two compounds in a 70:30 ratio. After dissolving the crude reaction product 
in methanol the prevalent compound 2 precipitated as a white powder and was 
separated by filtration. After concentration of the mother liquor, the other, more polar 
compound 3 was isolated almost pure with low yield by column chromatography. 
The 1H NMR spectra of the separated compounds gave interesting indications. First, for 
both compounds a surprising difference in the chemical shifts of the methine protons in 
the two N-substituents was observed: in fact, one methine hydrogen was detected at 
6.12 ppm, suggesting that the group was bound to a positively charged, quaternary 
nitrogen atom (also confirmed by means of 1H- and 15N HNMQC NMR experiments). 
Moreover, the presence of only one iodine-bearing carbon was observed in both 
compounds, for which elemental and MS analyses (m/z 473) gave identical results, 
suggesting that they were isomers. 
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At first, attempts to obtain crystals of the main compound suitable for X-ray structure 
determination by crystallization in different solvents proved unsuccessful. By chance, 
small crystals were observed after a few months in a residue coming from one of those 
attempts, although the original solvent was unknown. The X-ray analysis (Figure 1) 
showed the structure of the ammonium iodide 2, with the fused diazatricyclic skeleton 
and a C-iodomethyl substituent besides the N-substituents.  
 
 
On the other hand, the structure of the minor product 3 as well as the configuration of 
the iodo-substituted carbon were evinced by NMR studies. The COSY, HSQC, and CIGAR-
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HMBC experiments were in agreement with the proposed structure. The ROESY data, 
compared also with those of compound 2, indicated the reported stereochemistry. Trace 
amounts of another unidentified compound were detected in the 1H NMR spectrum of a 
chromatographic fraction mainly containing 3. 
Treating both salts 2 and 3, or the crude mixture of them, with organometallic reagents 
caused the iodine/metal exchange and subsequent β-cleavage of the intermediate 
organometallic reagent, i.e. the reversal of the alkene iodoamination step (Table 1). As 
a matter of fact, using isopropylmagnesium chloride at −30 °C, the lowest temperature 
allowing dissolution of 2 in tetrahydrofuran, we obtained the compound 9, featuring the 
2,5-diazabicyclo[2.2.1]heptane ring, with high yield. The bridged bicyclic structure of 4 
was confirmed by 1H NMR investigation. The same product resulted from the crude 
mixture of 2 and 3 by treatment with n-butyllithium and lithium aluminum hydride. On 
the other hand, the reaction with magnesium turnings, activated with a catalytic 
amount of iodine in THF, was sluggish.  
 
Reagents (molar equiv.)
i-PrMgCl (2.2)
n-BuLi (2.2)
n-BuLi (2.5)
LiAlH4 (1)
Zn (3)
Bu3SnH (2.5), Et3B (2.5)
Cr(OAc)2 (5), tBuSH (5)
Na2S2O4 (4)
g
Yield (%)a
90, 68c
97, 80c
97
82
95
80f
71f
69
Conditions 
THF, 0 °C, 1 hb
THF, 0 °C, 1 h
THF, 0 °C, 1 h
THF, 0 °C, 1 h
THF, AcOH
THF, -30 °C, 3 h
THF, 25 °C
MeOH-H2O-DMF
Table 1. Conversion of 2,3 to the bridged pyridazine 4.
a Yield of crude product, >95% pure by 1H NMR analysis.  
b The same result was obtained at -30 °C. 
c After crystallization (MeOH) of the crude product.
d Ratio 10a/10b = 35:65.
e Ratio 10a/10b = 65:35.
f After chromatography (SiO2) of the crude product.
g In the presence of  NaHCO3 (10 equiv.).
Substrate
2
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In the attempt to avoid the β-cleavage of the β−iodoammonium function and preserve 
the tricyclic skeleton, we tried the reductive deiodination of 2 by methods not involving 
the formation of an organometallic reagent by iodine-metal exchange, for example, by 
treatment with zinc in tetrahydrofuran-acetic acid4 and lithium aluminum hydride. 
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However, in all cases the partial or almost complete conversion to 4 was again observed 
(Table 1). Particularly, the result of the latter reaction is in contrast with the successful 
reduction of β-bromoamines by the same hydride, where no competing elimination was 
observed. 7 3b-e Even more surprisingly, we observed the complete conversion of 2/3 to 4 
using tributyltin hydride and triethylborane5 (2.5 equivalents each) in tetrahydrofuran at 
−30 °C, a procedure that proceeds by a radical pathway6 and was successfully employed 
to reductively de-iodinate a β-iodoamine.3 Similarly, the reactions of 2 with chromous 
acetate/t-butyl mercaptan in tetrahydrofuran,7 and sodium dithionite in methanol-
water-dimethylformamide13 8 followed the same pathway with slightly less efficiency. 
Moreover, hydrogenation of 2 with common palladium catalysts in different 
experimental conditions gave complex mixtures of products, in some cases containing 4 
with low yields (GC-MS and NMR analyses), but the results were not reproducible and in 
no case the desired reductive deiodination occurred to a significant extent. These 
results are in contrast to the results of the palladium-mediated hydrogenolysis of both 
N-benzyl and C-I bonds of a β-iodoalkylamine.3 These reactions imply the fragmentation 
of the β-ammonium radical derived from the salts 2/3. To the best of our knowledge, 
fragmentation of an ammonium salt by the unambiguous generation of a β-carbon 
radical has not been reported in the literature.9 
Hydrogenolysis of the benzylic N-substituents in 4, with concomitant hydrogenation of 
the C=C bond, was easily accomplished by treatment with ammonium formate and 5% 
palladium on carbon in refluxing ethanol. By this way, the bridged piperazine 5 was 
obtained in pure state through the dihydrochloride, which was crystallized from a 
toluene/methanol mixture and then treated with base.  
 
5
HN
NH
N
N Ph
Me
4
Ph
Me
1) HCO2NH4,  5% Pd/C, 
     EtOH, reflux 2) HCl
3) crystallization 4) NaOH
 
 
3.3. Mechanism of the iodine-mediated cyclization 
 
In order to assess the effect of different experimental conditions on the reaction 
outcome and especially to gain information on the reaction pathway/intermediates, 
further experiments were carried out on the diaminodiene 1. Repeating the reaction 
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with 2 equivalents of iodine and stirring for a longer time (further 12 h), or heating the 
reaction mixture at the reflux temperature for 3 h, the composition of the crude 
reaction mixture did not change. Similarly, by performing the reaction with 2 
equivalents of iodine in diethyl ether for 3 h, then adding aqueous sodium 
hydrogencarbonate to the still coloured solution, the same outcome was observed. 
Moreover, treatment of the diaminodiene 1 with only one equivalent of iodine gave a 
mixture of the starting material and products 2/3, rather than any intermediate. Finally, 
we carried out the reaction of the allyl-substituted bridged piperazine 4 with one 
equivalent of iodine and obtained the ammonium iodide 2 as the only product (Scheme 
5).  
N
N Ph
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Only product
I2, NaHCO3
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4
 
 
In the light of these and previous results, we suggest that products 2 and 3 are formed 
from the diaminodiene 1 by the pathways described below. The cyclization of one 5-
aminoalkene moiety gives the iodomethylpyrrolidines 6 and 7 through the corresponding 
diastereomeric iodonium ions or iodine-alkene complexes. It is apparent that 6 is prone 
to undergo cyclization to give the bridged piperazine 4 by intramolecular substitution of 
the primary iodide by the secondary amine. Then, a second iodoamination step from 4 
leads to the ammonium ion 2. On the other hand, 7 undergoes a stereospecific 
rearrangement to give the iodopiperidine 8. This ring expansion of 2-halomethyl and 2-
hydroxymethylpyrrolidines, occurring via aziridinium intermediates, has been described 
in the literature.[7j,15] 3 10 This is followed by a second iodo-amination step of the residual 
5-aminoalkene moiety, so affording the fused pyrrolidino-piperidine 9. Then, the 
ammonium salt 3 is formed from 4 by intramolecular substitution. 
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It is worth mentioning that 4 and 5 posses the 2,5-diazabicyclo[2.2.1]heptane skeleton 
that has been incorporated in a variety of medicinal agents11 like 10 and 11 to achieve 
enhanced microbiological activity, due to the increased rigidity with respect to the 
simple piperazine ring.  
 
N
N
N
O
O
CN
Bu
O
NNN
HN
CO2H
O
F
10 11  
 
Compounds 13 and their analogues with different N-substituents, as well as their 
enantiomers, have been prepared from (S)- and (R)-4-hydroxyproline, through the 
intermediates 12 which undergo cyclization by intramolecular SN2 reaction at 80-110 °C. 
12  
 
N
TsO
Ts
NHR
12 13
N
H
HO
CO2H
R = Bn or Me;
N
N
Ts
R
 
 
 It should be noted that our route is relatively short and requires milder reaction 
conditions for the cyclization step, taking advantage of the increased reactivity and 
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interchanged positions of the iodide and amino functions in the intermediates 5, 6 and 
8, as compared to 12.  
 
3.4. Iodine-mediated cyclization of 3,6-disubstituted-4,5-diamino-1,7-
octadienes 
 
Next step was to verify if the iodine-mediated cyclization could be usefully applied also 
to substituted diazadienes. We started with the 3,6 diphenyl-substituted diene 14 and 
used the same reaction protocol, then we again observed the formation of a mixture of 
two isomeric products 15 and 16 in 2:1 ratio. The 1H-NMR spectrum confirmed that they 
were quaternary ammonium salts and their structure was assigned by comparison with 
the previously prepared salts. Any attempts of crystallization did not give any good 
results, anyway when we treated the crude reaction mixture with buthyllithium in THF 
at 0 °C we obtained, as expected, the bridged piperazine 17 in very good yield. 
 
I2 (2 equiv., NaHCO3)
N
N Ph
Ph N
N Ph
Ph
I
II
+
Ph
NH HN
Ph
CH2Cl2-H2O
I
PhPh
Ph Ph
Ph Ph
14 15 16
N
N Ph
Me
75%, 17
Ph
Me
Ph
Ph
BuLi 2 eq
THF, 0 °C
95%, 15:16: 2:1
 
 
Next, we tested the vinyl-substituted diamine 18 in the same reaction condition, with 
great disappoint, we observed the formation of mixture of at least four products by TLC 
analysis. Chromatographyc separation was very difficult, impeding the structural 
assignments. Changing reaction condition by increasing the temperature, or using an 
excess of iodine or different solvents had no effect on the outcome of the reaction.  
I2 (2 equiv.) NaHCO3
Ph
NH HN
Ph
CH2Cl2-H2O
18
Misture of inseparable
 products
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3.4. Iodine-mediated cyclization of 1,8 disubstituted 4,5-diamino-1,7-
octadienes  
 
4,5-Diamino-1,8-disubstituted-1,7-octadienes were easily prepared by addition of allylic 
organolithium reagents to the 1,2-bis-imine 19. For example, additon of cinnamyllithium 
and pentadienyllithium proceeded smoothly at −78 °C gave the corresponding linear 
diamines 20 and 21 with good yields, although with only a modest stereocontrol. The 
main isomers could be in both cases separated by column chromatography.13 
 
N N
PhPh
NH HN
PhPh
PhPh
NH HN
PhPh
Ph Li
45%, 20
69%,21
Li
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
__
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Treating the diamine 20 with two equivalents of iodine yielded a major product, as 
stated by TLC analysis, but from the 1H-NMR spectrum of the crude reaction mixture it 
was evident that it was not an ammonium salt and that a C=C double bond was still 
present. After purification by column chromatography and a further crystallization from 
methanol we obtained crystals suitable for X-ray diffraction analysis, which confirmed 
the structure of the product as the bridged piperazine 22. This product is clearly formed 
by a mechanism analogue to the one above menthioned  before but, probably for steric 
and/or electronic reason, the second iodocyclization step is hampered. Similarly, the 
reaction of the diamine 21 with iodine gave mainly the bridged piperazine 23. 
 
I2 (1 eq.)  , NaHCO3 
CH2Cl2-H2O
N
N
PhPh
Ph
Ph
NH HN
PhPh
PhPh
20 74%, 22
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I2 (1 eq.)  , NaHCO3 
CH2Cl2-H2O
N
N
Ph
Ph
NH HN
PhPh
21 62%,23
 
 
 
3.5. Iodine-mediated cyclization of 4,5-diamino-1-alkenes 
 
We reasoned that the 2,5-diazabicyclo skeleton would be obtained by iodination of 1,2-
diamines bearing only one allylic substituent (4,5-diamino-1-alkenes). A few of such 
compounds can be easily prepared from the diamines 14 and 18 by reaction with three 
equivalents of an organolithium reagent in controlled conditions, following a protocol 
described in the past by our research group14. These transformation, displaying high 
level of stereocontrol, takes place by a complex pathway that involves metalation of 
one or two N-H bond(s), rearrangement of the branched allylic substituent(s) to the 
linear one(s), retroallylation of the homallylic moiety to give an intermediate imine, and 
final addition of the organolithium reagent to this imine. 
NH HN
PhPh
Ph
NH HN
PhPh
Ph
Ph
NH HN
Ph
PhPh
RLi, THF, 0°C
NH HN
PhPh
NH HN
PhPh
Ph
NH HN
Ph
NH HN
PhPh
Ph
18
14
52% 78%
62% 63%
74%  
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As expected, treatment of these compounds with only one equivalent of iodine gave the 
corresponding bridged piperazines with good yields in a single step. 
 
NH HN
PhPh
R2
R1 I2 /NaHCO3
N
N Ph
Ph
R1
CH2Cl2-H2O R
2
 
 
 
 
                 R1 = Me R1 = n-Bu R1 = Ph 
R2 = Phenyl 70%, 24 mixture  61%, 25 
R2 = Vinyl 68%, 26  58%, 27   
 
Experimental Section 
 
Melting points are uncorrected. Solvents were distilled over the appropriate drying agent 
in N2 atmosphere before use: THF (sodium benzophenone ketyl, then LiAlH4), CH2Cl2 
(P2O5). Optical rotations were measured on a digital polarimeter in a 1-dm cell and [α]D-
values are given in 10 1 deg cm3 g1. 1H NMR spectra were recorded on Varian Inova and 
Gemini instruments for samples in CDCl3 which was stored over Mg: 
1H chemical shifts 
are reported in ppm relative to CHCl3 δH 7.27), J-values are given in Hz. and in the 
assignments s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad 
singlet, bm = broad multiplet, dd = doublet of doublets and dt = doublet of triplets. 
Assignments were assisted with several 2D experiments for structural and 
stereochemical determinations. Infrared spectra were recorded on a Nicolet FT-210 
spectrometer and IR assignments are reported in wavenumbers (cm 1). MS spectra were 
taken at an ionising voltage of 70 eV on a Hewlett-Packard 5970 or 5890 spectrometer 
with GLC injection. Accurate Mass was determined on an Micromass QTOF2 spectrometer 
operated in ES ionization mode. Molecular weight was determined on an Agilent 
Technologies MS 1100 instrument. Chromatographic separations were performed on 
columns of SiO2 (Merck, 230-400 mesh) at medium pressure. The following materials 
were purchased from Aldrich: nBuLi (2.5 M in hexanes), iPrMgCl (2 M in THF), Et3B (1M in 
THF), LiAlH4, Zn, Bu3SnH, Cr(OAc)2, Na2S2O4.  
 
 - 38 - 
4.2. Iodine mediated cyclization of the diaminodiene 1. A solution of I2 (2.55 g, 10 
mmol) in CH2Cl2 (50 mL) was slowly added to a magnetically stirred mixture of the 
diaminodiene 1 (1.74 g, 5 mmol), dissolved in CH2Cl2 (15 mL), and sat aq NaHCO3 (30 
mL). After stirring was continued for 3 h, decoloration was observed. The organic phase 
was separated and the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The 
collected organic layers were dried over CaCl2 and evaporated at reduced pressure at a 
temperature <30 °C. The solid pale brownish residue was mainly composed of the two 
products in a 30:70 ratio by 1H NMR analysis. However, by dissolving the crude reaction 
product in MeOH (5 mL) at room temperature, then scratching the walls of the flask with 
a spatula a white precipitate of 2 was formed, then filtered off, washed with methanol 
and dried at reduced pressure: 1.60 g (53%). From the mother liquor, a further amount 
of 2 precipitated and was collected, for a total yield of 1.96 g (65%). Chromatography of 
the mother liquor, containing 2 and 3 in a 2:1 ratio, on a silica gel column eluting with 
EtOAc-MeOH mixture (4:1) gave pure fractions of compound 3, which were collected and 
concentrated to leave a white solid: 0.122 g (4%).  
4.2.1. Ammonium salt 2: m.p. 165-167 °C (dec). [α]D
25 +21.4 (c 0.69, CHCl3). IR (Nujol): 
νmax 3400, 1597. 
1H NMR (600 MHz, CDCl3, 25 °C, see Figure for atom numbering): δ 1.29 
(d, J 6.8, 3 H, H-11), 1.78 (d, J  6.5, 3 H, H-13), 2.03 (dd, J 3.7, 9.8 Hz, 1 H, H-9), 2.18 
(d, J 12.4 , 1 H, H-4), 2. 42 (m, 2 H, H-4, H-14), 3.07 (m, 1 H, H-9), 3.17 (dd, J 10.7, 
7.4, 1 H, H-14), 3.31 (d, J 11.3, 1 H, H-6), 3.42 (bs, 1 H, H-5), 3.53 (bs, 1 H, H-2), 3.60 
(q, J 6.8, 1 H, H-10), 3.86 (dd, J 11.3, 1.9, 1 H), 4.98 (m, 1 H, H-8), 5.28 (bs, 1 H, H-3), 
6.12 (q, J 6.9, 1 H, H-12), 7.20 (d, 2 H. Ph), 7.27 (t, 1 H, Ph), 7.32 (t, 2 H, Ph), 7.47-
7.51 (m, 3 H, Ph), 7.62 (d , 2 H, Ph). 13C NMR (150 MHz, CDCl3, 25 °C): δ 3.0, 17.3, 22.1, 
33.9, 38.3, 56.2, 61.0, 62.7, 64.7, 72.01, 76.8, 81.5, 126.8, 126.8, 127.9, 129.0, 129.0, 
129.2, 129.2, 129.9, 129.9, 131.0, 134.1, 143.7. ES MS (m/z) 473 (C24H30IN2
+). Anal. 
Calcd for C24H30I2N2 (600.32): C, 48.02; H 5.04; N 4.67. Found: C, 48.18; H, 5.08; N 4.60. 
4.2.2. Ammonium salt 3: mp 139-141 °C (dec). [α]D
25 +3.2 (c 0.30, CHCl3). IR (Nujol): 
νmax 3422, 1620, 1279, 1230, 1038, 706. 
1H NMR (600 MHz, CDCl3, 25 °C, see Figure for 
atom numbering) δ 1.26 (d, J 6.5 Hz, 3 H, H-12), 1.78 (d, J 7.5, 3 H, H-14), 1.86 (t, J 
12.9, 1 H, H-10), 2.09 (m, 1 H, H-4), 2.47 (d, J 12.9, 1 H, H-10), 3.11 (bs, 1 H, H-2), 3.33 
(d, J 12.4, 1 H, H-4), 3.38 (t, J 12.6, 1 H, H-8), 3.54-3.65 (m, 4 H, H-3, H-5, H-6, H-11),  
4.09 (m, 1 H, H-8), 4.46 (bd, J 11.3, 1 H, H-6), 4.84 (m, 1 H, H-9), 5.89 (q, J 7.5, 1 H, H-
13), 7.23-7.29 (m, 3 H, Ph), 7.32 (t, 2 H, Ph), 7.49-7.57 ( m, 5 H, Ph). 13C NMR (150 MHz, 
CDCl3, 25 °C): δ 10.0, 14.7, 22.2, 33.7, 38.9, 57.2, 60.1, 61.8, 63.4, 68.6, 70.1, 73.7, 
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126.9, 126.9, 127.9, 129.0,  129.0, 129.7, 129.7, 130.8, 130.8, 131.2, 132.0, 143.6. ES 
MS (m/z) 473 (C24H30IN2
+). Anal. Calcd for C24H30I2N2 (600.32): C, 48.02; H 5.04; N 4.67. 
Found: C, 48.21; H, 5.10; N 4.58. 
 
Preparation of (1R,3R,4R)-2,5-di[(S)-1-phenylethyl)]-3-(2-propenyl)-2,5-
diazabicyclo[2.2.1]heptane (4).  
Reaction of 2 with isopropylmagnesium chloride: To a solution of 2 (1.80 g, 3 mmol) in 
dry THF (30 mL) cooled to 0 °C under Ar atmosphere was added iPrMgCl (2 M in THF, 3.3 
mL, 6.6 mmol) over 5 min while stirring. After 1 h, the mixture was quenched with sat. 
aq NaHCO3 (15 mL) and extracted with CH2Cl2 (3 × 20 mL). The collected organic layers 
were dried over anhydrous CaCl2 and concentrated to leave 9 as an off-white solid (1.02 
g, 2.95 mmol, 98%), which was crystallized from MeOH: white needles, 0.71 g (2.05 
mmol, 68%); m.p. 71-72 °C. [α]D
25 -101.4 (c  0.4, CHCl3). IR (Nujol): νmax 1635, 1598, 
1299, 1213, 1103, 1095, 913, 770, 700. 1H NMR (500 MHz, 25 °C) δ 1.21 (d, J 6.5 Hz, 6 H; 
2 × CH3), 1.35 (bm, 2 H), 2.20 (bm, 1 H), 2.28 (dd, J 3.10 and 9.48, 1 H), 2.32 (dt, J 
5.34 and 10.30, 1 H), 2.81 (d, J 9.25, 1 H), 2.87-2.97 (m, 2 H), 2.99 (m, 1 H), 3.30 (q, J 
6.5, 1 H), 3.35 (q, J 6.5, 1 H), 4.93 and 4.81 (m + m, 2 H), 5.45 (m, 1 H), 7.16 – 7.35 (m, 
10 H; Ph). 13C NMR (200 MHz, CDCl3, 25 °C) δ 22.5, 23.6, 28.7, 36.5, 59.9, 61.4, 64.5, 
64.8, 69.5, 114.9, 126.5, 126.8, 128.1, 137.3, 140.1, 147.1. MS m/z (EI; GC-MS) 105 
(100%), 241 (29), 68 (28), 137 (25), 305 (24), 173 (17), 80 (15), 172 (12), 346 (2, M+). 
Anal. Calcd for C24H30N2 (346.24): C, 83.19; H, 8.73; N 8,08. Found: C, 83.28; H, 8.78; N, 
8.02. 
Reaction of 2 with n-butyllithium: The reaction was performed as in the above 
described experiment using nBuLi  (2.5 M in hexanes, 2.4 mL, 6 mmol) to give crude 4 
(1.01 g, 97%). Crystallization from MeOH gave pure 4: 0.83 g (80%). The reaction of  the 
mixture 7/8 (35:65 ratio) with nBuLi (2.5 equivalents) gave crude 4 in 97% yield. 
Reaction of 2 with zinc-acetic acid: Zinc powder (0.59 g, 9 mmol) was flamed under a 
stream of argon, then cooled and covered with dry THF (10 mL). Glacial AcOH (5 mL) 
was added, followed by 2 (1.80 g, 3 mmol), and the mixture was magnetically stirred for 
3 h, after which time 40% NaOH was carefully added until pH 11. The mixture was 
extracted with CH2Cl2 (3 × 20 mL) and the collected organic layers were washed with 
brine (10 mL), dried over CaCl2 and concentrated to leave crude 4 as an off-white solid: 
0.99 g, (95%). 
 - 40 - 
Reaction of 2 with lithium aluminum hydride: LiAlH4 (0.126 g, 3 mmol) was added to a 
stirred solution of 2 (1.80 g, 3 mmol) in THF (25 mL) at 0 °C under Ar atmosphere. After 
1 h, the mixture was quenched with sat aq NaHCO3 (10 mL) and stirred for a further 1 h. 
The organic phase was extracted with CH2Cl2 (3 × 20 mL) and the collected organic 
layers were washed with brine (10 mL), dried over CaCl2 and concentrated to leave 4 as 
an off-white white solid: 0.85 g (82%). 
Reaction of 2 with tributyltin hydride/triethyl borane/oxygen: Oxygen was bubbled 
for 2 min through a mixture of 2 (1.20 g, 2 mmol), Bu3SnH (1.73 g, 6 mmol) and Et3B (1 
M in THF, 4.2 mL, 4.2 mmol) in THF (30 mL) cooled at –30 °C. The mixture was stirred 
for 3h, then quenched with saturated aq NaHCO3 (20 mL) and extracted with CH2Cl2 (3 × 
20 mL). The collected organic layers were washed with brine (20 mL), dried over CaCl2 
and concentrated to leave a crude oil, which was subjected to chromatography on a 
silica gel column, eluting with cyclohexane/EtOAc 10:1, to give 4 as an off-white solid: 
0.55 g (80%). 
Reaction of 2 with chromous acetate/t-butylmercaptan: To a solution of 2 (1.20 g, 2 
mmol) in THF (30 mL) under an Ar atmosphere were added in order tBuSH (1.80 g, 20 
mmol) and freshly prepared Cr(OAc)2 (1.11 g, 10 mmol). The mixture was magnetically 
stirred for 15 h, then quenched with water (15 mL) and extracted with CH2Cl2 (3 × 20 
mL). The collected organic layers were washed with brine (10 mL), dried over CaCl2 and 
concentrated to leave a crude oil, which was subjected to chromatography on a silica 
gel column, eluting with cyclohexane/EtOAc 10:1, to give 4 as an off-white solid: 0.49 g  
(71%). 
Reaction of 2 with sodium dithionite: To a mixture of solvents: DMF (8 mL), water (8 
mL) and MeOH (12 mL) were added sequentially 2 (0.98 g, 2 mmol), NaHCO3 (1.68 g, 20 
mmol) and Na2S2O4 (1.54 g, 8 mmol) and the mixture was magnetically stirred overnight. 
The mixture was diluted with CH2Cl2 (100 mL) and washed with brine (3 × 50 mL), dried 
over CaCl2, then concentrated to leave 4 as an off-white powder: 0.48 g (69%). 
Preparation of (1R,3R,4R)-3-propyl-2,5-diazabicyclo[2.2.1]heptane (5). A mixture of 
4 (1.04 g, 3 mmol), NH4HCO2 (1.80 g, 27 mmol) and 5% Pd/C (0.45 g) in EtOH (40 mL) 
was heated at reflux temperature for 2 h, then cooled and the solid was filtered off. 37% 
HCl (0.5 mL, 6.5 mmol) was added to the solution, which was then concentrated at 
reduced pressure. Toluene (10 mL) and EtOH (10 mL) were added to the residue and the 
solution was concentrated. The operation was repeated to leave the salt 5-2HCl as an 
off-white solid (0.62 g), which was crystallised from toluene-EtOH mixture (4:1): 0.48 g 
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(76%); m.p. 289-291 °C (dec.). [α]D25 −28.7 (c 0.6, MeOH). 
1H NMR (500 MHz, CDCl3, 25 
°C, DMSO-d6) δ 0.88 (t, J 7.2, 3 H, CH3), 1.34 (m, 2 H, CH2CH2CH3), 1.76 (m, 2 H, 
CH2CH2CH3), 2.04 (m, 2 H, CHCH2CH), 3.54 (m, 2 H, NCH2), 3.62 (m, 1 H, CHCH2CH2), 
4.34 (s, 2 H, CHCH2CH), 9.0–11.0 (bm, 2 × NH2
+). The free base 5 was obtained from the 
salt (400 mg, 1.88 mmol) by treatment with 20% aq NaOH (2 mL) and extraction with 
CH2Cl2 (10 × 3 mL), drying the collected organic layers over CaCl2 and concentration: 
brownish oil, 0.164 g (62%). [α]D
25 −45.2 (c 0.6, CHCl3). IR (neat): νmax 3443, 3264, 1261, 
1169, 1116, 1063, 957, 751. 1H NMR (200 MHz, CDCl3, 25 °C): δ 0.94 (t, J 7.2, 3 H, CH3), 
1.20-1.60 (m, 4 H, CH2CH2CH3), 1.76 (m, 2 H, CHCH2CH), 1.82 (bs, 2 H, NH), 2.70 (d, J 
9.8, 1 H, NCH2), 2.97 (dd, J1 2.2, J2 9.8, 1 H, NCH2), 3.12 (dt, J1 1.4, J2 6.8, 1 H, 
CHCH2CH2), 3.37 and 3.52 (2 s, 2 H, CHCH2CH). 
13C NMR (300 MHz, CDCl3, 25 °C) δ 14.0, 
20.1, 34.2, 38.6, 53.9, 56.7, 57.7, 62.3. MS m/z (EI, GC-MS): 68 (100%), 69 (56), 98 (44), 
140 (M+, 22), 82 (19), 56 (11), 111 (10), 125 (M+ - CH3, 3). HRMS m/z calcd for C8H17N2 
(MH+): 141.1392, found 141.1392. 
Ammonium Salt 15: [α]D
25 +61.8 (c 0.65, CHCl3); IR: 2960, 2867, 2362, 1454, 1060, 703. 
1H NMR (300 MHz, 20 °C): δ = 1.05 e 1.12 (2 d, J = 6.7 Hz, 6 H; CH3-z e CH3-v), 1.85 (d, 
J =6.8 Hz, 1 H; CHPh ), 3.03 (q, J = 6.7 Hz, 1 H, NCHPh), 3.48 (dd, J = 7.8 Hz, 1 H), 3.68 
( q, J = 10.1 Hz, 1 H ), 3.91 (m, 3 H), 4.65 (m, 1 H), 4.96 (dd, J = 11.1 Hz e J = 17.2 Hz, 
2 H; N+CH2), 5.98 (q, J = 5.8 Hz, 1 H, N
+CH), 6.29 (d, J = 6.7 Hz, 1 H; N+CH), 6.90 (m, 5 
H; Ph), 7.00 (m, 5 H; Ph), 7.20 (m, 5 H; Ph), 7.50 (m, 5 H; Ph). C13 NMR (75 MHz, CDCl3): 
δ= 14.7, 17.7, 24.3, 27.1, 49.7, 56.4, 59.720, 67.3, 70.1, 70.3, 126.5,129.5, 143.5. 
Bridged piperazine 17: [α]D
25 +41.7 (c 1.06, CHCl3); IR: 2958, 2928, 1948, 1875, 1801, 
1451, 759. 1H NMR (300 MHz, 20 °C): δ = 0.29 (d, J = 6.2 Hz, 3 H; CHMe), 1.34 (d, J =7.3 
Hz, 3 H; CHMe ), 2.63 (dd, J = 8.4 e 2.4 Hz, 1 H, NCH), 3.04 (q, J = 6.2 Hz, 1 H, NCHPh ), 
3.16 (d, J =8.0 Hz, 1 H,PhCHCH=CH2), 3.32 (bs, 1 H, ), 3.55 (bs, 1 H), 3.55 (q, J =7.3 Hz, 
1 H, NCHPh), 3.62 (bs, 1 H), 4.30 (q, J = 6.7 Hz, 1 H), 5.04 (dd, J = 10.0, 17,1 Hz, 2 H, 
CH=CH2), 6.50 (ddd, J = 8.0, 10.0, 17,1 Hz, 1 H; CHCH=CH2), 6.90 (m, 5 H; Ph), 7.00 (m, 
5 H; Ph), 7.20 (m, 5 H; Ph), 7.50 (m, 5 H; Ph). C13 NMR (75 MHz, CDCl3) δ 21.2, 48.7, 
60.311, 62.5, 63.8, 64.3, 65.4, 114.956, 125.6, 140.0, 140.3, 143.8, 144.5, 148.5. 
Bridged piperazine 22: m.p. 59-61 °C; [α]D
25 -11 (c 0.75, CHCl3); IR: 2925, 2850, 1492, 
1450, 1100, 968, 749, 701. 1H NMR (300 MHz, CDCl3):  = 1.12 (d, J = 6.5 Hz, 3 H, CHMe), 
1.20 (d, J = 6.7 Hz, 3 H, CHMe), 1.64 e 1.81 (dd, J = 9.8 e 1.6 Hz, 1 H, NCHCH2CHN), 
2.37 (dt, J = 10,3 e 2.5 Hz, 1 H, CHCH2CH=CH), 2.52 (dt, J =10,3 e 2.5 Hz, 1 H, NCHCH) 
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3.19 (s, 1 H, NCHCH), 3.27 (s, 1 H, NCHCH), 3.38 (q, J = 6.5 Hz, 1 H, NCHMe), 3.46 (m, 1 
H, CH2CH=CH2), 3.62 (q, J = 6.7 Hz, 1 H, NCHMe), 3.81 (d, J = 2.5 Hz, 1 H, 
NCH(Ph)CHN), 5.80 (ddd, J = 15.8, 10,3 e 2.5 Hz, 1 H, CH=CHPh), 6.38 (d, J = 15.8 Hz, 1 
H, CH=CHPh), 6.69-7.53 (m, 20 H, Ph). 
C13 NMR (75 MHz, CDCl3):  23.9, 23.478, 31.8, 34.1, 62.8, 64.6, 65.2, 67.1, 70.4, 73.6, 
125.8, 129.2, 130.0, 137.8, 143.0, 146. 4. 
Bridged piperazine 23: [α]D
25   49.8 (c 0.60, CHCl3); IR:3024, 2971, 2010, 1960, 1903, 
1451, 1301, 1101, 1003, 910, 766, 700. 1H NMR (300 MHz, CDCl3): δ =.1.34 1.35 (d, 2 H, 
CHMe), 1.55 (bs, 2 H, NCHCH2CHN) 2.36 (dt, J = 9.6 2.5 Hz, 1 H, NCHCH2), 2.54 (dt, J = 
10.3 2.5 Hz, 1 H, NCHCH2), 3.08 (bs, 1 H, NCHCH2) 3.12 (bs, 1 H, NCHCH2) 3.14 (bs, 1 H, 
NCHCH=CH2), 3.26 (m, 1 H, CH2CH=CH), 3.50 (q, J = 6.2 Hz, 1 H, NCHMe), 3.59 (q, J = 
6.3 Hz, 1 H, NCHMe), 5.00 (dd, 2 H, CH=CH2), 5.20 (dd, 2 H, CH=CH2), 
5.39 (ddd, J = 6.3, 8.0, 15,1 Hz, 1 H, CH=CH2), 6.18 (m, 2 H, CH=CHCH=CH2), 6.44 (m, 1 
H, CH=CHCH=CH2), 7.26-7.46 (m, 10 h, Ph). 
C13 NMR (75 MHz, CDCl3): δ 23.5, 24.4, 31.3, 34.5, 63.1, 65.1, 65.3, 66.9, 70.3, 72.6, 
114.8, 115.1, 127.2, 127.4, 128.9, 132.3, 135.2, 142. 7, 145, 5, 146.8. 
Bridged piperazine 25: [ ]20D 25.9 (c 0.38, CHCl3); IR: 2927, 1954, 1900, 1840, 1496, 
1450, 1262, 1089, 739, 704. 1H NMR (300 MHz, CDCl3): δ = 0.85 (d, J = 6.7 Hz, 6 H, 
CHMe), 1.81 (d, J = 1.1 Hz, 2 H, CHCH2), 3.4 (q, J = 6.7 Hz, 2 H, NCHMe), 3.45 (s, 2 H, 
CHCH2), 3.77 (s, 2 H, NCHPh), 6.84-7.12 (m, 10 H, Ph), 7.27 (m, 5 H, Ph). 
C13 NMR (75 MHz, CDCl3): δ = 23.6, 32.1, 65.2, 67.7, 73.2, 76.4, 126.0, 129.2, 126.9, 
127.6, 128.2, 129.3, 142.3, 146.3. 
Bridged piperazine 24: [α]D
25  -65.0 (c 0.7, CHCl3); IR: 2924, 2852, 1731, 1450, 1372, 
1096, 802, 765, 700. 1H NMR (200 MHz, CDCl3): δ = 1.08 e 1.16 (2 d, J = 6.4 Hz, 6 H, 
NCHMe), 1.44 (d, J = 6.1 Hz, 3 H, NCHCH3), 1.74 (dd, J = 9.5 e 24.1 Hz, 2 H, CHCH2CH), 
2.69 (dq, J = 2.8 e 6.1 Hz, 1 H, NCHCH3), 3.06 (s, 1 H, CHCH2CH), 3.18 (s, 1 H, 
CHCH2CH), 3.37 e 3.61 (2 q, J = 6.6 Hz, 2 H, NCHPh), 3.79 (s, 1 H, NCHPh), 6.72-7.54 
(m, 15 H, Ph). C13 NMR (75 MHz, CDCl3): δ = 17.0, 24.1, 31.5, 63.9, 64.2, 64.8, 65.4, 
64.1, 73.3, 125.6, 126.2, 126.6, 127.0, 128.2, 142.7, 146.4. 
Bridged piperazine 26: [α]D
25 49.0 (c 0.6, CHCl3); IR: 2921, 2868, 1956, 1879 1801, 
1736, 1674, 1446, 1360, 1204, 694. 1H NMR (300 MHz, CDCl3): δ = 1.18 (d, J = 6.5 Hz, 3 
H, NCHMe), 1.23 (s, 3 H, CHCH3), 1.26 (d, J = 6.1 Hz, 3 H, NCHMe), 1.43 (q, J = 9.5 Hz, 2 
H, CHCH2CH), 2.56 (dq, J = 5.8 e 2.5 Hz, 1 H, CHCH3), 2.84, 2.92 e 2.95 (3 s, 3 H, 
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NCHCH), 3.35 (q, J = 6.5 Hz 1 H, NCHPh), 3.47 (q, J = 6.1 Hz, 1 H, NCHPh), 5.06 (dd, J = 
6.2 e 10.1 Hz, 2 H, CH=CH2), 6.30 (ddd, J = 6.3, 10.1 e 17.3 Hz, 1 H, CH=CH2); C
13 NMR 
(75 MHz, CDCl3): δ =.17.6, 23.5, 23.8, 30.9, 43.3, 64.2, 64.6, 64.7, 65.4, 66.9, 71.0, 
97.1, 113.9, 126.4, 126.5, 128.141, 142.1, 147.2, 164.1. 
Bridged piperazine 27: [α]D25  94.8 (c 0.47, CHCl3); IR: 2941, 2868, 2582, 1952, 1875, 
1813, 1446, 1102, 910, 702. 1H NMR (300 MHz, CDCl3): δ = 0.86 (t, J = 7.4 Hz, 4 H, 
CH2CH2CH3), 1.20 (t, J = 6.6 Hz, 6 H), 1.29 (m, 3 H), 2.32 (m, 2 H, CHCH=CH2), 2.93 (s, 1 
H, NCH), 2.97 (s, 2 H), 3.36 (q, J = 6.6 Hz, 1 H, NCHMe), 3.46 (q, J = 6.4 Hz, 1 H, 
NCHMe), 5.03 (dd, J = 10.1 e 9.6 Hz, 2 H), 6.35 (m, 1 H, CH=CH2), 7.26 (m, 10 H, Ph). 
C13 NMR (50 MHz, CDCl3): δ =.14.362, 23.201, 23.337, 23.800, 27.039, 29.194, 30.446, 
30.6, 62.5, 66.6, 70.0, 71.9, 113.9, 126.5, 126.8, 127.5, 127.7, 128.1, 128.2, 142.3, 
146.9, 147.1. 
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Chapter 4 
Asymmetric Synthesis of δ-Substituted δ-Lactams from Imines Exploiting 
the Ring Closing Metathesis Reaction. 
 
R N CO2Me R N
OSiMe3
R N
H
O
4) ring-closing 
    metathesis1) imine allylation
2) N-dealkylation 
3) N-acroylation  
 
4.1 Introduction 
 
The ring closing metathesis (RCM) of 1,n-dienes is a powerful and versatile tecnique for 
the construction of carbocyclic and heterocyclic compounds.1 In particular, this 
methodology has been exploited for the synthesis of azaheterocycles, as witnessed by 
several reviews dealing with the synthesis of natural compounds like piperidine and 
pyrrolidine alkaloids,2,3 dipeptide mimetics,4 and β-lactams of non-classical structure.5 
For example, LeBreton et all. employed the RCM reaction to build up the skeleton of 
four pipecoline alkaloids, In this case the  chiral centre was constructed with very high 
stereocontrol using B-allyldiisopinocampheylborane as the chiral reagent, but the 
conversion of the hydroxyl moiety to the amine functionality required four further 
steps2a. 
N
H
O
N
HO
N
N3
N
N
Cbz
N
N
Cbz
N
N
X
N
N
X
X=H: (S)-Anatabine 35% overall yield
X=Me: N-Methyl (S)-Anatabine 25% overall yield
X=H: (S)-Anabasine 30% overall yield
X=Me: N-Methyl (S)-Anabasine 25% overall yield
a b-c d-f
g
a) (+)-Ipc2BAll, Et2O, 94%, 94% e.e. b) MsCl, TEA, DCM, 100% c) NaN3, DMF 97% 94% e.e. d)SnCl2 MeOH, 98%
e)BnCOCl, K2CO3, DCM  76%, f)NaH, DMF, 76% g) HCl gas. then 1
st  Gen. Grubbs' Cat. (7.5 mol%), DCM , 79%  
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Much less work has been devoted to the synthesis of natural pyrrolidine products by 
application of RCM technology, Riera et al. reported a formal synthesis of (L)-3,4-di-
hydroxyproline, a natural α-amino acid isolated in 1994, as its protected derivative.2b 
employing a regioselective ring opening reaction of a chiral epoxide (easily available 
with 99% e.e by Sharpless epoxidation of cinnamyl alchool) as the key step followed by 
reduction of the diol moiety by the Corey/Hopkins reaction, RCM reaction and an 
unusual oxidation reaction of the phenyl ring. 
 
OH
O
OH
OH
N
Boc
N
Boc
N
Boc
HOOC
N
Boc
O
O
(L)-3,4 N-Boc Dihydroxyproline 
acetonide,37% overall yield
a-b c-d
e f-h
a) AllylNH2, Ti(OiPr)4, DCM, 97%, b) BOC2O, NaHCO3, MeOH, c)Cl2CS, DMAP, DCM, then d)
1,3-dimethyl-2-phenyl-1-3-2-diazaphospholidine, 72% e) 1st Gen. Grubbs' Cat. (5 Mol%), DCM, 99%, f) OsO4, K2FeCN6,
K2CO3, tBuOH/H2O, 99% g) 2-2-dimethoxypropane, (CH3)2CO, 96%, h) RuCl3, NaIO4, NaHCO3,
CCl4, CH3CN, H2O, 59%
 
 
As one can imagine, the required azadiene for the RCM reaction can be prepared by 
different methodologies. Among the others, a very simple route involves the addition of 
an unsaturated organometallic reagent to an imine and the subsequent N-alkylation with 
an unsaturated alkyl halide. In this case, the required asymmetric induction in the 
carbon-carbon bond formation step can be achieved by three different methodologies 
exploiting: (a) “substrate-induced diastereoselectivity” (SID),6 where the chirality is 
present in the imine, generally in the C-substituent, and is retained in the product; (b) 
“auxiliary induced diastereoselectivity” (AID), where the chirality is present in the 
imine, generally in the N-substituent, that is removed in a successive step; (c) “reagent 
induced stereoselectivity” (RIS),7 where the asymmetric induction is provided by a chiral 
ligand that is bound to the metal by covalent bond(s) or by Lewis acid-base 
interaction(s). 
The AID approach to the synthesis of substituted piperidines is illustrated in the 
following scheme. It involves allylation of the chiral imine 1 to give the homoallylic 
amine 2, and successive N-allylation to give the 5-aza-1,7-diene 3. The absolute 
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configuration of the new stereocenter α to the N formed in the allylmetalation step is 
controlled by the chiral auxiliary (N-substituent). When the allylmetal reagent bears a γ-
substituent (R2), two stereocenters are formed, whose relative stereochemistry is 
determined by the (E) or (Z) geometry of the substituted allylmetal reagent. Based on 
these reports, we considered that there was room for improvement. Above all, we 
foresaw a significant variant in the synthetic sequence by the conversion of the 
secondary homoallylic amine 2 to the acryloyl amide 4, as the N-acryloyl substituent 
provides at the same time a two carbon fragment to the ring being constructed and acts 
as a protective group of the amine function in the RCM step leading to the α,β-
unsaturated-δ-lactams 6.13,14. 
R1 N
R*
R1 NH*
R1 N R1 N
R1 N R1 N
H
*
**
*
1
5
4, R = R* or H 6, R = R* or H
7
R2
R2 R2
R2R2
*
* *
**
R*
R3
R4
O O R1 N
H
*
8
*
R3
R4
R5
R2
MR2
R1 N*
R2
*
R
R R
R
3
2
 
 
In principle, either the size and/or the position of the double bond of the unsaturated 
lactams can be varied by the proper choices of the ω-alkenylmetal reagent and the ω-
alkenyl/alkenoyl halide. However, the synthesis of six-membered rings takes advantage 
of the higher reactivity and ready availability of the allylic organometallic reagents and 
allyl/acryloyl halides. Following the general route described above we studied a 
synthesis of δ-substituted-α,β-unsaturated-δ-lactams 6 through 4.15 It is worthwhile 
observing that although a great number of methods are available for the synthesis of 
α,β-unsaturated-δ-lactams,16 we could find in the literature only few reports of optically 
pure δ-substituted-α,β-unsaturated-δ-lactams, having R1 = (R)-CO2Me,13a (S)-CO2Me,16a R1 
= (R)-[(3R,5S)-1-Cbz-5-(acetoxymethyl)piperidin-3-yl),13e R1 = (S)-CH2CO2Me,
13k R1 = (S)-n-
C15H31,
13l R1 = (S)-CO2H,
16u and R1 = (S)-CO2tBu (N-Boc derivative).
16t 
Obviously, the usefulness of our synthetic route is based on the capability to achieve the 
highest possible diastereoselectivity in the first allylmetalation step. In this respect, the 
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careful choice of the chiral auxiliary (amine) is the top priority , and should be based on 
the nature of the starting aldehyde.17 A variety of optically pure primary amines 
(including amino acid esters and amides, and β-aminoalcohols), hydrazines, 
hydroxylamines and sulfinamides are available for this purpose, each of them often 
provides excellent diastereoselectivity in organometallic additions, particularly with 
allylmetal reagents, as thoroughly described in recent reviews.17,18  
 
4.2 Results and discussion: 
 
We exploited (S)-valine methyl ester as chiral auxiliary for the preparation of the 
homoallylic amines 13 from the precursor imines 9 since we previously achieved high to 
complete stereocontrol in this crucial step by the addition of allylcopper, -tin, -lead and 
-zinc reagents to a variety of aromatic and aliphatic imines in anhydrous tetrahydrofuran 
at low temperature following the Grignard protocol.19 We also described a convenient 
Barbier reaction which relies on the reaction of imines with allyl bromide, zinc and a 
catalytic amount (generally 10 mol%) of cerium trichloride heptahydrate in anhydrous 
THF at 0 °C.9 The hydrated cerium salt may have different roles in the process, but 
above all it prevents the retroallylation reaction so preserving the stereochemical purity 
of the homoallylic zinc amide produced. As a matter of fact, almost complete 
diastereoselectivities were obtained with aromatic and aliphatic imines.  
 
 
ZnBr.CeCl3Br Br.CeCl3
R N
O
OMe
Ce
Cl
Cl Cl
Zn
Br
R N
O
OMe
BrZn
+ CeCl3
R N
H
O
OMe
H2O
 
 
After a seminal paper by our research group, other authors reported that this Barbier 
protocol worked efficiently and diastereoselectively with substituted allylic bromides 
and with 4-hydroxybenzaldimine and its O-substituted derivatives, suitable substrates 
for the preparation of supported chiral catalysts.20 More recently, the same procedure 
has been efficiently applied to imines derived from 2-thiophenecarboxaldehyde and 
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several α-aminoacid esters, as well as 9h; moreover, such addition reactions employing 
diimines or triimines with a polycyclic aromatic core produced the chiral multiallylic 
dendritic amines with similar diastereoselectivity.21 On this basis, we decided to 
implement the stereoselective synthesis of new homoallylic amines 10b-l by applying 
our Barbier protocol to the imines 9b-l, derived from either aromatic and aliphatic 
aldehydes. The primary homoallylic amine precursors of 13a-l were then obtained by the 
efficient reduction of the ester group by lithium aluminium hydride to give the 
intermediate amino-alcohols 12 and removal of the N-substituent by oxidative 
procedures. 
 
R N CO2Me
R N
H
CO2Me
R N
OSiMe3
9 10
LiAlH4 THF, 0 °C
R N
H
OH
1211
1) allylmetal
2) HCl, H2O
1) oxidn
a:  R = Ph
b:  R = 4-ClPh
c:  R = 4-FPh
d:  R = 4-MeOPh
e:  R = 3,4,5-(MeO)3Ph
f:   R = 2- Naphthyl
R N
H
13
O
R N
H
14
O
allylmetal
g:  R = 2-Furyl
h:  R = 2-Thienyl
i:   R = Ferrocenyl
j:   R = 3-Pyridyl
k:  R = 2-Quinolyl
l:   R = Cyclohexyl
m: R = 2-Pyridyl
2) acryloyl 
    chloride,
    base
 
 
The results of the Barbier allylmetalation of the imines 9a-l, derived from valine methyl 
ester, are reported in the table below. In almost all cases, as expected, we observed 
complete or almost complete diastereoselectivity (d.r. >99:1) and high yield of the 
desired homoallylic amines 10, which were purified from small amounts or traces of 
starting materials and, especially for the reaction on the p-fluorophenylimine 9c, 
products coming from overreaction (attack to the ester group). As we observed 
previously with the corresponding 2-pyridineimine, a low diastereoselectivity was 
obtained with the 2-quinolineimine 9k (d.r. 66:34). In this case, no attempt was made to 
separate the two diastereomers. 
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R N CO2Me
R N
H
CO2Me
9 10
AllylBr (1.5 eq.)
Zn (2 eq.)
CeCl3.7H2O (0,1 eq.)
THF, 0°C
LiAlH4 (2 eq)
THF, 0°C
R N
H
12
OH
 
 
Imine 9, R 10 D.r. c Yield (%) 12 from 10 (yield %)d 
9a, Ph 10a 100:0 86 98 
9b, 4-ClPh 10b >99:1 78 98 
9c, 4-FPh 10c >99:1 80 92 
9d, 4-MeOPh 10d >99:1 87 98 
9e, 3,4,5-(MeO)3Ph 10e >99:1 76 94 
9f, 2-Naphthyl 10f >99:1 91 100 
9g, 2-Furyl 10g >99:1 65 92 
9h, 2-Thienyl 10h >99:1 86 100 
9i, Ferrocenyl 10i >99:1e 80f 100 
9j, 3-Pyridyl 10j >99:1 88 71 
9k, 2-Quinolyl 10k 66:34 95g - 
9l, c-Hx 10l >99:1 79 90 
 
a:The reactions were performed on 5-10 mmol of imine by the Barbier protocol using allylBr (1.5 equiv.), Zn (2 
equiv.), CeCl3-7H2O (0.1 equiv.), THF, 0 °C, 1 h. 
b Reaction conditions: LiAlH4 (2 equiv. vs 10), THF, 10 °C, 1 h.
 
c Determined by GC-MS and 1H NMR analysis of the crude product. 
d Yield of product isolated by flash chromatography. 
e The product was not eluted by GC-MS; an impurity, detected in <5% amount by 1H NMR analysis, could not be 
identified. 
f The pure diastereomer was obtained by crystallization of the crude product from MeOH. 
g No attempt was made to separate the diastereomers. 
 
We previously reported that valine methyl ester is not the best auxiliary for the 
"Grignard" allylation of N,N-bidentate imine; the reaction carried out by the cerium-
catalyzed or other Barbier protocols gave even worse results in terms of 
diastereoselectivity. Instead we found out that O-silyl protected (S)-valinol was an 
excellent and convenient chiral auxiliary for the addition of organolithium, Grignard and 
organozincate reagents to the imines 11.22 In particular, it provided better stereocontrol 
than valine esters for the allylzincation of bidentate imines like those derived from 2-
pyridinealdehyde. Protection of the valinol OH group is opportune, otherwise an excess 
of organometallic reagent, a longer reaction time and higher temperatures are required, 
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consequently a lower diastereoselectivity is often obtained, as we observed, for 
example, in the Zn-mediated Barbier reaction on the benzaldimine 10a.9a  
It should also be noted that the O-silyl protection is easily introduced, as well as easily 
removed to obtain the secondary homoallylic amines 12 by a simple acidic hydrolysis or 
treatment with ammonium fluoride in protic solvent, hence it is more conveniently used 
than the O-methyl or O–benzyl protections reported by other authors.13,18 Moreover, the 
valinol-derived N-substituent can be directly removed from the amine 12 by an oxidative 
cleavage, whereas reduction of the ester group step of the secondary amine 10 is an 
additional step when starting from the imine 9. Hence, we carried out the 
allylmetalation of the 2-quinolineimine 11k using either allylzinc bromide or 
allylmagnesium chloride (Table 2). However, the homoallylic amine 12k was obtained 
with a diasteromeric ratio not exceeding 90:10 after a routine desilylation step, 
markedly differing from the almost complete diastereoselectivity obtained for the 2-
pyridine derivative 12m.22a The prevalent diastereomer was then isolated in a fair yield 
by column chromatography. 
 
R N
OSiMe3
R N
H
OH
1211
1) allylmetal
2) HCl, H2O
 
Imine 11, R Allylmetal 12 D.r.b Yield (%)c 
11k, 2-Quinolyl AllylZnBr 12k 80:20 45 
11k, 2-Quinolyl AllylMgCl 12k 90:10 45 
11m, 2-Pyridyl AllylMgCld 12m 99:1 87 
 
a The reactions were performed on 5-10 mmol of imine; allylmetal (2 equiv.), THF, 78 °C, 3 h. 
b Determined by 1H NMR analysis of the crude product. 
c Yield of the pure prevalent diastereomer isolated by column chromatography 
d Reaction described in ref. 22a. 
 
The diastereomerically pure β-aminoalcohols 12 were then subjected to cleavage of the 
auxiliary group (N-substituent) by an oxidative protocol using aqueous periodic acid in 
the presence of methylamine. The crude primary homoallylic amines were not purified 
but directly converted to N-acryloyl amides 13 by routine procedures using acryloyl 
chloride and different bases: sodium carbonate in acetone (procedure A) or 
triethylamine in dichloromethane with a catalytic amount of 4-dimethylaminopyridine 
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(procedure B). Only in the case of the aliphatic amine 12l the cleavage of the N-
substituent was preferably achieved with lead tetraacetate/hydroxylamine 
hydrochloride and the primary amine was then reacted with acryloyl chloride/sodium 
carbonate/acetone (procedure C). By these two-step procedures the unsaturated amides 
13 were obtained with good overall yields (Table 3). 
 
R N
H
OH
12
R N
H
13
O
Method A or B or C
 
 
Compound 12, R Methoda Product 15 Yield (%)b 
12a, Ph A 15a 74 
12b, 4-ClPh A 15b 75 
12c, 4-FPh A 15c 78 
12d, 4-MeOPh A 15d 87 
12e, 3,4,5-(MeO)3Ph A 15e 77 
12f, 2-Naphthyl A 15f 90 
12g, 2-Furyl B 15g 80 
12h, 2-Thienyl B 15h 67 
12i, Ferrocenyl A 15i 87 
12j, 3-Pyridyl A 15j 70 
12k, 2-Quinolyl B 15k 69 
12l, c-Hx C 15l 62 
12m, 2-Pyridyl B 15m 50 
 
a Method A: 1) H5IO6, MeNH2, MeOH 2) acryloyl chloride, Na2CO3, acetone. Method B: 1) H5IO6, MeNH2, MeOH 2) 
acryloyl chloride, triethylamine, DMAP (cat.). Method C: 1) lead tetraacetate, hydroxylamine hydrochloride 2) acryloyl 
chloride, Na2CO3, acetone.  b  Yield of pure product after column chromatography. 
 
The unsaturated amides 13 were then subjected to the RCM reactions in order to 
prepare the six-membered α,β-unsaturated lactams 14 (Scheme) exploiting the 
commercially available ruthenium benzylidene complexes the so called 1st and 2nd 
generation Grubbs' catalysts I and II, respectively.  
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Ru
PCy
3
Cl
PCy
3
Ph
Cl
Ru
Cl
PCy
3
Ph
NN
Mes Mes
Cl
. .
1st gen. Grubbs' 
catalyst
2nd gen. Grubbs' 
catalyst
 
Preliminary attempts carried out using I were not satisfactory, whereas II generally 
performed well, so the latter catalyst was chosen for the subsequent reactions. The 
results of the metathesis reactions performed on the unsaturated amides 13 are 
reported in the Table. In most cases good results were obtained by working with 5 mol% 
of catalyst in dichloromethane solution at the reflux temperature. Following the 
advancement of the reaction by t.l.c. or 1H-NMR analysis the disappearance of the 
starting compound 13 was observed after 3h. After usual work-up, the expected 
products 14 were isolated in good yields after separation from minor amounts of by-
products by medium pressure column chromatography. However, in the case of pyridyl 
containing substrates, the reaction did not work in the usual conditions. The 3-pyridyl 
derivative 13j could be converted to the corresponding unsaturated lactam 14j in 70% 
yield only in the presence of 2.5 equivalents of trifluoroacetic acid (TFA). However, for 
the 2-quinolyl and 2-pyridyl derivatives 13k and 13m, respectively, even the latter 
conditions did not allow for their satisfactory conversion. Surprisingly, the 2-quinolyl-
substituted lactam 14k was obtained in 40% yield by working in refluxing benzene in the 
absence of TFA. However, the 2-pyridyl-substituted lactam 14m could not be obtained 
from 13m working either in dichloromethane in the presence of TFA or HCl, or in 
benzene in the prescence of TFA. 
It should be observed that the furyl-substituted lactam 14g can be converted to the 
carboxy-substituted analogue 14 (R = CO2H) and then the corresponding ester
13a via 
routine oxidation of the furan ring.22b Similarly, Ni-Raney reduction/desulfurization of 
the thiophene ring23 of 14h would lead to the n-butyl-substituted lactam 14 (R = n-Bu); 
this route should be preferable to the alternative one starting from pentaneimines 9 or 
11 (R = n-Bu), as linear aliphatic aldimines are less easily prepared than aromatic 
imines. 
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R N
H
13
O
R N
H
14
O
Ru
Cl
Cl
PCy3
Ph
NN
Mes Mes
. .
Solvent
 
 
Acryloyl amides  
13 
II 
(mol%) 
Solvent Additive 
(equiv.) 
Lactam Yield (%)b 
13a, Ph 5 DCM  14a 76 
13b, 4-ClPh 5 DCM  14b 72 
13c, 4-FPh 5 DCM  14c 77 
13d, 4-MeOPh 5 DCM  14d 77c 
13e, 3,4,5-(MeO)3Ph 5 DCM  14e 69c 
13f, 2-Naphthyl 5 DCM  14f 80c 
13g, 2-Furyl 5 DCM  14g 60 
13h, 2-Thienyl 5 DCM  14h 62 
13i, Ferrocenyl 5 DCM  14i 78 
13j, 3-Pyridyl 5 DCM  14j 0 
13j, 3-Pyridyl 5 DCM TFA (2.5) 14j 70 
13k, 2-Quinolyl 5 DCM TFA (2.5) 14k 0 
13k, 2-Quinolyl 10 benzene  14k 40d 
13l, c-Hx 5 DCM  14l 82 
13m, 2-Pyridyl 5 DCM TFA (2.5) 14m 0 
13m, 2-Pyridyl 5 DCM HCl (1) 14m 0 
13m, 2-Pyridyl 10 benzene TFA (2.5) 14m 0 
a The reactions were carried out using the Grubbs’ catalyst II for 3 h at the reflux temperature of the solvent. b Yield 
of product purified by column chromatography. c Using 2 mol% of the catalyst incomplete ring closure was observed 
after 3 h. d About 80% conversion of the starting diene was determined by 1H NMR analysis. 
 
The synthetic sequence described for the preparation of aryl-substituted δ-lactams from 
mono-imines was then applied to the synthesis of the C2-symmetric dilactams 21 and 22, 
where the two rings are connected through a 1,3-disubstituted benzene ring or 2,6-
disubstituted pyridine ring.  
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N
1) allylZnBr, 
    THF, -78 °C
2) HCl, H2O
N
N
OTMS
16
HN
N
NH
N
allylBr, Zn, 
CeCl3-7H2O
N
15
HNNH
HNNH
19
O O
THF, 20 °C
1) LiAlH4, THF, 
     0 °C, 89%
HN
N
NH
20
O O
17, 72% 18, 70%
2) H5IO6, MeNH2, MeOH, 
3) CH2=CHCOCl, Na2CO3, 
    acetone, 55%
3) CH2=CHCOCl, 
    Et3N, DMAP, 
    80%
1) H5IO6, 
    MeNH2, 
    MeOH
CO2MeCO2Me
CO2MeCO2Me
TMSO
OHHO
HNNH
21, 75%
O O
HN
N
NH
22, 70%
O O
      II
(5 mol%)
       II
(10 mol%)
TFA (2.5equiv),
CH2Cl2, 40 °C, 3 h
CH2Cl2, 
40 °C, 3 h
 
 
The diimine 15 derived from isophtalaldehyde and (S)-valine methyl ester was allylated 
by the Barbier protocol and gave the expected di-homoallylic amine 17 in good yield and 
with almost complete diastereoselectivity. Reduction of the ester groups to alcohol, 
oxidative cleavage and reaction of the primary amines with acryloyl chloride gave the 
unsaturated diamide 19, then RCM gave the dilactam 21 in satisfactory overall yield. On 
the other hand, the imine 16 was prepared from (S)-valinol, followed by silylation of the 
hydroxyl groups. The Grignard protocol with allylzinc bromide at low temperature, gave 
the di-homoallylic amine 18 with d.r. 96:4 and the pure prevalent diastereomer was 
obtained in 70% yield after chromatography. Removal of the chiral auxiliaries and N,N'-
diacroylation gave the unsaturated diamide 20 with a good overall yield. With our 
surprise, the double RCM reaction in the presence of TFA (2.5 equiv.) was successful for 
this compound using 10 mol% of catalyst, despite the failure previously observed for the 
mono-amide 13m, as we obtained the dilactam 22 in a satisfactory yield. 
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4.3 Conclusions 
 
The stereoselective synthesis of simple δ-substituted α,β unsaturated δ-lactams has been 
accomplished starting from readily available materials: aldehydes, optically pure 
primary amines, allyl halides or allylmetal compounds and acryloyl chloride, which were 
assembled by established methodologies allowing the easy and efficient formation of a 
carbon-nitrogen bond (imine formation) and three carbon-carbon bonds. In particular, 
the highly diastereoselective formation of the C5-C6 bond has been accomplished by two 
alternative protocols for the allylmetalation of chiral imines, which were obtained from 
(S)-valine methyl ester or (S)-valinol. Then, after removal of the N-substituent and N-
acroylation of the primary homoallylic amine, the unsaturated lactam ring was built by a 
ring closing metathesis reaction.  
As noted in the introduction a C5 substituent could be introduced diastereoselectively by 
using a γ-substituted allylmetal reagent, so forming two new stereocenters by combined 
auxiliary-induced and simple diastereoselectivities.  
 
R
N
Aux
HN
R
O
R'
R' MM
HN
O
R
 
 
Moreover, the versatility of this route is further enhanced by the possibility to use the 
unsaturated lactams to construct more substituted/functionalized nitrogen heterocycles 
as the conjugated alkene and amide functions can undergo further transformations. For 
example, nucleophilic conjugate addition and reduction of the lactam carbonyl group 
can be sequentially used to prepare cis- and/or trans-2,4-disubstituted piperidines,24 a 
structural motif that is present in a number of biologically and pharmacologically active 
compounds.25 
 
Experimental section: 
 
The following compounds have been previously described: 9a, 9b 9d,9b 9h,21 9k,22c 10d,9b 
10h,21 10j,9b 12a,9b 12g,22b and 16.22d The preparation of racemic lactams 13a26 and 
14a16c has been previously reported. The novel imines were prepared by the same 
procedures described previously.  
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Barbier Allylation of Imines 9: Zinc dust (1.31 g, 20 mmol) was added in small portions 
to a solution of the imine 9 (10 mmol), allyl bromide (1.8 g, 1.3 ml, 15 mmol) and 
CeCl3.7H2O (0.372 g, 1 mmol) in anhydrous THF (15 mL) at 0 °C, and the mixture was 
then stirred at room temperature. The reactions were monitored by TLC and GC/MS 
analyses and were usually complete within 1.5 h. To the mixture was added: saturated 
aqueous NH4Cl (10 mL) and 40% NH3 (10 ml), and the organic phase was extracted with 
Et2O (2 x 15 mL). The combined ethereal layers were dried over Na2SO4 and 
concentrated at reduced pressure to give an oily residue, which was subjected to flash 
chromatography eluting with cyclohexane/ethyl acetate mixtures. Starting from the 
diimine 15, two-fold amounts of reagents were required. 
 
Reduction of Amino Esters 10 with LiAlH4: A solution of the amino ester 10 (5 mmol) in 
anhydrous THF was added dropwise to a suspension of LiAlH4 (0.380 g, 10 mmol) in THF 
(10 mL), cooled with an ice/NaCl bath. After 1 h, the reaction was quenched with 2.5 M 
NaOH (10 mL) (caution!, very exotermic) and then H2O (10 ml), and the organic phase 
was extracted with Et2O (2 x 15 mL). The combined ethereal layers were dried over 
Na2SO4 and concentrated at reduced pressure to give the products 12, which were used 
as obtained in the successive step. Starting from the diamine 17, two-fold amounts of 
reagents were required. 
 
Organometallic Addition to the Imines 11 and 16: A solution of allyl bromide (1.3 mL, 
1.8 g, 15 mmol,) in anhydrous THF (20 mL) was added dropwise to a stirred suspension 
of zinc dust (1.31 g, 20 mmol) in THF (8 mL). The reaction is exotermic and the rate of 
addition must be controlled to maintain the temperature below 50 °C. After the 
addition was complete, the mixture was stirred for 1 h, then stirring was stopped to 
allow the zinc dust to deposit on the bottom of the flask. The solution was taken with a 
syringe and transferred into an addition funnel, and finally added dropwise to a solution 
of the imine 11 (5 mL) in dry THF cooled at 78 °C. The reaction was monitored by TLC 
and GC-MS analyses and the O-trimethylsilyl amino alcohol was obtained by the usual 
work-up. The crude product was dissolved in Et2O (5 mL) and treated with 1 M HCl (10 
mL) for 1 h, then 2.5 M NaOH was added until pH 11 was reached and the organic 
material was extracted with Et2O (2 x 10 ml). The combined ethereal layers were dried 
over Na2SO4, concentrated at reduced pressure and subjected to flash chromatography 
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eluting with cyclohexane/ethyl acetate mixtures. Starting from the diimine 16, two-fold 
amounts of reagents were required. 
 
Preparation of Propenamides from β-Amino Alcohols. 
Procedure A: The amino alcohol 12a-j (1 mmol) was dissolved in a mixture of MeOH (15 
mL) and THF (5 mL), then 40% aq MeNH2 (12 mL) was added. A solution of H5IO6 (0.800 g, 
3.5 mmol) in H2O (15 mL) was added dropwise while stirring. The reaction was slightly 
exothermic. The reaction is monitored by TLC and GC/MS analyses. When the reaction 
appeared complete (1-3 h), the mixture was concentrated at reduced pressure to 
remove most of the MeOH, and H2O (15 ml) was added. The organic phase was extracted 
with Et2O (2 x 20 mL) and the combined ethereal layers were dried over Na2SO4 and 
concentrated at reduced pressure. The residue was dissolved in acetone and Na2CO3 
(0.372 g, 3 mmol) dissolved in 5 mL of H2O was added. To the vigorously stirred mixture, 
at 0 °C, was added dropwise acryloyl chloride (0.18 g, 163 L, 2 mmol) dissolved in 
acetone (10 mL). The reaction was monitored by TLC and GC/MS analyses, and when it 
appeared complete (ca 2 h) most of the solvent was evaporated at reduced pressure, 
H2O (15 mL) was added and the organic phase was extracted with Et2O (2 x 15 mL). The 
combined ethereal layers were dried over Na2SO4 and concentrated at reduced pressure 
and the residue was subjected to flash-chromatography to give the pure amide 13a-j. 
Compound 19 was similarly obtained from 17 by using two-fold amounts of reagents. 
Procedure B: Cleavage of the N-substituent of 12k,m was conducted as described 
above, then the crude primary amine was dissolved in THF (10 mL), and triethylamine 
(0.15 g, 0.21 mL) and DMAP (0.01 g) were added. To the vigorously stirred mixture at 0 
°C was added dropwise acryloyl chloride (0.13 g, 0.12 mL, 1.5 mmol) dissolved in THF 
(10 mL) and a white precipitate formed immediately. The reaction was monitored by 
TLC and GC/MS analyses. The solvent was removed at reduced pressure and the crude 
product was subjected to flash-cromatography to give the pure amide 13k,m. Compound 
20 was similarly obtained from 18 by using the proper amounts of reagents. 
Procedure C: The amino alcohol 12l (0.63 mmol) was dissolved in a 1:1 MeOH/DCM 
mixture (6 mL), then lead tetraacetate (0.332 g, 0.75 mmol) was added to the stirred 
solution cooled to 0 °C. When TLC analysis showed complete consumption of the starting 
material, hydroxylamine hydrochloride (0.040 g, 6.3 mmol) was added and the mixture 
was vigorously stirred for 3 h. H2O (5 mL) was added and the insoluble material was 
filtered off, then the organic phase was extracted with Et2O (2 x 10 mL). The combined 
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ethereal layers were dried over Na2SO4 and concentrated at reduced pressure to yield 
the crude primary amine, which was converted into the amide 13l as described in 
procedure A.  
 
Preparation of α,β-Unsaturated δ-Lactams: The unsaturated amide (1 mmol) was 
dissolved in anhydrous DCM or C6H6 (5 mL) and TFA (0.29 g, 192 µL, 2.5 mmol) was 
added for compounds 13j,k and 20. The solution was de-aerated by bubbling a stream of 
Ar through it, the Ru-complex II (0.042 g, 0.05 mmol) was added, the solution was again 
de-aerated and heated to reflux. The progress of the reaction was monitored by TLC 
analysis and the disappearance of the starting material was observed within 3 h. The 
solvent was removed at reduced pressure and the residue was subjected to flash-
chromatography. 
 
N
O
OMe
Cl  Methyl N-(4-chlorobenzylidene) (S)-valinate (9b): White solid; 
m.p. 52 °C; [α]D
20 +101.6 (c 0.9, CHCl3); IR (KBr) v = 2957.0, 1736, 1644, 1488, 1386, 
1194, 833. 1H NMR (300 MHz, CDCl3): δ= 8.21 (s, 1 H), , 7.73 (d, J = 8.1, 2 H), 7.39 (dd, J 
= 8.1 Hz, 2 H), 3.75 (s, 3 H), 3.67 (d, J = 7.4 Hz, 1 H), 2.38 (sept, J = 6.9 Hz, 1 H), 0.93 
(d, 3 H, J = 6.9 Hz, 3 H), 0.96 (d, 3 H, J = 6.9 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 
172.2, 161.9, 137.1, 134.1, 129.7, 128.8, 80.2, 52.0, 31.7, 19.5, 18.6. (EI) m/z = 194 
(100), 196 (35), 210 (20), 89 (19), 152 (12), 252 (1, M+). Anal. Calcd for C13H16ClNO2: C, 
61.54; H, 6.36; N, 5.52. Found C, 61.41; H, 6.38; N, 5.50. 
N
O
OMe
F  Methyl N-(4-fluorobenzylidene) (S)-valinate (9c): colourless oil; 
[α]D
20 -107.4 (1.8, CHCl3); IR (neat): v = 2962, 1740, 1644, 1602, 1509, 1231; 
1H NMR (300 
MHz, CDCl3): δ= 8.14 (s, 1 H), 7.71 (dd, J = 5.6 Hz J = 8.4 Hz, 2 H), 7.01 (dd, J = 8.4 Hz, 
J = 6.9 Hz, 2 H), 3.67 (s, 3 H), 3.62 (d, J = 7.2 Hz, 1 H), 2.32 (sept, J = 6.8 Hz, 1 H), 0.89 
(d, 3 H, J = 6.8 Hz, 3 H), 0.86 (d, J = 6.8 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 172.2, 
164.5 (d, J = 251.4 Hz), 161.6, 131.9, 130.4 (d, J = 8.6 Hz), 115.5 (d, J = 21.9 Hz ), 80.0, 
51.78, 31.6, 19.3, 18.5. MS (EI) m/z = 178 (100), 135 (25), 108 (24), 55 (20), 194 (21), 
238 (1, M+ 1). 
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N
O
OMe
MeO
MeO
OMe  Methyl N-(3,4,5-trimethoxybenzylidene) (S)-valinate (9e): 
colourless oil, [α]D
20 -87.8 (c 1.3, CHCl3); IR (neat): v = 3075.3, 2941, 1728, 1641, 1127.; 
1H NMR (300 MHz, CDCl3): δ= 8.15 (s, 1 H), 7.03 (s, 2 H), 3.91 (s, 6 H), 3.88 (s, 3 H), 3.75 
(s, 3 H), 3.63 (d, J = 7.6 Hz, 1 H), 2.37 (sept, J = 6.8 Hz, 1 H), 0.97 (d, J = 6.8 Hz, 3 H), 
0.93 (d, J = 6.8 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 172.4, 162.8, 153.4, 133.6, 131.2, 
105.6, 80.3, 60.9, 56.3, 51.9, 51.8, 31.7, 19.5, 18.7. MS (EI) m/z = 250 (100), 309 (M+, 
50), 206 (44), 192 (21), 294 (8).  
N
O
OMe
 Methyl N-(2-naphthylidene) (S)valinate (9f): pale yellow solid 
m.p. 122-123 °C; [α]D
20 −120.5  (c 0.8, CHCl3). IR (KBr): v = 3051.1, 2951.5, 2869.8, 
1733.8, 1635.2, 1434.4, 1350.2, 1161.9, 972.9 , 1H NMR (200 MHz, CDCl3): δ= 8.41 (s, 1 
H), 8.10 (m, 2 H), 7.89 (m, 3 H), 7.51 (m, 2 H), 3.78 (s, 3 H), 3.74 (d, J = 7.0 Hz, 1 H), 
2.42 (sept, J = 6.8 Hz, 1 H), 1.02 (d, J = 6.8 Hz, 3 H), 0.98 (d, J = 6.8 Hz, 3 H). 13C NMR 
(50 MHz, CDCl3): δ = 172.4, 163.3, 134.8, 133.3, 132.9, 130.4, 128.6, 128.4, 127.8, 
127.3, 126.4, 124.1, 80.5, 51.9, 31.8, 19.5, 18.7. MS (EI) m/z = : 210 (100), 167 (38), 
139 (29), 226 (21), 269 (13, M+). Anal. Calcd for C17H19NO2: C, 75.81; H, 7.11; N, 5.20. 
Found C, 76.00, H, 7.13, N, 5.18. 
O
N
O
OMe
 Methyl N-(2-furylidene) (S)-valinate (9g): pale yellow oil; [α]D
20 -
106.2 (c 1.1, CHCl3); IR (neat) v =3122, 2961, 1740, 1645, 1482, 1262, 1198, 1018. 
1H 
NMR (200 MHz, CDCl3): δ = 7.27 (s, 1 H), 7.56 (d, J = 1,7 Hz, 1 H), 6.86 (d, J = 3.4 Hz, 1 
H), 6.51 (dd, J = 3.4 Hz, J = 1.7 Hz, 1 H), 3.76 (s, 3 H), 3.60 (d, J = 7.7 Hz, 1 H), 2.41 
(sept, J = 6.8 Hz), 0.98 (d, J = 6.8 Hz, 3 H), 0.95 (d, J = 6.8 Hz, 3 H). 13CNMR (75 MHz, 
CDCl3): δ = 171.9, 151.4, 150.8, 144.9, 115.0, 111.5, 80.4, 51.7, 31.4, 19.2, 18.5. MS (EI) 
m/z = 150 (100), 166 (38), 111 (24), 55 (21), 80 (17), 209 (M+, 1). 
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Fe
N
O
OMe
Methyl N-ferrocenylidene (S)-valinate (9i): Red solid, m.p. 88-88.5 
°C; [α]D
20 -2.7 (c 0.37, CHCl3); IR (KBr): v = 2923, 2853, 1736, 1691, 1635, 1461, 1376. 
1H 
NMR (300 MHz, CDCl3): δ = 8.11 (s, 1 H), 4.69 (m, 2 H), 4.38 (d, J = 1.9 Hz, 1 H), 4.36 (d, 
J = 1.9 Hz, 1 H), 4.17 (s, 5 H), 3.72 (s, 3 H), 3.48 (d, J = 7.9 Hz, 1 H), 2.33 (dsept, J = 
7.9 Hz, J = 6.7 Hz, 1 H), 0.95 (d, J = 6.7 Hz, 3 H), 0.93 (d, J = 6.7 Hz, 3 H). 13C NMR (75 
MHz, CDCl3): δ = 172.3, 163.5, 80.9, 79.8, 70.6, 69.5, 69.1, 68.9, 68.4, 51.8, 30.9, 19.5, 
18.7. Anal. Calcd for C17H21FeNO2: C, 62.40; H, 6.47; Fe, 17.07; N, 4.28. Found C, 62.24; 
H, 6.50; Fe, 17.02; N, 4.26. 
N
O
OMe
 Methyl N-cyclohexylidene (S)-valinate (9l) colourless oil, [α]D
20 -
62.8 (c 1.6, CHCl3). IR (neat): v = 2927, 2853, 1739, 1664, 1449, 1196. 
1H NMR (300 MHz, 
CDCl3): δ = 7.43 (d, J = 5.8 Hz, 1 H), 3.73 (s, 3 H), 3.36 (d, J = 7.4 Hz, 1 H), 2.23 (sept, J 
= 6.8 Hz, 1 H), 1.78 (m, 6 H), 1.28 (m, 5 H), 0.89 (d, J = 6.8 Hz, 3 H), 0.85 (d, J = 6.8 
Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ 172.4, 171.7, 80.2, 51.6, 43.4, 31.1, 29.7, 29.4, 
25.7, 25.1, 19.2, 19.0, 18.2. (EI) m/z: 166 (100), 95 (70), 72 (54), 157 (61), 182 (44), 225 
(M+, 5). MS (EI) m/z = 166 (100), 95 (70), 157 (61), 72 (57), 182 (44), 225 (M+, 5). 
NN
OO
OMeM
eO
 (15): Yellowish oil; [α]D
20 -134.6 (c 0.58, CHCl3). IR (neat): v 
= 2962, 2872, 1740, 1643, 1468, 1198, 1027. 1H NMR (200 MHz, CDCl3): δ = 8.27 (s, 2 H), 
7.03 (s, 1 H), 8.01 (s, 1 H), 8.01 (dd, J = 7.7 Hz, J = 1.7 Hz, 2 H), 8.01 (t, J = 7.7 Hz, 1 
H), 3.73 (s, 6 H), 3.63 (d, J = 7.4, Hz, 2 H), 2.37 (sept, J = 6.9 Hz, 2 H), 0.96 (d, J = 6.9 
Hz, 6 H), 0.92 (d, J = 6.9 Hz, 6 H). 13C NMR (50 MHz, CDCl3): δ = 172.2, 162.6, 136.1, 
130.7, 128.9, 128.8, 80.2, 51.9, 31.6, 19.4, 18.6. MS (EI) m/z = 301 (100), 171 (15), 55 
(10), 194 (21), 360 (M+, 4). 
N
H
O
OMe
Cl Methyl N-[1(S)-(4-chlorophenyl)-3-buten-1-yl] (S)-valinate (10b): 
colourless oil; [α]D
20 -118.4 (c 1.1, CHCl3). IR (neat): v = 3077.9, 2961.6, 1732.3, 1640.5, 
1469.6, 1155.4, 994.1 . 1H NMR (300 MHz, CDCl3): δ = 7.27 (m, 5 H), 5.71 (m, 1 H), 5.12 
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(m, 2 H), 3.71 (s, 3 H), 3.47 (dd, J = 8.12 Hz, J = 5.5 Hz, 1 H), 2.72 (d, J = 6.1 Hz, 1 H), 
2.20-2.45 (m, 2 H), 2.00 (bs, 1 H), 1.81 (sept , J = 6.9 Hz, 1 H), 0.89 (d, J = 6.9 Hz, 3 H), 
0.85 (d, J = 6.9 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 175.8, 142.1, 134.8, 134.8, 132.6, 
128.6, 128.4 117.7 , 64.3, 60.1, 51.3, 43.8, 31.6, 19.4, 18.4. MS (EI) m/z = 254 (100), 
194 (58), 72 (48), 165 (42), 125 (40) 55 (31). Anal. Calcd for C16H22ClNO2: C, 64.97; H, 
7.50; N, 4.74. Found C, 64.87; H, 7.53; N, 4.68. 
N
H
O
OMe
F  Methyl N-[1(S)-(4-fluorophenyl)-3-buten-1-yl] (S)-valinate (10c): 
colourless oil; [α]D
20 -100.4 (c 0.96, CHCl3). IR (neat): v = 3077.1, 2962.0, 1735.2, 
1604.4, 1509.0, 1222.0; 1H NMR (300 MHz, CDCl3): δ = 7.27 (dd, J = 5.5 Hz, J = 8.6 Hz, 2 
H), 6.90 (dd, J = 8.6 Hz, J = 8.6 Hz, 2 H), 5.74 (m, 2 H), 3.69 (s, 3 H), 3.49 (dd, J = 5.6 
Hz, J = 7.6 Hz, 1 H), 2.73 (d, J = 6.2 Hz, 1 H), 2.20-2.45 (m, 2 H), 2.01 (bs, 1 H), 1.81 
(m, , 1 H), 0.89 (d, 3 H, J = 6.8 Hz, 3 H), 0.84 (d, J = 6.8 Hz, 3 H). 13C NMR (50 MHz, 
CDCl3): δ = 175.8, 161.9 (d, J = 240 Hz), 139.1 (d, J = 2.2 Hz), 134.9, 128.8 (d, J = 7.6 
Hz), 117.7, 114.9 (d, J = 22.2 Hz), 64.2, 59.9, 51.1, 43.8 31.5, 19.3, 18.3. MS (EI) m/z = 
238 (100), 178 (68), 149 (57), 109 (45), 72 (20). Anal. Calcd for C16H22FNO2: C, 68.79; H, 
7.94; F, 6.80; N, 5.01. Found C, 68.72; H, 7.98; N, 4.99. 
N
H
O
OMe
MeO
OMe
MeO
 Methyl N-[1(S)-(3,4,5-trimethoxyphenyl)-3-buten-1-yl] (S)-
valinate (10e): colourless oil; [α]D
20 -101.3 (c 0.9, CHCl3). IR (neat): v = 2960, 1737 
1585, 1127. 1H NMR (300 MHz, CDCl3): δ = 6.52 (s, 2 H), 5.70 (m, 1 H), 5.08 (m, 2 H), 
3.77 (s, 6 H), 3.75 (s, 3 H), 3.64 (s, 3 H), 3.37 (dd, J = 8.6 Hz, J = 4.4 Hz, 1 H), 2.77 (d, J 
= 5.7 Hz), 2.25-2.45 (m, 2 H), 1.95 (bs, 1 H), 1.77 (sept, J = 7.2 Hz, 1 H), 0.89 (d, J = 7.2 
Hz, 3 H), 0.85 (d, J = 7.2 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 175.8, 152.9, 134.8, 
139.3, 135.0, 117.5, 103.8, 64.0, 60.1, 55.7, 51.0, 43.5, 19.4, 31.5, 19.5, 18.2. MS (EI) 
m/z = 310 (100), 250 (25), 221 (16),190 (11), 55 (10), 211 (4). Anal. Calcd for C19H29NO5: 
C, 64.93; H, 8.32; N, 3.99; O, 22.76. Found C, 64.86; H, 8.35; N, 3.97. 
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N
H
O
OMe
 Methyl N-[1(S)-(2-naphthyl)-3-buten-1-yl] (S)-valinate (10f): 
colourless oil, [α]D
20 -140.6 (c 0.65, CHCl3). IR (neat): v = 3056, 2969, 1733, 1639, 1601, 
1154, 917. 1H NMR (200 MHz, CDCl3): δ = 8.00-7.65 (m, 4 H), 7.6-7.25 (m, 3 H), 5.80 (m, 
1 H), 5.13 (m, 2 H), 3.74 (s, 3 H) 3.70 (dd, J = 8.1 Hz, J = 5.7 Hz, 1 H), 2.83 (d, J = 6.2 
Hz, 1 H), 2.40-2.60 (m, 2 H), 2.12 (bs, 1 H), 1.77 (sept , J = 6.8 Hz, 1 H), 0.94 (d, J = 6.8 
Hz, 3 H), 0.88 (d, J = 6.8 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 176.00, 141.0, 135.1, 
133.3, 132.9, 127.9, 127.7, 127.6, 126.5, 125.8, 125.5, 125.4, 64.3, 60.8, 51.2, 43.6, 
31.7, 19.4, 18.4. MS (EI) m/z = 270 (100), 181 (50),  210 (40), 164 (30), 141 (20). Anal. 
Calcd for C20H25NO2: C, 77.14; H, 8.09; N, 4.50; O, 10.28. Found C, 77.00; H, 8.11; N, 
4.47. 
O
HN
O
MeO  Methyl N-[1(S)-(2-furyl)-3-buten-1-yl] (S)-valinate (10g): colourless oil; 
[α]D
20 -69.5 (c 1.7, CHCl3); IR (neat): v = 3332, 3076, 2961, 2925, 1735, 1604, 1509, 1221, 
1200, 1154, 836. 1H NMR (300 MHz, CDCl3): δ = 7.33 (dd, J = 1.8 Hz, J = 0.9 Hz, 1 H), 
6.28 (dd, J = 3.1 Hz, J = 1.8 Hz, 1 H), 6.15 (dd, J = 3.1 Hz, J = 0.9 Hz, 1 H), 5.73 (m, 1 
H), 5.13 (d, J = 16.7 Hz, J = 1.6 Hz, 1 H), 5.08 (d, J = 9.1 Hz, J = 1.6 Hz, 1 H), 3.7 (s, 3 
H), 3.65 (dd, J = 7.8 Hz, J = 6.0 Hz, 1 H), 2.97 (d, J = 5.6 Hz, 1 H), 2.53 (ddd, J = 13.9 
Hz, J = 6.0 Hz, J = 1.4 Hz, 1 H), 2.43 (ddd, J = 13.9 Hz, J = 7.8 Hz, J = 0.9 Hz, 1 H), 1.92 
(sept, J = 6.8 Hz ,1 H) 0.88 (d, J = 6.8 Hz, 3 H), 0.86 (d, J = 6.8 Hz, 3 H). 13C NMR (50 
MHz, CDCl3): δ = 183.0, 163.0, 175.6, 156.2, 141.6, 134.7, 117.8, 109.9, 106.6, 64.4, 
54.6, 51.4, 40.1, 31.7, 19.2, 18.4. MS (EI) m/z = 96 (100), 55 (73), 150 (62), 151 (8), 162 
(2), 191 (M+, 2). Anal. Calcd for C14H21NO3: C, 66.91; H, 8.42; N, 5.57. Found C, 66.97; H, 
8.45; N, 5.49. 
Fe
N
H
O
OMe
 Methyl N-[1(S)-(ferrocenyl)-3-buten-1-yl] (S)-valinate (10i): red 
crystals; m.p. = 84-84.5 °C; [α]D
20 -34.0 (c 0.4, CHCl3). IR (KBr): v = 3074, 2962, 1736, 
1643, 1445, 1317, 1153, 989, 812.; 1H NMR (300 MHz, CDCl3): δ = 5.87 (m, 1 H), 5.17 (m, 
2 H), 4.14 (s, 5 H), 4.13 (m, 4 H), 3.72 (s, 3 H), 3.36 (dd, J = 3.5 Hz, J = 9.6 Hz 1 H), 
3.31 (d, J = 6.0 Hz), 2.27 (ddd, J = 14.2 Hz, J = 3.5 Hz, J = 1.8 Hz ,1 H), 2.35 (ddd, J = 
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14.2 Hz, J = 9.6 Hz, J = 9.1 Hz ,1 H), 1.6 (bs, 1 H), 0.89 (d, 3H, J = 6.8 Hz, 3 H), 1.83 
(sept, , J = 6.8 Hz, 3 H), 0.89 (d, J = 6.8 Hz, 3 H), 0.86 (d, 3,H, J = 6.8 Hz, 3 H). 13C NMR 
(50 MHz, CDCl3): δ = 175.5, 136.1, 117.3, 91.5, 68.5, 68.3, 67.5, 66.6, 65.9, 63.9, 54.4, 
51.2, 41.7, 31.8, 18.8, 18.5. Anal. Calcd for C20H27FeNO2: C, 65.05; H, 7.37; Fe, 15.12; 
N, 3.79. Found C, 64.45; H,7.40; Fe, 15.10; N, 3.74. 
 
N
H
O
OMe
 Methyl N-[1(S)-cyclohexyl-3-buten-1-yl] (S)-valinate (10l): colourless 
oil, [α]D
20 -18.1 (c 1.3, CHCl3). IR (neat): v = 2929, 1735, 1640, 1592, 1420, 1129, 1012. 
1H NMR (200 MHz, CDCl3): δ = 5.73 (m, 1 H), 5.08 (m, 2 H), 3.70 (s, 3 H), 3.02 (d, J = 6.6 
Hz, 1 H), 2.22 (m, 2 H), 2.1-1.0 (m, 2 H), 0.95 (d, J = 6.6 Hz, 3 H), 0.91 (d, J = 6.6 Hz, 3 
H). 13C NMR (50 MHz, CDCl3): δ = 136.7, 116.6, 61.4, 60.4, 59.6, 40.8, 36.0, 29.2, 29.1, 
28.7, 26.7, 26.6, 19.6, 18.1. MS (EI) m/z = 226 (100), 184 (49), 72 (36), 95 (35), 166 (33), 
208 (22), 266 (M+, 1). Anal. Calcd for C16H29NO2: C, 71.86; H, 10.93; N, 5.24. Found C, 
71.80; H, 10.89; N, 5.20. 
H
N
H
N
OO
OMeMeO
 (17): colourless oil; [α]D
20 -138.2 (c 0.9, CHCl3). IR 
(neat): v = 3076, 2960.8, 1735, 1640, 1468, 1434, 1198, 994. 1H NMR (300 MHz, CDCl3): δ 
= 7.27 (m, 4 H), 5.10 (m, 2 H), 5.08 (m, 2 H), 3.70 (s, 6 H), 3.49 (dd, J = 8.1 Hz, J = 5.7 
Hz, 1 H), 2.78 (d, J = 6.1 Hz, 2 H), 2.25-2.45 (m, 2 H), 2.09 (bs, 1 H), 1.77 (sept , J = 6.7 
Hz, 1 H), 0.90 (d, J = 6.7 Hz, 3 H), 0.85 (d, J = 6.7 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 
176.1, 143.5, 135.3, 127.9, 126.6, 117.4, 62.2, 60.8, 51.2, 43.8, 31.7, 19.5, 18.4. MS (EI) 
m/z = 403 (100), 55 (67), 141 (52),272 (40), 247 (26), 385 (18). Anal. Calcd for 
C26H40N2O4: C, 70.24; H, 9.07; N, 6.30. Found C, 70.28; H, 9.09; N, 6.24. 
H
N
OH
Cl
 N-[1(S)-(4-Chlorophenyl)-3-buten-1-yl] (S)-valinol (12b): 
colourless oil; [α]D
20 -35.5 (c 1.2, CHCl3). IR (neat): v = 3423, 3017, 2958, 1640, 1490, 
1086, 917. 1H NMR (200 MHz, CDCl3): δ = 7.31 (d, J = 8.48 Hz, 2 H), 7.21 (d, J = 8.48 Hz, 
2 H), 5.71 (m, 1 H), 5.05 (m, 2 H) 3.77 (m, 1 H) 3.62 (dd, J = 10.8 Hz, J = 4.12 Hz, 1 H), 
3.41 (dd, J = 10.8 Hz, J = 4.53 Hz ,1 H), 2.42 (m, 2 H), 2.22 (ddd, J = 6.6 Hz, J = 4.12 
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Hz, J = 4.53 Hz 1 H), 1.71 (sept , J = 6.8 Hz, 1 H), 0.89 (d, J = 6.8 Hz, 3 H), 0.84 (d, J = 
6.8 Hz, 3 H). 13 CNMR (50 MHz, CDCl3): δ = 142.5, 134.8, 132.6, 128.4, 61.1, 59.9, 59.4, 
42.7, 29.28, 19.3, 18.9. Anal. Calcd for C15H22ClNO2: C, 67.28; H, 8.28; N, 5.23. Found C, 
67.22; H, 8.31; N, 5.20. 
H
N
OH
F
 N-[1(S)-(4-Fluorophenyl)-3-buten-1-yl] (S)-valinol (12c): colourless 
oil; [α]D
20 -34.2 (c 0.83, CHCl3). IR (neat) v = 3417, 3076, 2957, 1640, 1604, 1509, 1221, 
1048. 1H NMR (300 MHz, CDCl3): δ = 7.24(m, 2 H), 7.02 (m, 2 H), 5.66 (m, 1 H), 5.02 (m, 
2 H), 3.73 (t, J = 8.1 Hz, 1 H), 3.61 (dd, J = 10.8 Hz, J = 4.1 Hz, 1 H), 3.40 (dd, J = 10.8 
Hz, J = 4.5 Hz, 1 H), 2.40 (m, 2 H), 1.67 (sept, J = 6.9 Hz, 1 H), 0.87 (d, J = 6.9 Hz, 3 H), 
0.82 (d, J = 6.9 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 135.1, 128.5 (d, J = 8.1 Hz), 
117.5, 115.2 (d, J = 21.2 Hz), 61.1, 60.04, 59.4, 42.8, 29.4, 19.4, 18.9. Anal. Calcd for 
C15H22FNO: C, 71.68; H, 8.82; N, 5.57. Found C, 71.56; H, 8.85; N, 6.34. 
H
N
OH
MeO
 N-[1(S)-(4-Methoxyphenyl)-3-buten-1-yl] (S)-valinol (12d): 
colourless oil; [α]D
20 -24.8 (c 0.8, CHCl3). IR (neat): v = 3416, 2958, 1611, 1585, 1512, 
1246, 1037. 1H NMR (200 MHz, CDCl3): δ = 7.2 (d, J = 8.6 Hz, 2 H), 6.86 (d, J = 8.6 Hz, 2 
H) 5.68 (m, 1 H), 5.15 (d, J = 10.6 Hz, J = 1.3 Hz, 1 H), 5.05 (d, J = 8.6 Hz, J = 1.3 Hz, 1 
H), 3.83 (s, 6 H), 3.71 (dd, J = 17.6  Hz, J = 8.6 Hz, 1 H), 3.62 (dd, J = 10.6 Hz, J = 4.4 
Hz, 1 H), 3.37 (dd, J = 10.6 Hz, J = 4.0 Hz, 1 H), 2.36 (m, 2 H), 2.27 (dd, J = 4.4 Hz, J = 
4.0 Hz, 1 H), 1.71 (sept , J = 6.8 Hz, 1 H), 0.87 (d, J = 6.8 Hz, 3 H), 0.83 (d, J = 6.8 Hz, 3 
H). 13C NMR (50 MHz, CDCl3): δ = 159.9, 136.0, 127.9, 117.1, 113.7, 61.0, 59.9, 59.4, 
55.2, 42.7, 41.1, 29.4, 19.4, 18.9. Anal. Calcd for C16H25NO2: C, 72.96; H, 9.57; N, 5.32. 
Found C, 72.99; H, 8.59; N, 5.28. 
H
N
OH
MeO
MeO
OMe
 N-[1(S)-(3,4,5-Trimethoxyphenyl)-3-buten-1-yl] (S)-valinol (12e): 
colourless oil; [α]D
20 −29.6 (c 0.88, CHCl3). IR (neat): v = 3439, 2955, 1639,1592, 1436, 
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1325, 1232, 1009. 1H NMR (200 MHz, CDCl3): δ = 6.48 (s, 2 H), 5.72 (m, 1 H), 5.05 (m, 2 
H) 3.83(s, 6 H), 3.82 (s, 3 H), 3.71 (dd, J = 6.4 Hz, J = 6.2 Hz, 1 H) 3.60 (dd, J = 10.7 Hz, 
J = 4.31 Hz, 1 H), 3.40 (dd, J = 10.7 Hz, J = 4.22 Hz, 1 H), 2.36 (dd, J = 6.7 Hz, J = 6.6 
Hz, 1 H), 2.12 (m, 1 H), 1.68 (sept , J = 6.8 Hz, 1 H), 0.89 (d, 3 H, J = 6.8 Hz, 3 H), 0.83 
(d, J = 6.8 Hz, 3 H). 13C NMR (50 MHz, CDCl3): δ = 153.0, 139.9, 136.7, 135.3, 117.3, 
103.7, 60.9, 60.7, 60.1, 59.8, 56.0, 42.9, 29.3, 19.4, 19.0. Anal. Calcd for C18H29NO4: C, 
66.84; H, 9.04; N, 4.33. Found C, 66.88; H, 9.02; N, 4.35. 
H
N
OH
 N-[1(S)-(2-Naphthyl)-3-buten-1-yl] (S)-valinol (12f): colourless oil; 
[α]D
20 -34.8 (c 0.95, CHCl3). IR (neat): v = 3396, 3056, 2957, 1639, 1507, 1466, 1048. 
1H 
NMR (300 MHz, CDCl3): δ = 7.85 (m, 3 H), 7.70 (s, 1 H), 7.5 (m, 3 H), 5.75 (m, 1 H), 5.08 
(m, 2 H), 3.92 (dd, J = 6.7 Hz, J = 6.9 Hz, 1 H), 3.69 (dd, J = 10.8 Hz, J = 4.1 Hz, 1 H), 
3.69 (dd, J = 10.8 Hz, J = 4.5 Hz, 1 H), 2.55 (m, 2 H), 2.30 (ddd, J = 6.6 Hz, J = 4.13, J = 
4.42 Hz  1 H), 1.74 (sept, J = 6.7 Hz, 1 H), 0.90 (d, J = 6.7 Hz, 3 H), 0.84 (d, J = 6.7 Hz, 
3 H). 13C NMR (75 MHz, CDCl3): δ = 141.2, 135.2, 133.2, 132.8, 128.2, 127.7, 127.6, 
126.1, 126.0, 126.6, 124.7, 117.3, 61.0, 60.1, 59.8, 42.6, 29.3, 19.5, 18.9. Anal. Calcd 
for C19H25NO: C, 80.52; H, 8.89; N, 4.94; O, 5.65. Found C, 8.41; H, 8.93; N, 4.90. 
H
N
S OH
 N-[1(S)-(2-Thienyl)-3-buten-1-yl] (S)-valinol (12h): colourless oil; [α]D
20 -
37.2 (c 1.1, CHCl3) IR (neat): v = 3390, 3075, 2957, 1641, 1464, 1039, 918. 
1H NMR (300 
MHz, CDCl3): δ = 7.21 (m,1 H), 6.92 (m, 2 H), 5.76 (m, 1 H), 5.11 (m, 2 H), 4.06 (t, J = 
6.9 Hz, 1 H), 3.61 (dd, J = 10.9 Hz, J = 4.1 Hz, 1 H), 3.45 (dd, J = 10.9 Hz, J = 4.3 Hz, 1 
H), 2.54 (m, 2 H), 1.73 (sept, J = 7.0 Hz, 1 H), 0.89 (d, J = 7.0 Hz, 3 H), 0.86 (d, J = 7.0 
Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 18.6, 134.8, 126.1, 124.1, 123.7, 117.5, 61.0, 
59.9, 55.5, 43.3, 26.3, 16.3, 18.8. Anal. Calcd for C13H21NOS: 65.23; H, 8.84; N, 5.85; S, 
13.40. Found C, 65.17; H, 8.81; N, 5.81; S, 13.36. 
Fe
N
H
OH
 N-[1(S)-(Ferrocenyl)-3-buten-1-yl] (S)-valinol (12i): red oil; [α]D
20 +37.0 
(c 0.58, CHCl3). IR (neat): v = 3482, 3093, 2957, 1639, 1437, 1106. 
1H NMR (200 MHz, 
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CDCl3): δ = 5.86 (m, 1 H,), 5.09 (m, 2 H), 4.16 (s, 5 H), 4.11 (m, 4 H), 3.57 (dd, J = 10.5 
Hz, J =  4.8 Hz, 1 H), 3.57 (dd, J = 10.5 Hz, J =  6.3 Hz, 1 H), 3.49 (dd, J = 7.1 Hz, J = 
5.3 Hz, 1 H), 3.33  (dd, J = 10.5 Hz, J = 8.5 Hz, 1 H), 2.56 (m, 1 H), 2.40 (m, 2 H), 1.80 
(sept, 1 H, J = 6.8 Hz, 1 H),  0.91 (d, J = 6.8 Hz, 1 H), 0.91 (d, J = 6.8 Hz, 1 H). 13C NMR 
(50 MHz, CDCl3): δ = 136.0, 116.8, 92.8, 68.3, 67.4, 67.0, 66.8, 66.0, 61.0, 60.3, 54.2, 
41,0, 29.4, 19.9, 18.1. Anal. Calcd for C21H32FeNO: C, 68.11; H, 8.71; Fe, 15.08; N, 3.78. 
Found C, 68.02; H, 8.73; Fe, 15.05; N, 3.76. 
N
H
N
OH
 (S)-2-[(S)-1-(3-pyridyl)-3-butenylamino]-3-methyl-1-butanol 
(12j): yellowish oil; [α]D
20 
 -58.8 (c 2.0, CHCl3). IR (neat): v = 3373, 3078, 2957, 2926, 
2872, 1640, 1593, 1579, 1467, 1429, 1384, 1029, 918, 809, 716. 1H NMR (300 MHz, 
CDCl3): δ = 8.46 (m, 2 H), 7.02 (m, 2 H), 7.67 (dt, J = 2.0 Hz, J = 7.9 Hz, 1 H), 7.26 (ddd, 
J = 0.8 Hz, J = 4.7 Hz, J = 7.8 Hz, 1 H), 5.67 (m, 1 H), 5.04 (m, 2 H),  3.82 (t, J = 6.9 Hz, 
1 H), 3.64 (dd, J = 4.3 Hz, J = 11.0 Hz, 1 H), 3.47 (dd, J = 4.6 Hz, J = 11.0 Hz, 1 H), 2.41 
(m, 2 H), 2.17 (dd, J = 4.3 Hz, J = 4.6 Hz, 1 H),1.68 (sept, J = 6.9 Hz, 1 H), 0.85 (d, J = 
6.9 Hz, 3 H), 0.79 (d, J = 6.9 Hz, 3 H). 13C NMR (75 MHz, CDCl3): δ = 150.0, 148.4, 139.5, 
134.8, 134.4, 123.4, 118.0, 61.2, 60.1, 57.5, 42.7, 29.2, 19.1, 18.9. GC-MS (EI) m/z = 
193 (100), 132 (78), 107 (75), 130 (48), 117 (39), 203 (38), 92 (21). Anal. Calcd for 
C14H22N2O: C, 71.76; H, 9.46; N, 11.95. Found C, 71.50; H, 9.49; N, 11.91. 
H
N
OHN
 N-[1(S)-(2-Quinolyl)-3-buten-1-yl] (S)-valinol: (12k): yellow oil [α]D
20 -
52.2 (c 0.25, CHCl3). IR (neat): v = 3313, 2960, 1640, 1599, 1082, 837. 
1H NMR (300 MHz, 
CDCl3): δ = 8.14 (d, J = 8.4 Hz, 1 H), 8.02 (d, J = 8.2 Hz, 1 H), 7.83 (d, J = 8.1 Hz, 1 H), 
7.83 (ddd, J = 8.6 Hz, J = 6.9 Hz,  J = 1.5 Hz, 1 H), 7.54 (ddd, J = 8.1 Hz, J = 6.9 Hz, J = 
1.1 Hz, 1 H), 7.44  (d, J = 8.6 Hz, 1 H), 5.86 (m, 1 H), 5.11 (m, 2 H), 4.08 (dd, J = 7.3 
Hz, J = 5.9 Hz, 1 H), 3.71 (dd, J = 10.9 Hz, J = 4.1 Hz), 3.47 (dd, J = 10.9 Hz, J = 4.8 
Hz), 2.61 (m, 2 H), 2.28 (ddd, J = 6.3 Hz, J = 4.8 Hz, J = 4.4 Hz ,1 H), 1.72 (sept, J = 6.9 
Hz, 1 H), 0.91 (d, J = 6.9 Hz, 3 H), 0.82 (d, J = 6.9 Hz, 3H ). 13C NMR (75 MHz, CDCl3): δ = 
163.6, 147.5, 136.2, 135.1, 129.4, 128.9, 127.5, 127.3, 126.0, 120.1, 117.7, 62.8, 61.6, 
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60.2, 42.1, 29.3, 19.5, 18.8. Anal. Calcd for C18H24N2O: C, 76.02; H, 8.51; N, 9.85. Found 
C, 76.08; H, 8.54; N, 9.81. 
H
N
OH
 N-[1(S)-Cyclohexyl-3-buten-1-yl] (S)-valinol (12l): colourless oil; [α]D
20 
+25.5 (c 0.73, CHCl3). IR (neat): v = 3405, 2924, 1639, 1449, 1053. 
1H NMR (300 MHz, 
CDCl3): δ = 5.82 (m, 1 H), 5.06 (m, 2 H), 3.52 (dd, J = 10.6 Hz, J = 4.2 Hz, 1 H), 3.29 (dd, 
J = 10.8 Hz J = 6.3 H, 1 H), 2.1 (m, 1 H ) 2.05 (m, 1 H), 1.9-1.1 (m, 12 H) ,0.95 (d, J = 
7.0 Hz, 3 H), 0.89 (d, J = 7.0 Hz, 3 H). 13CNMR (50 MHz, CDCl3): δ = 136.7, 116.6, 61.4, 
60.4, 59.6, 40.7, 36.0, 29.2, 29.1, 28.7, 26.7, 26.6, 16.6, 18.1. MS (EI) m/z 198 (100), 55 
(60), 95 (50), 67 (49), 156 (48), 180 (32), 208 (29), 238 (M+  1, 2). Anal. Calcd for 
C15H29NO: C, 75.26; H, 12.21; N, 5.85. Found C, 74.06; H, 12.23; N, 5.83. 
H
N
H
N
OHOH
 1,3-Di[(1S)-(1)-[(2S)-1-hydroxy-3-methylbutan-2-yl]amino-3-
buten-1-yl]benzene: by reduction of 17 with LiAlH4; colourless oil; [α]D
20 -25.8 (c 0.31, 
CHCl3). IR (neat): v = 3384, 3076, 2926, 1639.8, 1465, 1046. 
1H NMR (200 MHz, CDCl3): δ 
= 7.20 (m, 4 H), 5.68 (m, 2 H), 5.04 (m, H), 3.71 (dd, J = 6.9 Hz, J = 6.9 Hz, 2 H), 3.61 
(dd, J = 11.1 Hz, J = 4.1 Hz, 2 H), 3.37 (dd, J = 11.4 Hz. J = 4.1 Hz, 2 H), 2.78 (bs, 2 H), 
2.46 (m, 4 H), 2.30 (ddd, J = 6.7 Hz, J = 4.1 Hz, J = 3.9 Hz, 2 H), 1.68 (sept , J = 6.9 Hz, 
2 H), 0.85 (d, J = 6.9 Hz, 6 H), 0.81 (d, J = 6.9 Hz, 6 H). 13C NMR (50 MHz, CDCl3): δ = 
144.0, 135.2, 128.1, 126.0, 125.4, 117.0, 61.0, 56.0, 59.6, 42.7, 29.1, 19.2, 18.8. MS (EI) 
m/z 347 (100), 141 (95), 244 (90), 158 (68), 55 (60), 357 (22). Anal. Calcd for C24H40N2O2: 
C, 74.18; H, 10.38; N, 7.21. Found C, 74.20; H, 10.40; N, 7.18. 
N
H
N
H
N
OHOH
 2,6-Di[(1S)-(1)-[(2S)-1-hydroxy-3-methylbutan-2-yl]amino-3-
buten-1-yl]pyridine (18): colourless oil; [α]D
20 -60.0 (c 0.86, CHCl3). IR (neat): v = 3346, 
3076, 2959, 1640, 1591, 1448, 1048. 1H NMR (300 MHz, CDCl3): δ = 7.56 (t, J = 7.3 Hz, 1 
H), 7.05 (d, J = 7.3 Hz, 2 H), 5.79 (m, 2 H), 5.02 (m, 4 H), 3.79 (dd, J = 7.1 Hz, J = 6.6 
Hz, 2 H), 3.61 (dd, J = 10.8 Hz  J = 4.1 Hz, 2 H), 3.61 (dd, J = 10.8 Hz, J = 4.4 Hz, 2 H), 
2.76 (bs, 2 H), 2.46 (m, 4 H), 2.30 (ddd, J = 6.5 Hz, J = 4.4 Hz, J = 4.1 Hz, 2 H), 1.74 
(sept, J = 6.8 Hz, 2 H,), 0.83 (d, J = 6.8 Hz, 6 H), 0.79 (d, J = 6.8 Hz, 6 H). 13C NMR (75 
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MHz, CDCl3): δ = 162.4, 136.3, 135.3, 120.9, 117.3, 62.5, 61.3, 59.9, 42.0, 29.5, 19.6, 
18.8. Anal. Calcd for C23H39N3O2: C, 70.91; H, 10.09; N, 10.79. Found C, 70.95; H, 10.11; 
N, 10.77. 
H
N
O
 (S)-N-(1-Phenyl-3-buten-1-yl) Propenamide (13a): white solid; m.p. 86-
86.5 °C; [α]D
20 -132.1 (c 0.5, CHCl3). IR (KBr); v = 3258, 3071, 1651, 1627, 1584, 1414, 
1247, 922. 1H NMR (200 MHz, CDCl3): δ = 7.32 (m, 5 H), 6.31 (dd, J = 17.2 Hz, J = 1.9 Hz, 
1 H), 6.12 (dd, J = 17.2 Hz, J = 9.8 Hz, 1 H), 5.96 (bs, 1 H), 5.72 (m, 1 H), 5.65 (dd, J = 
9.8 Hz, J = 1.9 Hz, 1 H), 5.14 (m, 3 H), 2.63 (m, 2 H). 13CNMR (75 MHz, CDCl3): δ = 164.8, 
141.4, 133.9, 130.8, 128.6, 127.3, 126.6, 126.5, 118.2, 52.5, 40.3. MS (EI) m/z = 106 
(100), 160 (90), 55 (29), 77 (13), 161 (10), 201 (M+, 2). Anal. Calcd for C13H15NO: C, 
77.58; H, 7.51; N, 6.96. Found C, 77.42; H, 7.54; N, 6.93. 
H
N
O
Cl
 (S)-N-[1-(4-Chlorophenyl)-3-buten-1-yl) Propenamide (13b): white 
solid; m.p. 125-126 °C; [α]D
20 -113.4 (c 0.48, CHCl3). IR (KBr): v = 3294, 1658, 1631, 
1545, 1406, 1296, 824. 1H NMR (200 MHz, CDCl3): δ = 7.27 (d, J = 8.6 Hz, 2 H), 7.20 (d, J 
= 8.6 Hz, 2 H), 6.24 (dd, J = 16.9 Hz, J =  2.0 Hz, 1 H), 6.13 (dd, J = 16.9 Hz, J = 9.8 Hz, 
1 H), 6.01 (d, J = 7.2 Hz, 1 H), 5.71 (m, 1 H), 5.59 (dd, J = 9.8 Hz, J = 2.0 Hz, 1 H), 5.07 
(m, 3 H), 2.53 (d, J = 7.1 Hz, 1 H), 2.50 (d, J = 6.7 Hz, 1 H). 13C NMR (75 MHz, CDCl3): δ 
= 164.9, 140.2, 133.5, 132.8, 130.5, 128.9, 128.5, 127.8, 126.6, 118.3, 52.1, 40.1. MS 
(EI) m/z = 140 (100), 194 (85), 55 (80), 142 (40), 196 (35), 129 (30), 235 (M+, 2). Anal. 
Calcd for C13H14ClNO: C, 66.24; H, 5.99; N, 5.94. Found C, 66.18; H, 6.00; N, 5.92. 
H
N
O
F
 (S)-N-[1-(4-Fluorophenyl)-3-buten-1-yl) Propenamide (13c): white solid; 
m.p. 83-83.5 °C; [α]D
20 - 98.1 (c 0.88, CHCl3). IR (Nujol): v = 3292, 3076.0, 1656, 1628, 
1546, 1226. 1H NMR (300 MHz, CDCl3): δ = 7.27 (dd, J = 8.7 Hz, J = 6.0 Hz, 2 H), 7.01 (t, 
J = 8.7 Hz, 2 H), 6.01 (d, J = 7.2 Hz, 1 H), 6.28 (dd, J = 17.1 Hz, J = 1.8 Hz 1 H), 6.14 
(dd, J = 17.1 Hz, J = 9.9 Hz, 1 H), 5.69 (m, 1 H), 5.63 (dd, J = 9.9  Hz, J = 1.8 Hz, 1 H), 
5.13 (m, 3 H), 2.57 (t, J = 6.9 Hz, 2 H). 13C NMR (75 MHz, CDCl3): δ = 164.9, 161.8 (d, J = 
227.1 Hz), 137.4, 133.7, 130.1, 128.1 (d, J = 6.8 Hz), 126.6, 118.2, 115.2 (d, J = 22.0 
 - 71 - 
Hz), 52.1, 40.3. MS (EI) m/z = 124 (100), 55 (93), 178 (70), 120 (20), 95 (15), 219 (M+, 2). 
Anal. Calcd for C13H14FNO: C, 71.21; H, 6.44; N, 6.39. Found C, 70.10; H, 6.45; N, 6.37. 
H
N
O
MeO
(S)-N-[1-(4-Methoxyphenyl)-3-buten-1-yl) l Propenamide (13d): white 
solid: m.p. 124-125 °C. [α]D
20 -130.1 (c 0.83, CHCl3). IR (KBr): v = 3318, 2958, 1656, 
1625.9, 1528, 1250. 1H NMR (300 MHz, CDCl3): δ = 7.22 (d, J = 9.0 Hz, 2 H), 6.85 (d, J = 
9.0 Hz, H), 7.26 (dd, J = 17.0 Hz, J = 1.8 Hz, 1 H), 6.19 (dd, J = 17.0 Hz, J = 10.2 Hz, 1 
H), 6.01 (d, J = 7.2 Hz, 1 H), 5.69 (m, 1 H), 5.64 (dd, J = 10.2 Hz, J = 1.8 Hz, 1 H), 5.01 
(m, 3 H), 3.78 (s, 3 H), 2.58 (m, 2 H). 13C NMR (50 MHz, CDCl3): δ = 164.7, 158.7, 134.1, 
133.6, 130.8, 127.7, 126.4, 117.9, 113.9, 55.2, 52.0, 40.2. MS (EI) m/z  136 (100), 190 
(80), 55 (20), 137 (15), 191 (10), 231 (M+, 2). Anal. Calcd for C14H17NO2: C, 72.70; H, 
7.41; N, 6.06. Found C, 72.52; H, 7.43; N, 6.04. 
H
N
O
MeO
OMe
MeO
 (S)-N-[1-(3,4,5-Trimethoxyphenyl)-3-buten-1-yl) Propenamide (13e): 
white solid; m.p. 100-100.5 °C; [α]D
20 -103.5 (c 0.53, CHCl3). IR (KBr): v = 3304, 3063, 
2945, 1655, 1592, 1465, 1236, 1001. 1H NMR (200 MHz, CDCl3): δ = 6.51 (s, 1 H), 6.30 
(dd, J = 16.8 Hz, J = 1.9 Hz, 1 H), 6.11 (dd, J = 16.8 Hz, J = 9.7 Hz, 1 H), 5.74 (m, 1 H), 
5.64 (dd, J = 9.7 Hz, J = 1.9 Hz 1 H), 5.11 (m, 3 H), 3.83 (s, 3 H), 3.82 (s, 6 H), 2.58 (dd, 
J = 7.0 Hz, J = 6.1 Hz, 2 H). 13C NMR (50 MHz, CDCl3) δ  = 164.7, 153.0, 137.4, 136.9, 
133.9, 130.7, 126.3, 117.8, 103.5, 60.5, 55.8, 52.8, 40.2. MS (EI) m/z = 196 (100), 55 
(85), 250 (75), 154 (10), 291 (M+, 5). Anal. Calcd for C16H21NO4: C, 65.96; H, 7.27; N, 
4.81; O, 21.97. Found C, 66.02; H, 7.29; N, 4.80. 
H
N
O
(S)-N-[1-(2-Naphthyl)-3-buten-1-yl) Propenamide (13f): pale yellow solid; 
m.p. 108-108.5 °C; [α]D
20 -169.3 (c 0.51, CHCl3). IR (KBr): v = 3448, 3326, 1652, 1622, 
1522, 1349, 1242. 1H NMR (300 MHz, CDCl3): δ = 7.83 (m, ,4 H), 7.45 (m ,H), 6.32 (dd, J 
= 17.1 Hz, J = 1.8 Hz, 1H), 6.17 (dd, J = 17.1 Hz, J = 11.7 Hz, 1 H), 5.74 (m, 1 H), 5.66 
(dd, J = 11.7 Hz, J = 1.8 Hz, 1 H), 5.35 (dd, J = 11.7 Hz, J = 1.8 Hz, 1 H), 5.14 (m, 2 H), 
2.72 (t, J = 6.9 Hz, 2 H). 13 CNMR (50 MHz, CDCl3): δ = 164.9, 150.9, 138.8, 133.2, 132.6, 
130.7, 128.3, 127.8, 127.5, 126.6, 126.1, 125.8, 125.1, 124.7, 52.7, 40.1. MS (EI) m/z = 
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156 (100), 210 (80), 55 (55), 179 (25), 127 (21), 251 (M+, 4). Anal. Calcd for C16H21NO4: C, 
65.96; H, 7.27; N, 4.81; O, 21.97. Found C, 66.02; H, 7.29; N, 4.80. 
N
H
O
O  (S)-N-[1-(2-Furyl)-3-buten-1-yl) Propenamide (13g): yellow oil; [α]D
20 -
124.3 (c 0.89, CHCl3). IR (KBr): v = 3276, 3077, 1655, 1542, 1408, 1246, 920. 
1H NMR (300 
MHz, CDCl3): δ = 7.36 (dd, J = 1.8, J = 0.9 Hz, 1 H), 6.31 (dd, J = 16.9 Hz, J = 1.5 Hz, 
1H), 6.33 (dd, J = 3.2, J = 1.9 Hz, 1 H), 6.20 (dd, J = 3.2, J = 0.9 Hz, 1 H), 6.11 (dd, J = 
16.9 Hz, J = 10.0 Hz, 1 H), 5.86 (bs, 1 H), 5.73 (m, 1 H), 5.67 (dd, J = 16.9 Hz, J = 10.0 
Hz, 1 H), 5.30 (dt, J = 8.5 Hz, J = 6.5 Hz, 1 H), 5.12 (m, 2 H), 2.63 (t, J = 6.5 Hz, 1 H). 
13C NMR (75 MHz, CDCl3): δ = 164.6, 153.7, 141.7, 133.4, 130.1, 126.6, 118.2, 110.1, 
106.4, 46.6, 38.0. MS (EI) m/z = 96 (100), 55 (80), 150 (60), 91 (18 ), 191 (M+, 2). Anal. 
Calcd for C11H13NO2: C, 69.09; H, 6.85; N, 7.32. Found C, 70.06; H, 6.87; N, 7.29. 
N
H
O
S  (S)-N-[1-(2-Thienyl)-3-buten-1-yl) Propenamide (13h): white solid; m.p. 75-
75.5 °C; [α]D
20 -144.3 (c 0.3, CHCl3). IR (neat): v = 3249, 1652, 1629.0, 1545, 1438, 1414, 
1250. 1H NMR (200MHz, CDCl3): δ = 7.21 (dd, J = 4.7, J = 1.6 Hz, 1 H), 6.96 (m, 2 H), 6.31 
(dd, J = 17.0 Hz, J = 2.0 Hz, 1 H), 6.12 (dd, J = 17.0 Hz, J = 10.0 Hz, 1 H), 5.77 (m, 1 H), 
5.65 (dd, J = 17.0 Hz, J = 10.0 Hz, 1 H), 5.48 (dt, J = 8.2 Hz, J = 6.8 Hz, 1 H), 5.14 (m, 2 
H), 2.67 (t, J = 6.8 Hz, 1 H). 13C NMR (50 MHz, CDCl3): δ= 164.6, 145.1, 133.5, 130.6, 
126.9, 126.8, 124.5, 124.3, 118.6, 48.2, 40.6. MS (EI) m/z = 112 (100), 55 (82), 166 (80), 
135 (33), 91 (17), (M+ 1, 1). Anal. Calcd for C11H13NOS: C, 63.74; H, 6.32; N, 6.76; S, 
15.47. Found C, 62.24; H, 6.30; N, 6.74; S, 15.42. 
Fe
N
H
O
(S)-N-(1-Ferrocenyl-3-buten-1-yl) Propenamide (13i): yellow powder: m.p. 
113-114 °C; [α]D
20 +33.2 (c 0.46, CHCl3). IR (KBr): v = 3282, 1655, 1626, 1542, 1408, 
1104. 1H NMR (200 MHz, CDCl3): δ = 6.33 (dd, J = 17.2 Hz, J = 1.8 Hz 1 H), 6.15 (dd, J = 
17.2 Hz, J = 10.0 Hz, 1 H), 5.82 (m, 1 H), 5.68 (dd, J = 10.0 Hz, J = 1.8 Hz, 1 H),. 5.10 
(m, 3 H), 4.17 (s, 5 H), 4.16 (m, 4 H) 3.96 (m, 1 H), 2.67 (ddd, J = 14.4 Hz, J = 4.7 Hz, J 
= 2.4 Hz, 1 H), 2.45 (ddd, J = 14.4 Hz, J = 7.2 Hz, J = 1.1 Hz, 1 H). 13C NMR (50 MHz, 
CDCl3): δ = 164.4, 134.4, 130.9, 126.3, 117.4, 90.1, 68.5, 67.7, 67.4, 66.5, 47.4, 40.3. 
MS (EI) m/z = 214 (100), 309 (M+, 95), 121 (90), 116 (80), 238 (71), 56 (69), 268 (68). 
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Anal. Calcd for C19H24FeNO: C, 67.47; H, 7.15; Fe, 16.51; N, 4.14. Found C, 67.13; H, 
7.16; Fe, 16.46; N, 4.12. 
N
H
O
N  (S)-N-[1-(3-Pyridyl)-3-buten-1-yl) Propenamide (13j): white solid; m.p. 66-
66.5 °C; [α]D
20 −99.0 (c 0.44, CHCl3). IR (KBr): v = 3302, 3051, 1655, 1629, 1542, 1411, 
1242. 1H NMR (300 MHz, CDCl3): δ = 8.64 (s, 1 H), 8.53 (d, J = 5.1 Hz, 1 H), 7.32 (dd, J = 
8.1 Hz, J = 5.1 Hz, 1 H), 6.31 (dd, J = 16.9 Hz, J = 1.6 Hz, 1 H), 6.14 (dd, J = 16.9 Hz, J = 
10.1 Hz, 1 H), 5.70 (m, 1 H), 5.69 (dd, J = 10.1 Hz, J = 1.6 Hz, 1 H), 5.17 (m, 3 H), 2.64 
(m, 2 H). 13C NMR (50 MHz, CDCl3): δ =:165.2, 147.9, 137.5, 134.5, 133.2, 130.4, 126.3, 
123.2, 118.1, 118.1, 50.7, 39.7. MS (EI) m/z = 107 (100), 161 (77), 55 (50), 130 (28), 147 
(15), 79 (14), 201 (M+  1, 1). Anal. Calcd for C12H14N2O: C, 71.26; H, 6.98; N, 13.85. 
Found C, 71.38; H, 7.00; N, 13.80. 
N
H
N
O
(S)-N-[1-(2-Quinolyl)-3-buten-1-yl) Propenamide (13k): light yellow solid; 
m.p. 105-105.5 °C; [α]D
20 - 137.2 (c 0.23, CHCl3). IR (KBr): v = 3284, 1655, 1626, 1541, 
1408, 1243. 1H NMR (300 MHz, CDCl3): δ = 8.15 (d, J = 8.4 Hz, 1 H), 8.10 (d, J = 8.4 Hz, 1 
H) , 7.84  (d, J = 8.1 Hz, 1 H), 7.74 (dd, J = 8.4 Hz, J = 1.4 Hz, 1 H), 7.56 (dd, J = 8.1 Hz, 
J = 1.4 Hz, 1 H), 7.50 (d, J = 6.7 Hz, 1 H), 7.37 (d, J = 8.4 Hz, 1 H), 6.35 (m, 2 H), ), 
5.73 (m, 1 H), 5.70 (dd, J = 9.0 Hz, J = 2.7 Hz, 1 H), 5.43 (m, 1 H), 5.03 (d, J = 6.7 Hz, 2 
H), 2.85 (dd, J = 15.8 Hz, J = 6.7 Hz, 1 H), 2.75 (dd, J = 15.8 Hz, J = 6.7 Hz, 1 H). 13C 
NMR (50 MHz, CDCl3): δ = 164.2, 159.1, 147.2, 136.1, 132.6, 130.5, 129.0, 128.3, 127.0, 
125.7, 119.6, 117.7, 53.0, 39.7. MS (EI) m/z = 15 (100), 211 (66), 55 (38), 129 (28), 180 
(23), 197 (18), 252 (M+, 6). Anal. Calcd for C16H16N2O: C, 76.16; H, 6.39; N, 11.10. Found 
C, 76.31; H, 6.41; N, 11.07.  
N
H
O
(S)-N-(1Cyclohexyl-3-buten-1-yl) Propenamide (13l): white powder; m.p. 
135-136 °C. [α]D
20 +197.7 (c 0.48, CHCl3). IR (KBr): v = 3274, 3076, 2916, 1656, 1626, 
1559, 1251. 1H NMR (200 MHz, CDCl3): δ = 6.27 (dd, J = 16.9 Hz, J =  2.1 Hz, 1 H), 6.01 
(dd, J = 16.9 Hz, J = 9.6 Hz 1 H), 5.74 (m, 1 H), 5.64 (dd, J = 9.6 Hz, J = 2.1 Hz, 1 H). 
5.04 (m, 2 H), 3.96 (m, 1 H), ), 2.33 (ddd, J = 14.4 Hz, J = 4.7 Hz J = 2.4 Hz, 1 H), 2.15 
(ddd, J = 14.4 Hz, J = 7.2 Hz, J = 1.1 Hz, 1 H), 1.9-1.6 (m, 5 H), 1.5-0.8 (m, 6 H). 13C 
NMR (50 MHz, CDCl3): δ = 165.2, 134.7, 131.2, 126.0, 117.5, 52.9, 41.2, 36.3, 29.6, 28.6, 
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29.3, 26.1. MS (EI) m/z = 166 (100), 55 (75), 95 (55),112 (50), 70 (48), 124 (40). Anal. 
Calcd for C13H21NO: C, 75.32; H, 10.21; N, 6.76. Found C,74.44; H, 10.23; N, 6,74.  
N
H
O
N (S)-N-[1-(2-Pyridyl)-3-buten-1-yl) Propenamide (13m): white solid; m.p. 61-
61.5 °C; [α]D
20 −38.7 (c 0.31, CHCl3). IR (KBr): v = 3302, 3051, 1655, 1629, 1542, 1411, 
1242. 1H NMR (300 MHz, CDCl3): δ = 8.37 (d, J = 4.0 Hz, 1 H), 7.74 (d, J = 6.6 Hz, 1 H), 
7.49 (dt, J = 7.8 Hz, J = 1.3 Hz, 1 H), 7.13 (d, J = 7.8 Hz, 1 H), 7.03 (dt, J = 6.6 Hz, J = 
1.3 Hz, 1 H), 6.09 (m, 2 H), 5.54 (m, 1 H), 5.40 (m, 1 H), 5.11 (q, J = 6.6 Hz, 1 H), 4.85 
(d, J = 12.6 Hz, 2 H), 2.51 (t, J = 6.6 Hz, 2 H). 13C NMR (50 MHz, CDCl3): δ = 164.6, 
159.3, 148.6, 136.3, 133.4, 130.5, 125.9, 122.1, 122.0, 117.6, 53.4, 39.8.  MS (EI) m/z 
107 (100), 161 (90), 55 (28), 130 (21), 79 (14), 147 (10), 203 (M+ + 1, 1). Anal. Calcd for 
C12H14N2O: C, 71.26; H, 6.98; N, 13.85. Found C, 72.18; H, 7.01; N, 13.80. 
H
N
O
H
N
O
(S,S)-1,3-Di[1-(propenoylamino)-3-buten-1-yl]benzene (19): white 
solid; m.p. 138-139 °C; [α]D
20 −203.3 (c 0.7, CHCl3). IR (KBr): v = 3253, 3067, 1650, 1226, 
1550, 1411, 1247, 989, 958, 920. 1H NMR (200 MHz, CDCl3): δ = 7.26 (m, 4 H), 6.31 (dd, J 
= 16.7 Hz, J = 1.8 Hz 2 H), 6.13 (dd, J = 16.7 Hz, J = 9.8 Hz,  2 H), 5.94 (m, 2 H), 5.76 
(m, 2 H), 5.66 (dd, J = 9.8 Hz, J = 1.8 Hz, 2 H), 5.13 (m, 6 H), 2.61 (t, J = 7.0 Hz, 4H). 
13C NMR (50 MHz, CDCl3): δ = 165.0, 141.9, 133.4, 130.8, 128.7, 126.4, 125.7, 125.0, 
117.9, 52.6, 40.2. MS (EI) m/z 55 (100), 229 (80), 283 (70), 158 (30), 133 (20). Anal. 
Calcd for C12H14N2O: C, 71.26; H, 6.98; N, 13.85. Found C, 72.18; H, 7.01; N, 13.80. 
N
H
N
O
H
N
O
 (S,S)-2,6-Di[1-(propenoylamino)-3-buten-1-yl]pyridine (20): white 
solid; m.p. 155-156 °C; [α]D
20 -175.5 (c 0.22, CHCl3). IR (KBr): v. 3305, 3044, 1658, 1631, 
1545, 1422, 1241. 1H NMR (200 MHz, CDCl3): δ = 7.63 (t, J = 7.6 Hz, 1 H), 7.13 (d, J = 7.6 
Hz, 2 H), 6.24 (dd, J = 16.9 Hz, J =  2.0 Hz  2 H), 6.13 (dd, J = 16.9 Hz, J = 9.8 Hz, 2 H), 
6.01 (d, J = 7.4 Hz, 1 H), 5.59 (dd, J = 9.8 Hz, J = 2.0 Hz, 1 H), 5.63 (m, 2 H), 5.25 (dd, J 
= 7.4 Hz, J = 6.6 Hz  2 H), 5.03 (m, 2 H), 2.67 (t, 4 H, J = 6.6 Hz). 13C NMR (75 MHz, 
CDCl3): δ = 126.8, 158.8, 137.3, 133.4, 130.9, 126.5, 120.5, 118.2, 53.3, 40.2. MS (EI) 
m/z = 284 (100), 55 (92), 156 (33), 134 (29), 230 (18), 325 (M+, 3). Anal. Calcd for 
C20H24N2O2: C, 74.04; H, 7.46; N, 8.64. Found C, 73.90; H, 7.48; N, 8.62. 
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H
N O
 (S)-5,6-Dihydro-6-phenylpyridin-2(1H)-one (14a): White solid; m.p. 117-
117.5 °C; IR (KBr): v = 3221, 2925, 2852, 1672, 1609, 1449, 1320, 1141, 817; [α]D
20 -
216.5 (c 0.3, CHCl3). 
1H NMR (200 MHz, CDCl3): δ = 7.37 (m, 5 H), 6.55 (ddd, J = 10.0 Hz, 
J = 5.0 Hz, J = 3.3 Hz, 1 H), 6.0 (d, J = 10.0 Hz, 1 H), 4.71 (dd, J = 10.6 Hz, J = 6.3 Hz, 1 
H), 2.53 (m, 2 H). 13C NMR (50 MHz, CDCl3): δ = 166.5, 141.1, 140.0, 128.8, 128.1, 126.3, 
124.5, 55.6, 32.9. MS (EI) m/z = 174.2 (M + H)+, 347.1 (2 M + H)+, 369.2 (2 M + Na)+. 
Anal. Calcd for C11H11NO: C, 76.28; H, 6.40; N, 8.09. Found C, 76.14; H, 6.42; N, 8.08. 
H
N O
Cl
 (S)-5,6-Dihydro-6-(4-chlorophenyl)pyridin-2(1H)-one (14b): white solid; 
m.p. 126-127 °C. [α]D
20 - 193.1 (c 0.82, CHCl3). IR (KBr) v = 3187, 2930, 1670, 1611, 1493, 
1089, 823. 1HNMR (300 MHz, CDCl3): δ =7.41 (d, J = 8.6 Hz, 2H, ArH), 7.35 (d, J = 8.6 Hz, 
2 H), 6.65 (ddd, J = 9.9 Hz, J = 2.5 Hz, J = 1.1 Hz, 1 H), 6.28 (bs, 1 H),. 6.03 (d, J = 9.9 
Hz, 2 H), 4.77 (dd, J = 10.6 Hz, J = 9.9 Hz, 1 H), 2.66 (ddd, J = 17.9 Hz, J = 5.9 Hz J = 
1.1 Hz, 1 H), 2.50 (ddd, J = 17.9 Hz, J = 10.6 Hz, J = 2.5 Hz, 1 H). 13C NMR (75 MHz, 
CDCl3): δ = 166.45, 139.8, 139.7, 129.0, 127.7, 124.6, 54.9, 32.8. MS (ES) m/z = 415.0 (2 
M + H)+, 437.1 (2 M + Na)+. Anal. Calcd for C11H10ClNO: C, 63.62; H, 4.85; N, 6.75. Found 
C, 63.82; H, 4.87; N, 6.72. 
H
N O
F
 (S)-5,6-Dihydro-6-(4-fluorophenyl)pyridin-2(1H)-one (14c): white solid; 
m.p. 121-122 °C; [α]D
20 - 206.0 (c 0.20, CHCl3). IR (KBr): v = 3184, 3049, 2941, 1667, 
1603, 1512, 1414, 1219, 834. 1H NMR (300 MHz, CDCl3): δ = 7.32 (dd, J = 8.2 Hz, JF-H = 
5.7 Hz , 2 H), 7.04 (dd, J = 8.2 Hz, JF-H = 7.8 Hz , 2 H), 6.60 (ddd, J = 10.0 Hz, J = 3.2 Hz, 
J = 1.1 Hz, 1 H), 6.1 (bs, 1 H), 5.97 (d, J = 10.0 Hz, 2 H), 4.71 (dd, J = 11.0 Hz, J = 5.9 
Hz, 1 H), 2.57 (ddd, J = 17.8 Hz, J = 5.9 Hz J = 1.1 Hz, 1 H), 2.45 (ddd, J = 17.8 Hz, J = 
11.0 Hz, J = 3.2 Hz, 1 H). 13C NMR (75 MHz, CDCl3): δ = 166.5, 162.4 (d, J = 248.5 Hz), 
139.9, 136.9, 128.0 (d, J = 8.1 Hz), 124.5, 115.6 (d, J = 21.5 Hz), 54.7, 33.0. MS (ES) 
m/z = 192.3 (M + H)+, 383.3 (2 M + H)+, 405.1 (2 M + Na)+. Anal. Calcd for C11H10FNO: C, 
69.10; H, 5.27; N, 7.33. Found C, 68.09; H, 5.27; N, 7.31. 
H
N O
MeO
 (S)-5,6-Dihydro-6-(4-methoxyphenyl)pyridin-2(1H)-one (14d): white 
solid; m.p. 138-139 °C. [α]D
20 -188.6 (c 0.36, CHCl3). IR (KBr): v = 3183, 2963, 1682, 
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1614, 1512, 1252, 1026, 836. 1H NMR (300 MHz, CDCl3): δ = 7.27 (d, J = 8.4 Hz, 2 H), 6.89 
(d, J = 8.4 Hz, 2 H), 6.60 (ddd, J = 9.9 Hz, J = 3.4 Hz, J = 1.3 Hz  1 H), 6.1 (bs, 1 H). 5.96 
(d, J = 9.9 Hz, 2 H), 4.67 (dd, J = 10.9 Hz, J = 6.2 Hz, 1 H), 3.79 (s, 3 H), 2.50 (m, 2 H). 
13C NMR (75 MHz, CDCl3): δ = 166.5, 159.2, 140.1, 132.9, 127.5, 124.3, 114.0, 55.1, 54.9, 
32.9. MS (ES) m/z = 407.3 (2 M + H)+, 429.1, (2 M + Na)+. Anal. Calcd for C12H13NO2: C, 
70.92; H, 6.45; N, 6.89. Found C, 79.87; H, 6.44; N, 6.90. 
H
N O
MeO
OMe
MeO
 (S)-5,6-Dihydro-6-(3,4,5-trimethoxyphenyl)pyridin-2(1H)-one (14e): 
whitish oil; [α]D
20 - 181.7 (c 0.20, CHCl3). IR (neat): v = 3188, 2956, 1689, 1622, 1505, 
1249, 1030, 840. 1H NMR (300 MHz, CDCl3): δ = 6.60 (ddd, J = 9.9 Hz, J = 2.8 Hz, J = 1.4 
Hz  1 H), 6.55 (s, 2 H), 5.97 (d, J = 9.9 Hz, 2 H), 5.91 (bs, 1 H). 4.64 (dd, J = 11.4 Hz, J = 
5.7 Hz, 1 H), 3.83 (s, 6 H), 3.81 (s, 3 H), 2.54 (ddd, J = 17.4 Hz, J = 5.7 Hz J = 1.4 Hz, 1 
H), 2.46 (ddd, J = 17.9 Hz, J = 11.4 Hz, J = 2.8 Hz, 1 H). 13C NMR (75 MHz, CDCl3): δ = 
166.4, 153.4, 140.2, 136.6, 124.4, 103.2, 60.7, 56.0, 33.2. MS (ES) m/z = 264.1 (M + H)+, 
528.3 (2 M + 2 H)+, 549.3 (2 M + Na)+. Anal. Calcd for C14H17NO4: C, 63.87; H, 6.51; N, 
5.32. Found C, 64.06; H, 6.54; N, 5.30. 
H
N O
(S)-5,6-Dihydro-6-(2.naphthyl)pyridin-2(1H)-one (14f): white solid; m.p. 
137-138 °C. [α]D
20 -132.0 (c 2.6, CHCl3). IR (KBr): v = 3288,2945, 2876, 2852, 1676, 1660, 
1601, 1482, 1380, 1350, 1322, 1226, 1148, 1136, 809, 763, 741, 700. 1H NMR (300 MHz, 
CDCl3): δ = 7.83 (m, 4 H), 7.51 (m, 3 H), 6.64 (m, 1 H),. 6.04 (d, J = 9.9 Hz, 1 H), 5.89 
(bs, 1 H), 4.77 (dd, J = 10.2 Hz, J = 6.3 Hz, 1 H), 2.64 (m, 2 H). 13C NMR (75 MHz, CDCl3): 
δ = 166.5, 140.1, 138.4, 133.2, 133.1, 128.9, 127.9, 127.7, 126.5, 126.3, 125.4, 124.5, 
124.0, 55.8, 32.9. MS (ES) m/z = 224.1, (M + H)+, 447.1, (2 M + H)+, 469.2, (2 M + Na)+. 
Anal. Calcd for C15H13NO: C, 80.69; H, 5.87; N, 6.27. Found C, 80.75; H, 5.89; N, 6.24. 
N
H
O
O
 (S)-5,6-Dihydro-6-furylpyridin-2(1H)-one (14g): white powder; m.p. 98-99 
°C; [α]D
20 -93.0 (c 0.49, CHCl3). IR (KBr:): v = 3289, 3117, 2950, 1671, 1593, 1475, 804. 
1H NMR (200 MHz, CDCl3): δ = 7.31 (d, J = 1.6 Hz, 1 H), 6.8 (bs, 1H), 6.55 (dt, J = 10.0 
Hz, J = 4.1 Hz, 1 H), 6.29 (dd, J = 3.0 Hz. J = 1.6 Hz , 1 H), 6.21 (d, J = 3.0 Hz, 1 H), 
5.57 (dd, J = 10.0 Hz, J = 1.8 Hz, 1 H), 4.74 (t, J = 7.1 Hz, 1 H), 2.62 (m, 2 H). 13C NMR 
(50 MHz, CDCl3): δ = 166.0, 153.4, 142.1, 139.5, 124.3, 110.2, 106.3, 48.6, 28.5, MS (ES) 
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m/z = 164.1 (M + H)+, 327.0 (2 M + H)+], 349.1 (2 M + Na)+. Anal. Calcd for C9H9NO2: C, 
66.25; H, 5.56; N, 8.58. Found C, 65.75; H, 5.55; N, 8.56. 
N
H
S
O
 (S)-5,6-Dihydro-6-thienylpyridin-2(1H)-one (14h): white solid, m.p. 109-110 
°C, [α]D
20 -151.8 (c 1.2, CHCl3). IR (KBr): v = 3478, 2924, 1671, 1608, 1407, 1303, 1124.
 
1H NMR (200 MHz, CDCl3): δ = 7.31 (d, J = 5.3 Hz, 1 H), 6.98 (m, 2 H), 6.64 (dt, J = 10.1 
Hz, J = 4.0, 1 H), 6.02 (d, J = 10.1 Hz, 1 H), 5.01 (dd, J = 9.4 Hz, J = 6.4 Hz, 1 H), 2.69 
(m, 2 H). 13C NMR (50 MHz, CDCl3): δ = 165.8, 144.4, 139.9, 126.8, 125.1, 125.0, 124.7, 
51.1, 33.3. MS (ES) m/z = 180.1 (M + H)+, 359.0 (2 M + H)+, 381.0 (2 M + Na)+. Anal. Calcd 
for C9H9NOS: C, 60.31; H, 5.06; N, 7.81; S, 17.89. Found C, 60.45; H, 5.08; N, 7.80; S, 
17.82. 
Fe
N
H
O
 (S)-5,6-Dihydro-6-ferrocenylpyridin-2(1H)-one (14i): red solid; m.p. 143-
144 °C; [α]D
20 +94.3 (c 0.66, CHCl3). IR (KBr): v = 1675, 1611, 1420, 1315, 1105, 814. 
1H 
NMR (300 MHz, CDCl3): δ = 6.65 (ddd, J = 9.9 Hz, J = 5.6 Hz, J = 2.7 Hz, 1 H), 5.96 (d, J = 
9.9 Hz, 1 H), 5.88 (bs, 1 H), 4.38 (dd, J = 12.0 Hz, J = 5.5 Hz, 1 H), 4.21 (m, 5 H), 4.18 
(m, 4 H), 2.48 (ddd, J = 17.7 Hz, J = 5.6 Hz, J = 5.5 Hz, 1 H), 2.31 (ddd, J = 17.7 Hz, J = 
12.0 Hz, J = 2.7 Hz, 1 H). 13C NMR (50 MHz, CDCl3): δ = 166.2, 150.9, 140.4, 124.5, 89.4, 
68.5, 68.2, 66.7, 65.1, 50.6, 33.2. Anal. Calcd for C17H21FeNO: C, 65.61; H, 6.80; Fe, 
17.95; N, 4.50. Found C, 64.85; H, 6.82; Fe, 17.90; N, 4.48. 
H
N ON
 (S)-5,6-Dihydro-6-(3-pyridyl)pyridin-2(1H)-one (14j): yellowish oil; [α]D
20 -
143.9 (c 1.7, CHCl3). IR (neat) v = 3187, 3056, 2928, 1688, 1611, 1431, 812. 
1H NMR (200 
MHz, CDCl3): δ = 8.57 (m, 2 H), 7.72 (d, J = 8.0 Hz, 1 H), 7.31 (dd, J = 8.0 Hz, J = 4.9 Hz, 
1 H), 6.60 (ddd, J = 9.8 Hz, J = 5.0 Hz, J = 3.5 H, 1 H), 6.53 (bs, 1 H), 6.0 (dd, J = 9.8  
Hz, J = 1.3  Hz, 1 H), 4.78 (dd, J = 10.1 Hz, J = 6.1 Hz, 1 H), 2.66 (ddd, J = 17.5 Hz, J = 
6.1 Hz J = 5.0 Hz  1H), 2.50 (ddd, J = 17.5 Hz, J = 10.1 Hz,  J = 6.1 Hz, 1 H). 13CNMR (50 
MHz, CDCl3): δ = 166.3, 149.6, 148.2, 139.7, 136.6, 133. 9, 124.7, 123.7, 53.2, 32.5. MS 
(ES) m/z = 175.2 (M + H)+, 349.1 (2 M + H)+, 371.2 (2 M + Na)+. Anal. Calcd for C10H10N2O: 
C, 68.95; H, 5.79; N, 16.08. Found C, 69.09; H, 5.81; N, 16.01. 
N
H
N O
(S)-5,6-Dihydro-6-(2-quinolyl)pyridin-2(1H)-one (14k): white solid; m.p. 
107-107.5 °C; [α]D
20 - 39.6 (c 0.33, CHCl3). IR (KBr): v = 3184, 3052, 2925, 1681, 1609, 
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1423, 1101, 808. 1H NMR (300 MHz, CDCl3): δ = 8.23 (d, J = 8.4 Hz, 1 H), 8.09 (d, J = 8.4 
Hz, 1 H), 7.84 (d, J = 8.1 Hz, 1 H), 7.31 (dd, J = 7.2 Hz, J = 6.6 Hz, 1 H), 7.7 (dd, J = 8.1 
Hz,  J = 6.6 Hz, 1 H), 7.59 (dd, J = 8.4 Hz,  J = 6.6 Hz, 1 H,), 7.44 (d, J = 8.4 Hz, 1 H), 
7.01 (bs, 1 H), 6.71 (ddd, J = 9.8 Hz, J = 6.3 Hz, J = 2.7 Hz,  1 H), 6.11 (d, J = 9.8  Hz, 1 
H),  5.06 (dd, J = 11.7 Hz, J = 5.4 Hz, 1 H), 2.92 (ddd, J = 17.7 Hz, J = 6.3 Hz, J = 5.4 
Hz, 1 H), 2.66 (ddd, J = 17.7 Hz, J = 11.7 Hz  J = 2.7 Hz, 1 H). 13C NMR (75 MHz, CDCl3): 
δ = 165.6, 158.3, 147.2, 139.6, 137.3, 130.0, 129.1, 127.5, 127.3, 126.8, 125.4, 117.8, 
55.5, 30.6. MS (ES) m/z = 225.2 (M + H)+, 449 (2 M + H)+, 471.0 (2 M + Na)+. Anal. Calcd 
for C14H12N2O: C, 74.98; H, 5.39; N, 12.49. Found C, 75.03; H, 5.40; N, 12.44. 
H
N O
 (S)-5,6-Dihydro-6-cyclohexenylpyridin-2(1H)-one (14l): white powder; m.p. 
137-137.5 °C; [α]D
20 -67.0 (c 0.32, CHCl3). IR (KBr): v = 3248, 2928 1652, 1545, 1415, 
1250. 1H NMR (300 MHz, CDCl3): δ = 6.65 (ddd, J = 9.8 Hz, J = 5.2 Hz, J = 3.3 Hz  1 H), 
6.35 (bs, 1 H), 5.96 (dd, J = 9.8 Hz, J = 1.9 Hz ,1 H), 3. 36 (ddd, J = 11.8 Hz, J = 6.1 Hz, 
J = 1.0 Hz, 1 H), 2.26 (m, 2 H), 1.73 (m, 4 H), 1.41 (m, 3 H), 1.09 (m, 5 H). 13C NMR (50 
MHz, CDCl3): δ = 166.5, 140.6, 124.2, 55.4, 41.5, 28.6, 28.5, 26.4, 26.1, 25.8. MS (ES) 
m/z = 180.2 (M + H)+, 381.2 (2 M + H)+. Anal. Calcd for C11H17NO: C, 73.70; H, 9.56; N, 
7.81. Found C, 72.58; H, 10.00; N, 7.80. 
H
N O
H
NO
 (S,S)-1,3-Di[5,6-dihydropyridin-2(1H)-one-6-yl]benzene (21): white 
solid; m.p. 175-176 °C; [α]D
20 - 270.0 (c 0.94, CHCl3). IR (KBr): v = 3223, 3042, 1678, 
1604, 1420, 1305, 1126, 812. 1H NMR (300 MHz, CDCl3): δ = 7.60 (m, 3 H), 7.32 (dt, J = 
6.8 Hz, J = 1.6 Hz, 1 H), 7.21 (dd, J = 6.8 Hz, J = 1.4 Hz, 2 H), 6.57 (ddd, J = 9.9 Hz, J = 
5.4 Hz, J = 2.9 Hz, 2 H), 5.93 (d, J = 9.8 Hz, 2 H),  4.75 (dd, J = 11.3 Hz, J = 5.7 Hz, 2 
H), 2.56 (ddd, J = 17.9 Hz, J = 5.4 Hz, J = 5.4  Hz, 2 H) 2.41 (ddd, J = 17.9 Hz, J = 11.3 
Hz, J = 2.9 Hz, 2 H). 13C NMR (50 MHz, CDCl3): δ = 167.0, 141.9, 139.8, 128.8, 126.0, 
124.4, 123.7, 55.1, 32.8. MS (ES) m/z = 270.2 (M + 2 H)+, 561.2 (2 M + 2 H)+. Anal. Calcd 
for C16H16N2O2: C, 71.62; H, 6.01; N, 10.44. Found C, 72.01; H, 6.03; N, 10.40. 
N
H
N O
H
NO
 (S,S)-2,6-Di[5,6-dihydropyridin-2(1H)-one-6-yl]pyridine (22): white 
solid, m.p. 79-80 °C. [α]D
20 - 99.3 (c 0.5 , MeOH); IR (KBr): v = 3386, 3067, 2925, 2848, 
1654, 1596, 1458, 1313, 1124. 1H NMR (300 MHz, DMSO-d6): δ = 7.60 (m, 3 H), 7.32 (dt, J 
= 6.8 Hz, J = 1.6 Hz, 1 H), 7.21 (dd, J = 6.8 Hz, J = 1.4 Hz, 2 H), 6.57 (ddd, J = 9.9 Hz, J 
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= 5.4 Hz, J = 2.9 Hz, 2 H), 5.93 (d, J = 9.8 Hz, 2 H),  4.75 (dd, J = 11.3 Hz, J = 5.7 Hz, 2 
H), 2.56 (ddd, J = 17.9 Hz, J = 5.4 Hz, J = 5.4 Hz, 2 H), 2.41 (ddd, J = 17.9 Hz, J = 11.3 
Hz, J = 2.9 Hz, 2 H). 13C NMR (75 MHz, DMSO-d6): δ = 165.7, 160.1, 140.4, 138.3, 125.3, 
119.9, 54.9, 30.16.MS (ES) m/z 270.2 (M + H)+, 539.3 (2 M + H)+. Anal. Calcd for 
C15H15N3O2: C, 66.90; H, 5.61; N, 15.60. Found C, 65.97; H, 5.62; N, 15.55. 
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Chapter 5 
Steric effects in the enantioselective allylic alkylation catalyzed by 
cationic (η3-allyl)palladium complexes bearing chiral pyridine-aziridine 
ligands.  
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5.1 Introduction: 
 
C2-Symmetric enantiopure N,N-bidentate ligands have been widely used in the asymmetric 
Pd-catalyzed allylic substitution reactions, like the reaction of 1,3-diphenylpropenyl 
acetate 1a with the anion of dimethyl malonate, in the presence of allylpalladium chloride 
dimer to give the substitution product 2 which has become the prototype reaction for test 
of new chiral ligands. 
 
Ph Ph
OCR
PhPh
1 2
[Pd-L*] (cat.)
MeO2C CO2Me
*
MCH(CO2Me)2
a: R = Me
b: R = OEt
O
 
 
The accepted mechanism for this reaction involves first the oxidative addition of a Pd(0) 
specie on the allylic substrate to yield a η3 allyl-Pd(II) complex. The equilibrium between 
the neutral complex 3 and the cationic specie 4 depends on many factors like the solvent 
and the nature of the ligand, but with bidentate ligands it is usually shifted to the side of 
the cationic complex. This is highly reactive towards soft nucleophiles, which attack at the 
less substituted allylic terminus leading to a η2-olefin-Pd0 complex, then to the final 
product and a Pd(0) complex that restarts another catalytic cycle. 
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In literature are described many examples of ligands that can efficiently catalyze this 
reaction in an asymmetric fashion, and a few of them contain the pyridine or aziridine ring. 
For example the C2-symmetric bis(aziridine) 5
[1] afforded a complete enantioselectivity, 
while the pyridine derivative 6[2] gave a 64% e.e.. In C1-symmetric 2-(2’-pyridyl)oxazolines 
7a,b[4] and 8[4c,5] a remarkable effect of the substituent in both rings was observed; 
particularly, the substitution of Ph for the i-Pr group in the oxazoline was beneficial, as a 
better e.e. was provided by 8 with the same pyridine substituent (R = H). Most 
importantly, the presence of a (chiral) bulky substituent at the pyridine-C6, or the 
presence of a benzo[b]-fused ring as in 9, caused an increase of the enantioselectivity.[4,5] 
It should be observed that the ligands 7-9 form a rigid five-membered chelation ring in the 
cationic (η3-allylic)Pd complexes but also six-membered chelation rings like those derived 
from the ligands 10-12 have been studied. In the case of 8-quinoline-oxazolines 8, an 
unexpected effect of the substitution was observed, as with R = Me[6] and the benzo[b]-
derivative[4] the opposite enantiomer of 2 was produced. Similarly, the 2-
(quinolylmethyl)oxazoline 12 displayed the opposite enantioselectivity with respect to 
11.[6] 
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We observed that (N,N')* ligands containing both the pyridine and aziridine rings were not 
described in the literature and envisioned a simple two-step route to 1-[1(S)-(2-
pyridyl)alkyl]-2(S)-isopropylaziridines 13 from N-(2-pyridylmethylidene) (S)-valinol.[7] In a 
preliminary report we have described the preparation of 13 and its cationic η3-
allylpalladium complex 14, which is more effective than the free base in the above 
mentioned Pd-catalysed allylic substitution reaction, providing (R)-2 with moderate yield 
and 41% e.e. (Table 1, entry 1).[8] The ligand 13 differs from 5-12 for the presence of a 
stereocentre in the carbon chain linking the two nitrogen atoms, besides the one present 
on the aziridine carbon. The two stereocentres in 13 have a combined role compelling the 
aziridine nitrogen to assume the R configuration when forming the Pd complex, as shown 
by the X-ray structure analysis of 14. This happens to avoid the severe interaction of the 
two iPr substituents, which instead would occur in the alternative complex with the S 
configuration. 
N
N
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N
N
O
OH
NH2
N
N
H
OH
N N
O
NN
N
N
Pd
+ SbF6
+
1) MgSO4, CH2Cl2
2) TMSCl, TEA, CH2Cl2
1) iPrMgCl, THF,
    -78 °C, 1.5 h
2) HCl, r.t
79%, d.r. >99:1
1)
CH2Cl2, r.t.
2) THF/H2O
1) (AllilPdCl)2,
    CH2Cl2, r.t., 1h
2) AgSbF6, THF, 
     r.t., 0.5 h13, 65% 14, 80%
(CDI)
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Ph Ph
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3 (10 mol %). THF, r.t., 36 h
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Since then, we have directed our efforts to the preparation of other C1-symmetrical (N,N')* 
ligands and their palladium complexes, having general structure 16 and 17, respectively, 
by the same previously applied route that involves the initial organometallic addition step 
to the imine 15 to give the 1,2-aminoalcohol 16, from which the aziridine ring is 
constructed. This route is flexible, as it allows to vary the ligand skeleton and the size of 
the Pd-chelated ring (starting from the proper aldehyde) and all the substituents, like, for 
example the heterocyclic rings (ring-substituted aza-heteroaromatic aldehyde and chiral 
1,2-aminoalcohol) and the tether connecting them (organometallic reagent). Similarly, the 
influence of a new substituent R1 or a benzo[b]-fused pyridine ring can be studied 
preparing the ligand from a suitable aldehyde. As a corollary of this study, owing to the 
low reactivity of the acetate 1 in the reaction catalyzed by 14, we have checked the more 
reactive 1,3-diphenyl-2-propenyl ethyl carbonate 1b as the substrate in the same 
substitution reaction. 
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N N
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N
R1
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N
R1
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R3R3
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5.2. Results and Discussion 
 
5.2.1.  Influence of the aziridine ring substituent 
In order to determine the effect of the aziridine C2-substituent on the enantioselectivity 
we have chosen to replace the iPr group, present in 13, with a different group. This has 
been accomplished by preparing the free imine 18 and the O-protected one 19, from 2-
pyridinaldehyde and (R)-phenylglycinol, and optimising the preparation of the amino-
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alcohol 20 from them. Although phenylglycinol has been widely exploited for the 
diastereoselective addition of organometallic reagents to imines,[9] in our hands the 
addition of i-PrMgCl to 18 in THF at 0 °C gave the secondary amines 20 with moderate 
sterocontrol. No attempt was made to separate the main (S,S)-diastereomer. The 
experimental conditions used by Spero[10] for similar Grignard reactions on 2-pyridyl 
ketimines were then applied to 18, involving the use of CH2Cl2 as the solvent and the 
presence of MgBr2.[10] By this way, a 95% yield and a 75:25 d.r. (
1H NMR spectroscopy) were 
obtained for 20. Also the addition of iPrMgCl to the O-protected imine 19 in THF at 78 °C 
gave 20 with a moderate diastereoselectivity (65:35), but a better d.r. (80:20) was finally 
obtained applying the Spero protocol to the protected imine 19 and the main diastereomer 
of 20 was isolated pure in 45% yield by column chromatography of the reaction mixture. 
The conversion of the amino alcohol 20 to the aziridine 21 by treatment with carbonyl 
diimidazole (CDI)[8,11] was not satisfactory. In this case, a better result was achieved by the 
reaction with mesyl chloride and triethylamine at −78 °C, after which 21 was isolated with 
55% yield. The cationic (η3-allyl)-Pd complex 22 was then prepared by the routine 
procedure.  
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The complex 22 (10 mol%) was used for the catalytic allylation of sodium dimethyl 
malonate with the acetate 1a, but almost no reaction was observed after 1 day at 25 °C. 
However, using the carbonate 1b, almost complete conversion (TLC) after 12 h at 25 °C in 
THF was observed and the product (S)-2 was isolated by column chromatography with 70% 
yield and e.e. 90% (Table 1, entry 3). It is noteworthy that using 14 as the catalyst (5 
mol%)  the malonate 2 was obtained with 85% yield from the carbonate 1b after only 3 h at 
25 °C, but with lower e.e. (19%, entry 2) with respect to the reaction on the acetate 1a 
(entry 1); unfortunately, almost no reaction took place with 1b at 0 °C. The reaction of 
the carbonate 1b with dimethyl malonate in the presence of 10 mol% of either sodium 
hydride[12]  and complex 22 at 25 °C stopped after a few hours, at which time a black Pd 
precipitate was formed; then the product 2 was detected in poor amounts by T.L.C. 
analysis. The reaction of 1b with sodium dimethyl malonate (1.5 equiv) in the presence of 
allylpalladium chloride dimer (5 mol%) and ligand 21 (10 mol%), forming in situ the reactive 
complex 22, gave (S)-2 with 74% yield and e.e. 86% (entry 4). On the other hand the 
reaction of 1b with dimethyl malonate (2.5 equiv), bis(trimethylsilyl)acetamide (BSA, 3 
equiv.), potassium acetate (1 mol%) and the palladium complex 22 (10 mol%) gave a largely 
incomplete conversion to (S)-2, which was isolated after 12 h with only 33% yield although 
with high  e.e. (90%). It should be underlined that the two complexes 14 and 22 have 
opposite chirality consequently, they induced the same sense of asymmetric induction in 
the formation of (R)-2 and (S)-2, respectively. 
 
Ph Ph
OCX
Ph Ph
CO2MeMeO2CNaCH(CO2Me)2
THF
1a, X= Me
1b, X= OEt
O
 
 
Entry Substrate Catalyst (eq.) Time (h) Product Yield % Ee% 
1 1a 14(0.1) 36 (R)-2 50 42 
2 1b 14 (0.05) 3 (R)-2 85 19 
3 1b 22 (0.1) 12 (S)-2 70a 90 
4 1b 22 (0.1) b 12 (S)-2 74 86 
[a] Almost no reaction occurred at 0°C or when using 10mol-% of sodium hydride.  [b] Catalyst generated in situ with 0.05 
eq. of (allylPdCl)2 
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5.2.2.  Influence of the ligand skeleton and C6-pyridine substituent 
We aimed to assess the effect of the modified N,N-ligand skeleton or pyridine-substitution 
pattern on the enantioselectivity of the substitution reaction, we synthesized the imines 
24a-c from commercially available 2- and 8-quinolinaldehydes and prepared 6-benzyl-2-
pyridinaldehyde. We wished to study the effect of the steric interaction between the 
pyridine-fused benzene ring or the C6-benzyl substituent with the phenyl group of the η3-
allylic ligand in the reactive allylic complex. On the other hand, a six membered Pd-
chelation is formed from the ligand 26b derived from 24b, possibly resulting in a modified 
structure of the allylic complex.  
The addition of iPrMgCl to 24a was plagued by poor chemoselectivity, affording the β-
aminoalcohol 25a with 25% yield after chromatographic separation from several 
unidentified by-products and its diastereomer (d.r. 75:25 was determined by GC-MS 
analysis of the crude product). A more selective addition of the same Grignard reagent was 
observed to the 8-quinolineimine 24b (d.r. 85:15) and the pure diastereomer 25b was 
isolated with 38% yield. Finally, the imine 24c was prepared from 6-benzyl-2-
bromopyridine[13] by bromine-lithium exchange at low temperature, followed by reaction 
with DMF. The reaction of 24c with iPrMgCl gave the aminoalcohol 25c with good yield and 
diastereoselectivity (d.r. 90:10), and the pure diastereomer was isolated with 56% yield by 
column chromatography. The aziridines 26a-c and their cationic (η3-allyl)Pd complexes 
27a-c were readily prepared by the routine sequence with good yields. 
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The reactions carried out on the acetate 1a catalysed by the complexes 27a-c gave 
unexpected results. A low enantioselectivity for (R)-2 was obtained using 27a (e.e. 4%, 
entry 5) while an inversion of the enantioselectivity was observed in the reaction catalysed 
by 27b: in fact, (S)-2 was prevalently formed, although with low e.e. (23%, entry 6). In 
both cases, the pyridine substituent caused an increase of the reaction time needed to 
achieve a satisfactory conversion. An even more sluggish reaction was observed using the 
6-benzylpyridine derivative 27c, so that in this case we worked on the more reactive 
carbonate 1b and obtained (S)-2 with reasonable yield and moderate enantioselectivity 
(e.e. 47%, entry 7). When the same reaction was performed at higher temperature (50 °C) 
the reaction rate considerably increased and (S)-2 was isolated with 75% yield, but slightly 
lower e.e. (37%, entry 8).  
 
 
Ph Ph
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Ph Ph
CO2MeMeO2CNaCH(CO2Me)2
THF
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Entry Substrate Catalyst (eq.) Time (h) Product Yield % Ee% 
5 1a 27a (0.1) 36 (R)-2 22 4 
6 1a 27b (0.1) 24 (S)-2 35 23 
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7 1b 27c (0.1) 18 (S)-2 43 42 
8 1b 27c (0.1) 6a (S)-2 75 35 
[a] The reaction was performed at 50 °C. 
 
5.2.3. X-Ray studies of (η3-1,3-diphenylallyl)Pd complexes. Tentative explanation of 
the divergent enantioselectivity 
 
In order to explain the stereochemical outcomes of the reaction we started studying the x-
ray structure of the (N,N')*(η3-allyl)palladium salts 14 and 27a,b that we prepared. All the 
complexes showed the palladium atom in a distorted square-planar geometry, also it is 
important to note the unique conformation of the cationic nitrogen atom, that is R for the 
complexes 14, 27a,b,c derived from (S)-valinol, and S for the complex 22 derived from 
(R)-phenylglycinol, this avoids the steric interaction between the iPr group present in the 
tether linking the nitrogen atoms and the aziridine substituent (iPr or Ph). Another 
important point is that all the structures showed a longer carbon-palladium bond anti to 
the nitrogen of the aziridine ring (Pd-C3) than to the pyridine (Pd-C1). All the (N,N')*(η3-
allyl)palladium salts are present, even in the crystal structure in a mixture of exo/endo 
rotamers and that ratio is usually different in solution as witnessed from their 1H-NMR 
spectra. X-Ray analyses of the re-crystallised salts 27a,b showed structures similar to that 
of 14.[8] However, two independent cations are present in the crystals of the 2-quinoline 
derivative 27a, and in both of them the endo-allyl rotamer predominates. In the crystal of 
the 8-quinoline derivative 27b, featuring a six-membered Pd-chelation ring, an exo/endo 
ratio 56:44 of the allyl rotamers was observed. It is noteworthy that the ligands in the salts 
14 and 27a,b present similar envelope or puckered conformations.  
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If we think that these all these features characterize also the (η3-1,3-diphenylallyl)Pd 
complexes which are the real intermediates of the reaction, we can explain the 
enantioselectivity observed by the attack of the nuclefile (malonate anion) at the most 
electrophilic carbon atom (anti to the aziridine ring) of the prevalent endo rotamer. This 
model worked fine to describe the results obtained with all the complexes but couldn’t 
explain the inverted enantioselectivity obtained with catalyst 27c with respect to 22. 
  
PhPh
MeO2C CO2Me
N
N
Pd iPr
N
N
Pd iPr
Ph Ph
PhPh
iPr
Ph Ph
MeO2C CO2Me (R)
(S)
iPr
Nu Nu
exo endo
 
Bond Distance (Ǻ) 
 Pd- C19 2.148 
Pd-C21 2.106 
Pd-N1 2.145 
Pd-N2 2.101 
Bond Distance (Ǻ) 
 Pd- C21 2.150 
Pd-C19 2.118 
Pd-N1 2.126 
Pd-N2 2.098 
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With the hope to find important clues for the understating of the course of these reactions, 
we prepared the corresponding cationic (η3-1,3-diphenylallyl)Pd complexes as 
hexafluoroantimonate salts 28 and 29, which are the possible intermediates in the 
enantio-discriminating steps.  
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    CH2Cl2, r.t.
2) AgSbF6,
    THF, r.t.
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29, 77%
73%
61%
21
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SbF6
 
 
 
X-Ray diffraction analysis showed that the structures of these complexes are similar to 
each other as well as to those of 14[8] and 27a,b.[14]  However, only the endo rotamers of 
the 1,3-diphenylallyl ligand were present in 28 and 29. For clarity, the aziridine and 
pyridine nitrogen atoms are indicated as NA and NP, respectively, and the allylic carbons CA 
(trans to aziridine) and CP (trans to pyridine).  
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In the (η3-1,3-diphenylallyl)]Pd complex 28, two independent cations are present, the Pd-
NP bonds are in the range 2.180-2.200(5) Å, that are considerably longer than the Pd-NA 
bonds (2.133-2.152(6) Å). This is noteworthy because NP and NA use sp
2 and sp3-type 
orbitals, respectively. The lengths of the two Pd-NA bonds in the calculated structure of 
the complex [3-(η3-1,3-diphenylallyl)Pd][SbF6] were 2.131 and 2.134 Å,1b,f which are 
comparable to the values observed in 28 and 29. On the contrary, in the reported X-ray 
structure of an [(N,N')(η3-1,3-diphenylallyl)Pd]+ cation, the metal formed a longer bond 
with pyrrolidine (2.15 Å) with respect to pyridine (2.08 Å).2a Moreover, the two Pd-N bonds 
in the [(sparteine)(η3-1,3-diphenylallyl)Pd]+ cation were 2.19 and 2.24 Å long.[16] Hence, it 
appears that the aziridine nitrogen generally forms with palladium cation a bond shorter 
than other sp3-hybridised nitrogen atoms. 
It should also be considered that the complexes 28 and 29 in CDCl3 solution are present as 
syn,syn-endo/syn,syn-exo mixtures (72:28 and 85:15, respectively), and that in no case 
anti,syn allyl species were detected. The endo/exo ratios and the Pd-C bond lengths are 
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determined by steric effects like the non-bonding interactions of the (N,N')* and allyl 
ligands, whereas electronic effects are not relevant. In the hypothesis that the endo and 
exo rotamers have the same reactivity and undergo a completely regioselective attack, the 
e.e.’s of the product would be correlated to the endo/exo ratio. For example, this was 
true in reactions catalysed by 8-(2-oxazoline)quinoline ligands.[20] The high 
enantioselectivity observed for (S)-2 in the reaction catalyzed by the complex 28 is the 
result of two convergent factors: the prevalence of the rotamer endo-28 in solution, and 
the relatively low activation energy of the transition state deriving from the nucleophilic 
attack to the more electrophilic CA allylic terminus and leading to the η2-complex. 
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In the case of complex 29, the relative ratio and reactivity of endo and exo rotamers must 
be considered.[21] The different reactivity is probably associated to the relative stability of 
the late transition states leading to the alternative η2-complexes which are precursors of 
the product 2. It should be observed that the formation of the η2-complex by attack to the 
less abundant rotamer exo-29 occurs by "preferential rotation"[22] and does not suffer for 
severe steric interactions, contrary to the alternative η2-complex which would be derived 
from endo-29.  
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5.3 Conclusions 
 
We have investigated the synthetic route to enantiopure C1-symmetric N,N'-bidentate 
ligands carrying either a 1,2-disubstituted aziridine and an aza-aromatic ring. The ligands 
were prepared from imines derived pyridine- and quinolinealdehydes and optically pure β-
amino alcohols. The ligands were then converted to the [(N,N')*(η3-allyl)Pd][SbF6] 
complexes, which were used as catalysts in the allylic substitution reaction of 1,3-
diphenyl-2-propenyl esters with sodium dimethyl malonate in THF.[16,23] Although the 
synthetic route to the ligand proved to be more efficient and stereoselective starting from 
(S)-valinol as the chiral precursor, it was observed that the analogous ligand prepared from 
(R)-phenylglycinol was considerably more enantioselective in the catalytic application (e.e. 
90%), as a consequence of the more demanding steric effect of the phenyl substituent in 
the aziridine ring, which is oriented towards the Pd-allylic ligand. On the other hand, 
structural variations in the starting heterocyclic aldehyde, the capability of the ligand to 
form either a five- or six-membered ring with palladium, the substitution pattern in the 
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aza-heteroaromatic ring had relevant effects on either reactivity and stereocontrol. 
Especially, inversion of enantioselectivity was observed using the ligand bearing a 6-benzyl-
substituted pyridine. The X-ray diffraction studies of two [(N,N')*(η3-1,3-
diphenylallyl)Pd][SbF6] complexes which afforded the most marked difference in 
enantioselectivity showed the similarity of their structures and the presence of only the 
endo allylic rotamers, at a difference with the unsubstituted allyl Pd complexes. Hence, 
the solid state structure does not always correspond to the more reactive conformer in 
solution, and the steric effects of the different skeleton or substituents on the regio- and 
stereoselectivity are not easily evaluated.[24] Interestingly, the Pd-N(aziridine) bonds in 
most allylic complexes studied are shorter than the Pd-N(pyridine) bonds. 
Lack of reactivity was observed with cyclohexenyl acetate, as previously reported for the 
reaction catalysed by the bis(aziridine) 5.[1] The moderate efficiency of the alkylation 
reactions catalysed by our ligands/complexes can be attributed to the weakness of the Pd-
N(pyridine) bond(s), which affects the stability of the chelated [(N,N')*(3-allyl)Pd]+ 
cations. Similarly, the absence of a pi-acceptor N ligand in (N,N')* probably does not allow 
the effective stabilization/dissolution of the Pd(0) species which are formed by 
nucleophilic attack to the intermediate cationic complex. With regard to this, it should be 
worth studying the effect of electron-withdrawing substituents on the pyridine ring of the 
ligand, particularly at C4 where steric effects are absent.  
 
Experimental Section 
 
General Remarks 
Melting points are uncorrected. Solvents were distilled over the appropriate drying agent in 
N2 atmosphere before use: THF (sodium benzophenone ketyl, then LiAlH4), CH2Cl2 (P2O5). 
Optical rotations were measured on a digital polarimeter in a 1-dm cell and [α]D-values are 
given in 101 deg cm3 g1. 1H NMR spectra were recorded on a Varian Gemini instrument at 
300 or 200 MHz for samples in CDCl3 which was stored over Mg: 
1H chemical shifts are 
reported in ppm relative to CHCl3 (δH 7.27) and J-values are given in Hz. MS spectra were 
taken at an ionising voltage of 70 eV on a Hewlett-Packard 5970 or 5890 spectrometer with 
GLC injection. Chromatographic separations were performed on columns of SiO2 (Merck, 
230-400 mesh) at medium pressure. The following materials were purchased from Aldrich: 
nBuLi (1.6 M in hexanes), iPrMgCl (2 M in THF), [(allyl)PdCl]2, AgSbF6, 3-methyl-2-butenyl 
bromide, 2-pyridinaldehyde, 2-quinolinaldehyde, (S)-valinol, (S)-phenylglycinol, 1,1'-
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carbonyldiimidazole, thionyl chloride. 8-Quinolinealdehyde was prepared from 8-
methylquinoline by oxidation with SeO2.[25] η3-(1,3-Diphenylallyl)palladium chloride dimer 
was prepared from the allylic chloride by reaction with PdCl2-SnCl2-NaCl in DMF following a 
procedure described for the preparation of different η3-allylic Pd(II) complexes.[26] All the 
organometallic reactions were performed in a flame-dried apparatus under a static 
atmosphere of dry N2. 
 
Preparation of the  imines 
 
The imines were prepared in the 5 mmol scale by the previously described procedure[27] 
and used avoiding purification.  
(S)-N-[(2-Pyridyl)methylidenelphenylglycinol (18).[28] Yellow oil: 100%. [α]D
20 +19.6 (c 
0.83, CHCl3). We observed a 55:45 mixture of imine and 1,3-oxazolidine by 
1H NMR in CDCl3 
(200 MHz): δ = 8.49 (s, 1 H, CH=N), 5.65 (s, 1 H, NCHO). The 1H NMR spectra in CDCl3 and 
THF-d8 have been partially described.[28] 
(S)-N-[(2-Pyridyl)methylidene]-O-trimethylsilylphenylglycinol (19). Yellow oil: 84%. 
[α]D
20 −15.5 (c, 0.62, CHCl3). 
1H NMR (300 MHz, CDCl3): δ = 8.63 (d, J 4 Hz, 1 H, pyridine), 
8.43 (s, 1 H, CH=N), 8.15 (d, J = 8 Hz, 1 H, Py), 7.73 (t, J = 8 Hz, Py), 7.55-7.20 (m, 6 H, Py 
and Ph), 4.50 (m, 1 H, CHPh), 3.84 (m, 2 H, CH2O), 0.0 (s, 9 H, SiMe3). GC.-MS: m/z 
(relative intensity) 195 (100, M+ – CH2OSiMe3), 92 (30), 73 (18), 66 (12), 163 (10), 298 (M
+ – 
1, 4). 
(S)-N-[(2-Quinolyl)methylidene]-O-trimethylsilylvalinol (24a): Yellow oil; 94%. [α]D
20  
−23.2 (c 1.1, CHCl3). 
1H NMR (200 MHz, CDCl3): δ = 8.48 (s, 1 H, CH=N), 8.15 (m, 3 H, 
quinoline), 7.90-7.50 (m, 3 H, quinoline), 3.92 (dd, J = 4.2 and 10.5 Hz, 1 H, CH2O), 3.75 
(dd, J = 8.1 and 10.5 Hz, 1 H, CH2O), 3.18 (m, 1 H, CHN), 2.0 (m. 1 H, CHMe2), 0.95 (2 d, J 
6.7 Hz, 6 H, CHMe2), 0.05 (s, 9 H, SiMe3). GC-MS: m/z (relative intensity) 211 (100, M
+ – 
CH2OSiMe3), 169 (42), 142 (34), 73 (31), 181 (25), 271 (10), 115 (5), 299 (5, M
+ – Me) 
(S)-N-[(8-Quinolyl)methylidene]-O-trimethylsilylvalinol (24b). Yellow oil: 98%; [α]D
20  
−32 (c, 1.80, CHCl3). 
1H NMR (200 MHz, CDCl3): δ = 9.58 (s, 1 H, CH=N), 8.98 (dd, J = 2.0 
and 4.2 Hz, 1 H, quinoline), 8.46 (dd, J = 1.6 and 7.4 Hz, 1 H, quinoline), 8.19 (dd, J = 4.8 
and 8.0 Hz, 1 H, quinoline), 7.90 (dd, J 1.40 and 8.0 Hz, 1 H, quinoline), 7.60 (t, J = 7.4 
Hz, 1 H, quinoline), 7.44 (dd, J = 4.4 and 8.4 Hz, 1 H, quinoline), 3.95 (dd, J = 6.6 and 10.6 
Hz, 1 H, CH2O), 3.75 (dd, J = 7.8 and 10.2 Hz, 1 H, CH2O),  3.25 (m, 1 H, N-CH), 2.05 (m, 1 
 - 100 - 
H, CHMe2), 1.00 (d. J = 7.0 Hz, 6 H, CHMe2), 0.07 (s, 9 H, SiMe3). GC-MS: m/z (relative 
intensity) 155 (100), 211 (38, M+ CH2OSiMe3), 142 (36), 156 (18), 73 (17), 299 (M
+ – Me, 4). 
(S)-N-[(6-Benzyl-2-pyridyl)methylidene]-O-trimethylsilylvalinol (24c): 6-Benzyl-2-
bromopyridine was prepared from 2,6-dibromopyridine according to the reported 
procedure:[13] yellowish oil (61%). 1H NMR (200 MHz, CDCl3): δ = 7.48-7.18 (m, 7 H, Ar), 7.00 
(d, J = 7.0 Hz, 1 H, Py), 4.15 (s, 2 H, CH2); MS: m/z (relative intensity) 248 (100), 246 (95), 
247 (44), 167 (43), 249 (41), 166 (27), 168 (24), 65 (11), 83 (10), 139 (9). To the solution of 
this compound (1.36 g, 5.5 mmol) in THF  (8 ml) cooled at −78 °C was slowly added nBuLi 
(1.6 M in hexanes, 3.44 ml, 5.5 mmol) while magnetically stirring. The mixture was stirred 
for 1 h at –78 °C, then dry DMF (0.66 ml) was directly added to the solution. After stirring 
was continued for 1 h, H2O (10 ml) was added and the organic phase was extracted with 
Et2O (3 × 10 mL). The collected organic layers were dried (Na2SO4) and concentrated to 
leave an oily residue. Chromatography on a silica gel column, eluting with cyclohexane-
ethyl acetate 10:1, gave 6-benzyl-2-pyridinealdehyde as an oil  (0.65 g, 60%): 1H-NMR (200 
MHz, CDCl3):  10.10 (s. 1 H, CHO), 7.80 (m, 2 H, Py), 7.48-7.10 (m, 6 H, Ar), 4.27 (s, 2 H, 
CH2); MS: m/z (relative intensity) 196 (100), 197 (28), 167 (21), 168 (15), 166 (14), 91 (9), 
65 (7), 115 (5). The imine 24c was then obtained from the aldehyde by the previously 
described procedure as a yellowish oil (1.08 g, 90%). [α]D
20 −9.4 (c 0. 38, CHCl3). 
1H NMR 
(200 MHz, CDCl3): δ = 8.32 (s, 1 H, CH=N), 7.89 (d, J = 7.6 Hz, 1 H, Py),7.60 (t, J = 7.6 Hz, 1 
H, Py), 7.40-7.17 (m, 5 H, Ph), 7.08 (d, J = 7.8 Hz, 1 H, Py), 4.20 (s, 2 H, CH2), 3.87 (dd, J 
= 4.4 and 10.2 Hz, 1 H, CH2O), 3.67 (t, J = 10.2 Hz, 1 H, CH2O), 3.09 (m, 1 H, NCHCH2O), 
1.97 (m, 1 H, CHMe2), 0.94 and 0.93 (2 d, J = 6.6 Hz, 6 H, CHMe2), 0.06 (s, 9 H, SiMe3). GC-
MS: m/z (relative intensity) 251 (100), 73 (26), 209 (18), 183 (11), 221 (10), 354 (M+, 9), 
339 (7), 311 (5). 
 
Preparation of secondary amines by addition of iPrMgCl to imines 
 
N-[1(R)-(2-pyridyl)-2-methylpropyl]-(R)-phenylglycinol (20): To the solution of the imine 
18 (1.782 g, 6 mmol) in CH2Cl2 (60 mL), cooled at 0 °C, was added anhydrous MgBr2 (1.656 
g, 9 mmol), and the mixture was stirred for 1 h, meanwhile the temperature rose to 20 °C. 
Then iPrMgCl (2 M in Et2O, 9.0 mL, 18 mmol) was added during 10 min and the mixture was 
further stirred 3 h, then quenched with sat. NaHCO3 (20 mL). The organic layer was 
separated and the organic material was extracted from the aqueous phase with CH2Cl2 (3 × 
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20 mL). The collected organic layers were concentrated and the residue was treated with 
NH4F (2.0 g) in MeOH-H2O (1:1, 20 mL) for 6 h, then solid NaOH was added to reach pH 11 
and the organic material was extracted with Et2O (3 × 20 mL). The collected ethereal 
layers were dried (Na2SO4) and concentrated to leave an oily residue. The diastereomeric 
ratio 80:20 was determined by GC-MS and 1H NMR spectroscopy. Chromatography on a SiO2 
column eluting with cyclohexane-ethyl acetate mixture gave the compound 20 as a pure 
diastereomer: yellowish oil: 0.736 g, (45%);. [α]D
20 −23.3 (c 1.0, CHCl3). 
1H NMR (300 MHz, 
CDCl3): δ 8.46 (d, J = 4.8 Hz, 1 H, Py), 7.46 (t, J = 7.6 Hz, 1 H, Py), 7.2-7.0 (m, 6 H, Ar), 
7.95 (d, J = 7.6 Hz, Py), 3.8-3.5 (m, 3 H, CHCH2), 3.41 (d, J = 7.2 Hz, 1 H, CHiPr), 2.01 (m, 
1 H, CHMe2), 1.25 (broad, 2 H, OH and NH), 1.05 and 0.79 (2 d, J = 6.9 Hz, CHMe2). Found: 
C 75.30, H 8.10, N 10.31; C17H22N2O requires: C 75.52; H 8.20, N 10.36%. The product 
decomposed during GC-MS analysis. The minor diastereomer was not isolated in a pure 
state by column chromatography.. 
 
Preparation of the amines 25a-c  
 
The reagent iPrMgCl (6 mmol) was added to the solution of the imine (3 mmol) in THF (10 
mL), magnetically stirred and cooled at –78 °C. After 1.5 h, the reaction mixture was 
quenched by adding saturated aq NaHCO3 (10 mL) and the organic phase was extracted 
with ether (3 × 10 mL). The collected ethereal phases were dried over Na2SO4 and 
concentrated to leave a yellowish oil. Treatment with 1 N HCl (6 mL) at 25 °C for 2 h, 
addition of NaOH until pH 11, extraction with Et2O (3 × 5 mL), drying (Na2SO4) and 
evaporation of the solvent gave a yellow thick oil. The diastereomeric ratios were 
determined by GC-MS and 1H NMR analyses: 25a 75:25, 25b 85:15, 25c 90:10. The major 
diastereomers of  25a-c were separated by column chromatography (SiO2; hexane/ethyl 
acetate with increasing polarity) with d.r. >95:5 and were used as such in the subsequent 
step. For analytical purpose, the pure diastereomers were obtained by repeated 
chromatography with slightly decreased yield. No attempt was made to isolate the minor 
diastereomers of 25a-c. The minor diastereomers were not isolated in a pure state by 
column chropmatography. 
N-[1(S)-(2-Quinolyl)-2-methylpropyl]-(S)-valinol (25a): Yellowish oil; 0.215 g (25%). [α]D
20 
−70.7 (c 1.05, CHCl3). 
1H NMR (200 MHz, CDCl3): δ = 8.08 (dd, J = 5.4 and  8.0 Hz, Ar), 7.80 
(dd, J = 1.2 and 8.0 Hz, 1 H, Ar). 7.70 (m, 1 H, Ar), 7.51 (m, 1 H, Ar), 7.31 (d, J = 8.4 Hz, 1 
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H, Ar), 3.70 (dd, J = 3.6 and 10.6 Hz, 1 H, CH2O), 3.61 (d, J = 6.6 Hz, 1 H, ArCHN), 3.45 
(dd, J = 3.8 and 10.8 Hz, 1 H, CH2OH), 2.5 (broad, 2 H, OH and NH), 2.13 (m, 1 H, CHN), 
2.06 (m, 1 H, CHMe2), 1.32 (s, 1 H, NH), 1.65 (m, 1 H, CHMe2), 1.04 (d, J = 6.6 Hz, 3 H, 
CHMe), 0.86, 0.84 and 0.77 (3 d, J = 7.0 Hz, 9 H, CHMe2). GC-MS m/z (relative intensity): 
243 (100, M+ iPr), 184 (98), 142 (51), 199 (50), 154 (30), 158 (28), 157 (20), 169 (19), 170 
(18), 255 (10, M+ CH2OH). Found: C 75.55, H 9.18, N 9.70%; C18H26N2O requires: C 75.48; H 
9.15, N 9.78%. 
N-[1(S)-(8-Quinolyl)-2-methylpropyl]-(S)-valinol (25b): Yellowish oil; 0.325 g (1.14 mmol, 
38%). [α]D
20 −49.1 (c 1.05, CHCl3). 
1H NMR (200 MHz, CDCl3): δ 8.87 (dd, J = 1.8 and  4.4 Hz, 
Ar), 8.16 (dd, J = 1.8 and 8.4 Hz, 1 H, Ar), 7.72 (m, 1 H, Ar), 7.47 (d, J = 5.2 Hz, 2 H, Ar), 
7.39 (dd, J = 4.4 and 8.0 Hz, 1 H, Ar), 3.95 (broad, 1 H, OH), 3.71 (dd, J = 4.0 and 10.6 Hz, 
1 H, CH2O), 3.43 (dd, J = 1.8 and 10.6 Hz, 1 H, CH2O), 2.55 (m, 2 H, ArCHN and NH), 1.99 
(m, 1 H, CHMe2), 1.55 (m, 1 H, CHMe2), 1.24 (d, J = 6.6 Hz, 3 H, CHMe), 0.64, 0.59 and 
0.56 (3 d, J = 6.6 Hz, 9 H, CHMe2). GC-MS m/z (relative intensity): 243 (100, M
+ – iPr), 184 
(98), 142 (51), 199 (51), 158 (28), 154 (26), 157 (20), 167 (19), 168 (18). Found: C 75.34, H 
9.17, N 9.72%; C18H26N2O requires: C 75.48; H 9.15, N 9.78%. 
N-[1(S)-(6-Benzyl-2-pyridyl)-2-methylpropyl]-(S)-valinol (25c): Yellowish oil; 0.546 g 
(56%). [α]D
20 −64.4 (c 0.68, CHCl3). 
1H NMR (200 MHz, CDCl3): δ 7.49 (t, J = 7.6 Hz, 1 H, Py), 
7.36-7.14 (m, 5 H, Ph), 6.94 (t, J = 7.6 Hz, 2 H, Py), 4.14 (s, 2 H, CH2Ph), 3.60 and 3.41 (2 
dd, J = 3.8 and 10.8 Hz, 2 H, CH2O), 3.30 (d, J = 7.4 Hz, 1 H, ArCHN), 2.15 (m, 1 H, 
NCHCH2), 1.96 and 1.56 (2 m, 2 H, CHMe2), 1.42 (broad, 2 H, NH and OH), 1.04, 0.77, 0.75 
and 0.74 (4 d, J = 7.0 Hz, 12 H, CHMe2). Found: C 77.33, H 9.32, N 8.52%; C21H30N2O 
requires: C 77.25; H 9.26, N 8.58%. The product decomposed during the GC-MS analysis. 
 
Preparation of aziridines 
 
1-[1(R)-(2-Pyridyl)-2-methylpropyl]-2(R)-phenylaziridine (21): Triethylamine (0.755 g, 
7.4 mmol) and methanesulfonyl chloride (0.493 g, 4,44 mmol) were added to the solution 
of the diastereomerically pure aminoalcohol 17 (0.400 g, 1.48 mmol) in CH2Cl2 (12 mL) 
cooled at −78 °C and the mixture was stirred for 3 h. After quenching with sat. NaHCO3 (5 
mL), the organic layer was separated and the organic bases were extracted from the 
aqueous layer with CH2Cl2 (3 × 5 mL). The collected organic layers were dried (CaCl2) and 
concentrated to leave an oil, which was chromatographed on a SiO2 column eluting with 
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cyclohexane-ethyl acetate mixture, to obtain the compound 21 as a yellowish oil: 0.202 g, 
(55%). [α]D
20 −129.6 (c 0.44, CHCl3).
 1H NMR (300 MHz, CDCl3): δ 8.51 (d, J = 4.5 Hz, 1 H, 
Py), 7.56 (dt, J = 1.5 and 7.5 Hz, 1 H, Py), 7.42 (d, J = 7.5 Hz, 1 H, Py), 7.35-7.0 (m, 6 H, 
Ar), 2.71 (d, J = 6.0 Hz, 1 H, NCHPy), 2.35 (dd, J = 3.3 and 6.5 Hz, PhCHCH2), 2.28 (m, 1 H, 
CHMe2), 2.16 (d, J = 3.3 Hz, 1.H, CHCH2), 2.02 (d, J = 6.5 Hz, 1 H, CHCH2), 1.10 and 0.97 (2 
d, J = 6.6 Hx, 6 H, CHMe2). GC-MS m/z (relative intensity): 118 (100, PhCHCH2N), 91 (86), 
136 (21), 119 (8), 78 (6), 182 (5), 104 (5), 209 (4, M+ - iPr). Found: C 80.97, H 8.04, N 
11.05%; C17H20N2 requires: C 80.91; H 7.99, N 11.10%. 
 
Preparation of the aziridines 26a-c  
 
The solution of 1,2-aminoalcohol (3 mmol) and 1,1'-carbonyldiimidazole (0.540 g, 3.3 
mmol) in dry CH2Cl2 (10 mL) was stirred at room temperature for 1.5 h, then the solvent 
was evaporated and the yellow-brown residue was dissolved in a 1:3 THF-H2O mixture (80 
mL). The mixture was vigorously stirred overnight, then THF was evaporated at reduced 
pressure and the organic phase was extracted with Et2O (3 × 30 mL). The collected organic 
phases were dried (Na2SO4), then evaporated to leave an oily residue, which was 
chromatographed on a SiO2 column, eluting with cyclohexane-ethyl acetate mixtures. 
1-[1(S)-(2-Quinolyl)-2-methylpropyl]-2(S)-isopropylaziridine (26a): Yellowish oil; 0.507 g 
(63%), d.r. 95:5 (GC/MS). [α]D
20 −32.6 (c 1.05, CHCl3).
 1H NMR (200 MHz, CDCl3): δ 8.12 (dd, 
J 8.8 and 15.8 Hz, 1 H, Ar), 7.82 (d, J = 8.0 Hz, 1 H, Ar), 7.71 (t, J  Hz, 2 H, Ar), 7.53 (t, J 
= Hz, 1 H, Ar), 2.41 (m, 2 H, NCH2), 1.81 (t, J = Hz, 2 H, CHMe2), 1.64 (d, J = 5.8 Hz, 1 H, 
ArCHN), 1.21 (d, J = 5.6 Hz, 3 H, ArCHCHMe2), 1.15 (m, 1 H, NCHCH2), 0.74 (t, J Hz, 6 H, 
CHMe2), 0.35 (d, J = 6.4 Hz, 3 H, ArCHCHMe). GC-MS m/z (relative intensity): 155 (100), 
197 (60), 142 (50), 168 (22), 225 (18, M+ – iPr). Found: C 80.59, H 9.06, N 10.42%; C18H24N2 
requires: C 80.55; H 9.01, N 10.40%. 
1-[1(S)-(8-Quinolyl)-2-methylpropyl]-2(S)-isopropylaziridine (26b): Yellowish oil; 0.523 g 
(65%), d.r. 96:4 (GC/MS). [α]D
20 +15.7 (c 0.53, CHCl3).
 1H NMR (200 MHz, CDCl3): δ 8.89 (m, 
1 H, Ar), 8.15 (d, J = 8.1 Hz, 1 H, Ar), 8.05 (d, J = 6.4 Hz, 1 H, Ar), 7.70 (d, J = 8.1 Hz, 1 H, 
Ar), 7.60 (m, 1 H, Ar), 7.38 (m, 1 H, Ar), 3.86 (d, J 8.7 Hz, 1 H, ArCHN), 2.38 (m, 1 H, 
NCHCH2), 1.80 (m, 2 H, NCHCH2), 1.22 (d, J = 6.6 Hz, 3 H, CHMe), 1.03 (m, 2 H, CHMe2), 
0.67 and 0.66 (2 d, J = 6.6 Hz, 6 H, CHMe2), 0.26 (d, J = 6.6 Hz, 3 H, CHMe). GC-MS m/z 
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(relative intensity): 155 (100), 197 (60), 142 (50), 225 (18), 168 (15), 184 (13), 268 (M+, 10), 
253 (5). Found: C 80.61, H 9.03, N 10.42%; C18H24N2 requires: C 80.55; H 9.01, N 10.44%.  
1-[1(S)-(6-Benzyl-2-pyridyl)-2-methylpropyl]-2(S)-isopropylaziridine (26c): Yellowish oil; 
0.545 g (59%), d.r. 98:2 (GC/MS). [α]D
20 −44.5 (c 0.63, CHCl3).
 1H NMR (200 MHz, CDCl3): δ 
7.53 (t, J = 7.8 Hz, 1 H, 7.35-7-13 (m, 6 H, Ar), 6.93 (d, J = 7.8 Hz, 1 H, Py), 4.14 (s, 2 H, 
CH2Ph), 2.28 (m, 1 H, CHCH2), 2.18, d, J = 8.8 Hz, 1 H, NCHAr), 1.77 (d, J = 3.6 Hz, 1 H, 
CHCH2), 1.54 (d, J = 6.2, 1 H, CHCH2), 1.20 and 1.05 (2 m, 2 H, CHMe2), 1.14, 0.74, 0.69 
and 0.34 (4 d, J = 6.6 Hz, 12 H, CHMe2). GC-MS m/z (relative intensity): 225 (100), 265 
(88), 210 (58), 84 (47), 236 (35), 197 (33), 91 (20), 55 (17), 182 (16), 167 (13). Found: C 
81.83, H 9.18, N 9.04; C21H28N2 requires: C 81.77; H 9.15, N 9.08%.  
 
Preparation of [(N,N')*(η3-allylic)Pd][SbF6] complexes 
 
Allylpalladium chloride dimer (0.157 g, 0.43 mmol) was added to the solution of aziridine 
(0.86 mmol) in CH2Cl2 (15 mL). After stirring during 1 h, the solution became green, then a 
solution of silver hexafluoroantimonate (0.300 g, 0.86 mmol) in THF (6 mL) was added and 
the mixture was stirred for 30 min, during which time a white precipitate was formed. The 
solid was filtered off through a small pad of celite. The organic phase was washed with 
brine, dried (Na2SO4) and evaporated to leave a solid residue, which was then crystallised. 
The complex 12 has been previously described.[8] 
Complex 22: Colourless crystals (CH2Cl2-Et2O), 57% yield; m.p. 213-214 °C (dec.). [α]D
20 
−31.6 (c 0.4, CHCl3). The 
1H NMR (300 MHz, CDCl3) showed the presence of two rotamers in 
60:40 ratio (the absorptions of the prevalent rotamer are reported in bold character): δ 
8.58 and 8.46 (2 d, J = 5.6 Hz, 1 H, Ar), 8.08 (m, 1 H, Ar), 7.77 (m, 1 H, Ar), 7.52 (m, 1 H, 
Ar), 7.47 (m, 1 H, Ar), 7.30 (m, 4 H, Ar), 7.10 (m, 1 H, Ar), 6.96 (m, 1 H, Ar), 5.53 and 
4.55 (m, 1 H, CH2CHCH2), 3.93 and 3.73 (2 d, J = 6.6 Hz, 1 H, CH2CHCH2), 3.68 and 3.59 (2 
d, J = 6.6 Hz, 1 H, PyCH), 3.58 and 3.26 (2 d, J = 6.6 Hx, 1 H, CH2CHCH2), 3.50 and 3.38 (2 
dd, J = 7.3 and 5.0 Hz, 1 H, NCHCH2), 3.11 and 3.0 (2 m, 2 H, NCHCH2), 2.85 and 2.56 (2 d, 
J = 12.6 Hz, 1 H, CH2CHCH2), 2.55 and 2.27 (2 m, 1 H, CHMe2), 1.44 (d, J = 12.6 Hz, 1 H, 
CH2CHCH2), 1.23, 1.16, 1.09 and 0.87 (4 d, J = 6.8 Hz, CHMe2). 
Complex 28: Orange crystals (MeOH), 72% yield; m.p. 225-227 °C (dec.). [α]D
20 +26.5 (c 
0.58, CHCl3). IR (KBr) 2980, 1607, 1533, 1490, 1474, 1446, 1388, 1159, 1015, 758, 698 
cm−1. The 1H NMR (200 MHz, CDCl3) showed the presence of two rotamers in 70:30 ratio 
 - 105 - 
(the absorptions of the prevalent rotamer are reported in bold character): δ 7.95 (t, J = 6.6 
Hz, 1 H, Ar), 7.80-6.95 (m, 17 H, Ar), 6.50 and 6.31 (2 d, J = 5.2 and 7.4 Hz, 1 H, Ar), 6.25 
and 5.67 (2 dd, J = 11.0 and 11.4, 12.4 and 10.6 Hz, 1 H, CHCHCH), 5.03 and 3.82 (2 d, J 
= 12.4 and 11.4 Hz, 1 H, CHCHCH), 4.47 and 2.82 (2 d, J = 10.6 and 11.0 Hz, 1 H, 
CHCHCH), 3.73 and 3.37 (d, J = 6.8 and 7.2 Hz,1 H, CHPy), 3.33 and 2.90 (2 m, 2 H, 
NCHCH2),  2.83 and 2.11 (m, 1 H, CHMe2), 2.43 and 2.27 (2 dd, J = 2.2, 8.0 Hz, 2.2 and 
7.4 Hz, 1 H, NCHCH2), 1.34, 1.0, 0.96 and 0.86 (4 d, J = 6.6 and 7.0 Hz, 6 H, CHMe2). 
13C 
NMR (75 MHz, CDCl3): δ (major diastereomer) = 159.7, 149.0, 139.2, 136.2, 136.1, 132-126 
(m), 125.0, 124.7, 106.0, 81.4, 75.8, 45.2, 34.85, 20.1, 18.8. Found: C 48.68, H 4.40, N 
3.48; C32H33F6N2PdSb requires: C 48.79; H 4.22, N 3.56%. 
Complex 27a: Colourless crystals (CH2Cl2-Et2O), 70% yield; m.p. 182-185 °C (dec.). [α]D
20 
+101.1 (c 1.06, CHCl3). The 
1H NMR (300 MHz, CDCl3) showed the presence of two rotamers 
in 65:35 ratio (the absorptions of the prevalent rotamer are reported in bold character): δ 
= 8.50 (2 d, J = 8 Hz, 1 H, Ar), 8.18-7.88 (m, 3 H, Ar), 7.70 (m, 2 H, Ar), 5.88 and 5.75 (2 
m, 1 H, CH2CHCH2), 4.79 and 4.50 (2 d, J = 7.2 and 7.2 Hz, 1 H, CH2CHCH2), 4.13 and 
3.95 (2 d, J = 6.6 and 7.2 Hz, 1 H, CH2CHCH2), 3.53 and 3.43 (2 d, J = 7.8 Hz, 1 H, ArCH), 
3.45, 3.38, 3.32 and 3.16 (4 d, J = 12.6 Hz, 2 H, CH2CHCH2), 2.82 and 2.49 (2 m, 1 H, 
NCHCH2), 2.75 and 2.40 (2 m, 2 H, NCHCH2), 1.92 and 1.86 (2 m, 1 H, CHMe2), 1.41, 1.28, 
1.10, 1.00, 0.93, 0.91, 0.74 and 0.51 (8 d, J = 6.6 Hz, 12 H, CHMe2). 
Complex 27b: Colourless crystals (CHCl3), 79% yield; m.p. 215-218 °C (dec.). []D
20 +54.5 (c 
0.58, CHCl3). The 
1H NMR spectrum (200 MHz, CD2Cl2) showed the presence of two rotamers 
in 55:45 ratio (the absorptions of the prevalent rotamer are reported in bold character): δ 
= 9.29 and 9.21 (2 d, J = 5.0 Hz, 1 H, Ar), 8.51 (t, J = 8.7 Hz, 1 H, Ar), 7.99 (d, J  = 5.7 Hz, 
1 H, Ar), 7.63 (m, 3 H, Ar), 6.12 (m, 1 H, CH2CHCH2), 4.12 and 4.01 (2 d, J = 7.4 and 5.8, 1 
H, CH2CHCH2), 3.76 (m, 1 H, CH2CHCH2), 3.53 (d, J = 7.0 Hz, 1 H, ArCH), 3.43 and 3.31 (2 
d, J = 12.2 and 12.4 Hz, 1 H, CH2CHCH2), 3.10 (m, 1 H, NCHCH2), 3.09 and 3.67 (2 d, J = 
11.8 and 10.4 Hz, 1 H, CH2CHCH2), 2.55 and 2.42 (2 m, 2 H, NCHCH2), 1.61 and 1.25 (2 m, 
2 H, CHMe2), 1.50, 1.33, 0.91, 0.84, 0.61, 0.57, 0.20, 0.07 (8 d, J = 6.6 Hz, 12 H, CHMe2). 
Complex 27c: Colourless crystals (MeOH), 61% yield; m.p. 223-224 °C (dec.). [α]D
20 +4.2 (c 
1.0, CHCl3). The 
1H NMR spectrum (300 MHz, CDCl3) showed the presence of two rotamers 
in 55:45 ratio (the absorptions of the prevalent rotamer are reported in bold character): δ 
7.85 (2 t, J = 7.8 Hz, 1 H, Py), 7.53-7.28 (m, 4 H, Ar), 7.15 (m (3 H, Ar), 5.72 (m, 1 H, 
CH2CHCH2), 4.36 and 4.27 (2 s, 2 H, CH2Ph), 4.35 and 4.28 (2 d, J = 6.6 Hz, 1 H, 
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CH2CHCH2), 4.06 and 3.89 (2 d, J = 6.6 Hz, 1 H, CH2CHCH2), 3.34, 3.22, 3.14 and 3.10 (4 d, 
J = 12.4 Hz, 2 H, 2 CH2CHCH2), 3.24 and 3.13 (2 d, J = 8.2 Hz, 1 H, NCHAr), 2.84 and 2.50 
(2 m, 1 H, NCHCH2), 2.68 and 2.38 (2 m, 2 H, CHCH2), 1.88, 1.81, 1.45 and 1.18 (4 m, 2 H, 
CHMe2), 1.37, 1.25, 1.05, 1.03, 0.94, 0.90, 0.89 and 0.65 (8 d, J = 6.7 Hz, 12 H, CHMe2). 
Complex 29: Orange crystals (MeOH), 77% yield; m.p. 218-219 °C (dec.). [α]D
20 +84.9 (c 
0.68, CHCl3). IR (KBr) 2950, 1607, 1570, 1540, 1491, 1464, 1023, 889, 756, 697 cm -1. The 
1H 
NMR spectrum (300 MHz, CDCl3) showed the presence of two rotamers in 85:15 ratio (the 
absorptions of the prevalent rotamer are reported in bold character): δ 7.80-7.10 (m, 16 H, 
Ar), 6.90-6.60 (m, 2 H, Ar), 6.55 and 6.44 (2 dd, J = 11.2 and 11.4 Hz, 1 H, CHCHCH), 5.33 
and 4.86 (2 d, J = 10.8 Hz, 1 H, CHCHCH), 4.78 and 4.72 (d, J = 12.0 Hz, 1 H, CHCHCH), 
4.29, 3.75, 3.21 and 3.01 (4 d, J = 17.0 and 14.0 Hz, 2 H, CH2Ph), 2.91 (d, J = 8.7 Hz, 1 H, 
NCHPy), 2.72 (m, 1 H, NCHCH2), 1.60-1.40 (m, 4 H, 2 CHMe2 and NCHCH2), 1.14, 1.02, 
0.91, 0.89, 0.87, 0.55. 0.50 and 0.40 (8 d, J = 6.6 Hz, CHMe2). 13C NMR of the major 
diastereomer (75 MHz, DMSO-d6): δ = 162.1, 160.5, 139.8, 137.2, 136.1, 132-128, 123.8, 
122.6, 107.9, 81.8, 80.0, 76.9, 45.9, 35.9, 33.1, 21.1, 21.0, 20.0, 19.6. Found: C 51.35, H 
5.02, N 3.42; C36H41F6N2PdSb requires: C 51.24, H 4.90, N 3.32%. 
 
(E)-1,3-Diphenyl-2-propen-1-yl ethyl carbonate: Ethyl chloroformate (1.84 g, 17 mmol) 
was slowly added to the stirred solution of 1.3-diphenyl-2-propen-1-ol (1.05 g, 5 mmol), 
pyridine (1.5 g, 19 mmol), and 4-dimethylaminopyridine (10 mg) in THF (10 mL) at 0 °C. 
The mixture was stirred at 20 °C for 48 h, after which time H2O was added and the organic 
phase extracted with Et2O (3 × 10 mL). The collected organic layers were washed with 1 N 
HCl (10 mL), with sat. NaHCO3 and brine, then dried (Na2SO4) and concentrated to leave 
1b in almost quantitative yield. The compound decomposed during GC analysis, but a 
purity >95% was determined by 1H NMR analysis and was used without further purification. 
1H NMR (200 MHz, CDCl3): δ 7.60-7.20 (m, 10 H, Ph), 6.82 (d, J = 15.4 Hz, 1 H, PhCH=CH), 
6.42 (d, J = 8.4 Hz, 1 H, CHO), 6.27 (dd, J = 15.4 and 8.4 Hz, 1 H, PhCH=CHCHPh), 4.21 
(dq, J = 1.0 and 6.2 Hz, CH2O), 1.31 (t, J = 6.2 Hz, 3H, CH3). 
 
Palladium-catalysed allylic substitution reactions. Preparation of (S)-2. 
The palladium salt 22 (0.061 g, 0.1 mmol) was added to a stirred solution of 1,3-diphenyl-
2-propenyl ethyl carbonate 1b (0.28 g, 1 mmol) in THF (5 mL) under Ar at room 
temperature. Then, a solution of sodium dimethyl malonate, generated from dimethyl 
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malonate (0.198 g, 1.5 mmol) and NaH (0.036 g, 1.5 mmol) in THF 6 mL), was added 
dropwise and the mixture was magnetically stirred overnight. 1 N HCl (5 mL) was added 
and the mixture was extracted with Et2O (3 × 10 mL), the organic phase was dried (Na2SO4) 
and evaporated. Chromatography of the residue on a SiO2 column eluting with 
cyclohexane-ethyl acetate (15:1) gave the product (S)-2: 0.227 g (70%); [α]D
25 −15.4 (c 
0.42, EtOH); the e.e. 90% was determined by HPLC analysis (Daicel ChiralcelTM OD column, 
n-hexane/iPrOH 99:1, flow rate 0.5 mL/min, the product was eluted at 21.15 (R 
enantiomer) and 22.22 min (S enantiomer).  
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Chapter 6  
New chiral ligands featuring two aziridine rings separated by an aromatic 
spacer. Synthesis and applications. 
 
Ph Ph
OCO2Et
CHR(CO2Me)2
(allylPdCl)2(cat.), 
L* (cat.), BSA,
AcOK, CH2Cl2
PhPh
MeO2C CO2Me
N
NN
R2R2
R1R1
R = H, Bn, Ph: e.e. 97-99%
R
NN
L*
R2R2
R1R1
Fe
N
N
R2
R2
R1
R1
 
 
6.1. Introduction 
 
Nitrogen-containing ligands are increasingly being applied in asymmetric catalysis,[1] since 
they present several advantages with respect to the more conventional phosphorus-
containing ligands, even in transition metal-catalyzed reactions, since the amine 
functionality can coordinate any metal species, ranging from lithium and magnesium to 
zinc, copper, early transition metal complexes and also precious metals. 
A significant niche in the domain of nitrogen ligands is hold by N,N’,N”-terdentate ligands, 
especially those having C2-symmetry. The pyridine ring is present in most compounds of 
this type, where it has the role of a spacer between two identical N-containing moieties as 
in the widely used and highly performing pyridine-bis(oxazolines) 1 (Pybox’s)[2] and the 
more recently developed pyridine-bis(oxazines) (Pyboxazines) ligands 2[3] and pyridine-
bis(imidazolidines) 3.[4] Both ligands 1 and 2 are readily prepared from 2,6-
pyridinedicarboxylic acids and enantiopure β- and γ-aminoalcohols, respectively, without 
need to construct new stereocenters. 
Pyridinediimines 4, which are similarly prepared from 2,6-pyridinedicarbaldehyde, have 
been also used as ligands in metal-catalyzed asymmetric reactions.[5] Moreover, N,N’,N”-
terdentate ligands 5[6] bearing two chiral amine functions in the lateral chains of the 
pyridine ring were prepared from 2,6-di(chloromethyl)pyridine, then used in 
transamination reactions with moderate enantioselectivities. However, only a few 
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compounds with stereocenters at the benzylic positions have been described. The (R,R)- 
and (S,S)-enantiomers of the ligands 6[6a] and 7[7] were obtained after separation from the 
meso-compounds and resolution of the racemic mixture or copper complex, but no 
application of these ligands in asymmetric syntheses has been until now described. Also, 
chiral C2-symmetric substituted bipyridines and terpyridines have been exploited as metal 
ligands for asymmetric synthesis.[1c]  
 
N
HNNH R2R2
R1R1
N
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Me Me
Me Me
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NN
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O O
R1 R1
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1
O O
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As an evolution of the chiral pyridine-aziridine chiral ligands we described in the previous 
chapter, we envisioned a similar three step route to enantiopure C2-symmetrical N,N’,N”-
terdentate ligands involving the addition of organometallic reagents to a chiral diimine 
derived from 2,6-pyridinedicarbaldehyde 8a and 8b and (S)-valinol and (S)-phenylglycinol, 
respectively. As a matter of fact, preliminary experiments showed that Grignard reagents 
were poorly effective. While the reactions with allylic zinc reagents have been described in 
chapter 4, best results were obtained with organolithium compounds, then the conversion 
of the β-aminoalcohol products 9 to 2,6-di[1-(1-aziridinyl)alkyl]pyridines (DIAZAP’s) 10 was 
achieved by a Mitsunobu reaction. By this strategy, the carbon skeleton of the starting 
chiral aminoalcohol and the absolute configuration of the inherent stereocenters are 
retained in the final molecule. The new ligands were then used in palladium catalyzed 
asymmetric allylic alkylation (AAA) of stabilized carbanions, providing higher 
enantioselectivity with respect to the analogous, previously described, bidentate pyridine-
aziridine ligands.[8]  
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6.2. Preparation of the DIAZAP ligands 
 
The starting O-silylated diimines 8a and 8b were prepared in almost quantitative yields 
from the corresponding diimines bearing unprotected OH groups by the protocol previously 
described for the analogous monoimines, [8][9] and then used directly in the following step 
without purification. As stated before, Grignard reagents were not effective and led 
generally to mixture of products coming from the further attack to the pyridine moiety. 
Organolithium compounds were found to be the reagents of choice to achieve a highly 
efficient, regio- and diastereoselective double addition to the azomethine groups in 
anhydrous tetrahydrofuran (THF) at -78 °C under an inert atmosphere. 3,3-
Dimethylbutyllithium was prepared by the reaction of t-butyllithium (2 equivalents) with 
THF (solvent) at room temperature, involving the addition of t-butyllithium to ethylene, 
which is formed together with the lithium enolate of acetaldehyde following the initial 
cleavage of THF by t-butyllithium.[10] It is noteworthy that almost all the reactions gave the 
expected products 9a and 9b in high yields and with very high diastereoselectivities. As a 
matter of fact, apart from the addition of t-butyllithium to both imines (entries 3 and 8), 
which provided the corresponding aminoalcohols with low diastereomeric ratios, the 
reactions of organolithium reagents with the valinol-derived imine 8a occurred in most 
cases with higher diastereoselectivities (d.r. of 9a 94:6) with respect to the phenylglycinol-
derived imine 8b (d.r. of 9b 91:9). For the imine 8a, the best result was obtained with 
phenyllithium, which afforded the aminoalcohol 9ae' in 95% yield and d.r. 98:2. However, 
the addition of methyllithium to 8b (entry 6) was even more diastereoselective, as the 
pure diastereomer (S,S)-9ba’ was obtained in 94% yield after column chromatography of 
the crude reaction product, where no other diastereomer was detected by 1H NMR 
spectroscopy.  
8
N
HNNH
9
R2R2
N
NN
10
R2R2S S S S
DEAD, 
PPh3
THF, 
25 °C R1R1
a': R2 = Me
b': R2 = n-Bu
c': R2 = t-Bu
d': R2 = t-BuCH2CH2
e': R2 = Ph
f': R2 = H
N
NN
1) 3 R2Li, THF, -78 to 0 °C
    or NaBH4, THF, 0 °C
2) HCl 3) NaOH
a: R1 = i-Pr
b: R1 = Ph
R1R1 R1R1
Me3SiO OSiMe3 OHHO
 
 
Entry Imine (R1) R2Li Product D.r.
[a] 9, Yield %[b] 10, Yield %[c] 
1 8a (i-Pr) MeLi 9aa’ 95:5 95 10aa' (85) 
2 “ n-BuLi 9ab’ 95:5 95 (79)[c] 10ab' (87) 
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3 “ t-BuLi[d] 9ac’ 84:16 95 (54)[c] 10ac' (84)[e] 
4 “ t-BuCH2CH2Li
[f] 9ad’ 94:6 84 (70)[c] 10ad' (86) 
5 “ PhLi 9ae’ 98:2 95 10ae' (90) 
6 8b (Ph) MeLi 9ba’ >99:1 94[g] 10ba' (85) 
7 “ n-BuLi 9bb’ 91:9 93 (76) 10bb' (90)[h] 
8 “ t-Bu[d] 9bc’ 86:14 94(59) 10bc' (86)[i] 
9 “ PhLi 9be’ 92:8 98 (84) 10be' (89)[j] 
[a] Determined by 1H NMR spectroscopy of the crude reaction products. [b] Yield of the crude reaction product. Unless otherwise 
indicated, the diastereomers were not separated. [c] Yield of pure (S,S)-9 isolated after column chromatography. [d] The reaction was 
performed in diethyl ether. [e] The product was obtained after column chromatography as a 89:11 mixture of diastereomers. [f] The reagent 
was prepared in situ by adding t-BuLi to THF (solvent) at 0 °C. [g] The crude product was apparently pure by 1H NMR spectroscopy. [h] 
The product was obtained after column chromatography as a 91:9 mixture of diastereomers. [i] The product was obtained after column 
chromatography as a 86:14 mixture od diastereomer. [j] The product was obtained after column chromatography as a a 92:8 mixture of 
diastereomers 
 
It should be observed that all the organometallic additions produced only two of three 
possible diastereomers of the compounds 9: the prevalent one had C2-symmetry, as 
observed by 1H NMR spectroscopy. The S,S configuration of the two newly formed 
stereocenters at the benzylic positions was at first assumed considering the sense of 
asymmetric induction previously observed in the addition of organolithium reagents to the 
analogous 2-pyridine monoamine,[8][9] and was then confirmed by the X-ray structure 
obtained for one palladium complex derived from one of these ligands (see later). Column 
chromatography of the crude reaction products often allowed isolation of the main 
diastereomer only, however, enriched chromatographic fractions of the minor 
diastereomer were obtained, allowing its C1 symmetry to be determined. In particular, the 
separation of the diastereomers was difficult for 9aa’ and 9ac’, and low yields of the pure 
main (S,S)-diastereomer were obtained. In these cases, it was preferable to merely filter 
the crude reaction mixtures through a small pad of silica and use the diastereomeric 
mixtures in the subsequent step, that is the cyclization to DIAZAP’s 10aa’ and 10ac’, since 
the diastereomers of the latter compounds were more readily separated by 
chromatography.  
The reaction protocols that were successful for the construction of the mono-aziridine 
ligands here they did not give good results. Instead we found that the Mitsunobu reaction 
using (diethylazadicarboxylate (DEAD) and triphenylphosphine in THF at room temperature) 
gave much better results. DIAZAP’s 10a and 10b were so obtained with high yields. In the 
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case of phenylglycinol derivatives, the diastereomers of the aminoalcohols 9bb’, 9bc' and 
9be’ and the corresponding aziridines 10bb’, 10bc'and 10be’ could not be separated.  
 
6.3. Pd-catalyzed AAA reactions in the presence of DIAZAP ligands 
  
The major drawbacks of previously used bisdentate ligands (pyridine-aziridines) were their 
low reaction rates, even with the reactive 1,3-diphenylallyl carbonate 14b, and their 
incapability to adequately stabilize zerovalent palladium emanating from the nucleophilic 
attack on the intermediate η3-allylic complex, causing the precipitation of Pd black and 
consequently a low to moderate yield of product 15. Hence, we designed the structure of 
the N,N’,N”-terdentate DIAZAP ligands to overcome those problems. Our idea was also 
based on the report that a higher reaction rate was obtained using a P,N,N-terdentate 
ligand instead of a bidentate P,N-ligand in Pd-catalyzed AAA reactions;[11] a result that may 
have been the consequence of the capability of the terdentate ligand to effectively 
stabilize either Pd(0) or the (allylic)Pd(II)+ complexes involved in the catalytic cycle. 
However, in the case of our terdentate ligands, taking into account the effects of 
substituents in the bidentate ligands on enantioselectivity, it was difficult to foresee the 
importance of the C6 pyridine substituent (aziridine-alkyl group) in 10, which could 
potentially oppose the asymmetric induction of the aziridine substituent. 
A number of reactions were carried out on the allylic carbonate 14b with the anion of 
dimethyl malonate, generated by treatment of dimethylmalonate with either sodium 
hydride or bis(trimethylsilyl)amide (BSA) and a catalytic amount of potassium acetate in 
different solvents (Scheme 2 and Table 2). Allylpalladium chloride dimer and the 
terdentate ligands 10a and 10b were used as precursors of the effective enantioselective 
catalyst. The ligands derived from (S)-valinol were examined first. The carbonate 14b was 
treated with the pre-formed sodium salt of dimethyl malonate (1.5 molar equivalents) and 
catalytic amounts of allylpalladium chloride dimer (5 mol%) and ligand 10aa' (10 mol%) in 
tetrahydrofuran at room temperature. The course of the reaction was monitored by GC and 
TLC analysis and an almost complete conversion of the starting compounds was observed 
after 24 h. The product 15 was isolated in high yield and 76% e.e. in favour of the R 
enantiomer (Table 2, entry 1). It should be observed that the prior preparation of the 
palladium salt [(η3-allyl)(10aa')Pd][SbF6] was unnecessary, as a smooth reaction occurred 
and the formation of black palladium was observed only when the reaction was almost 
complete. In a second run (entry 2) at -20 °C, with all the other experimental conditions 
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being unchanged, we observed that the same e.e. was obtained, but a longer reaction time 
was required to obtain a satisfactory yield of product. Hence, all the successive reactions 
were carried out at 25 °C.  
Ph Ph
OCO2Et
(allylPdCl)2 (5 mol%), 
L* , Solvent, Base
Ph Ph
MeO2C CO2MeCH2(CO2Me)2
N
NN
R2R2
i-Pri-Pr
 
 
Entry Ligand (mol%) Base Solvent Time (h) Yield (%) E.e. (%) 
1 10aa’ (10) NaH THF 24 79 76 
2 10aa’ (10) [b] " THF 96 69 76 
3 10aa’ (10) " CH2Cl2 48 85 73 
4 10ab’ (10) " THF 24 81 63 
5 10ab’ (10) " CH2Cl2 48 86 60 
6 10ac’ (10, d.r. 89:11) BSA/AcOK CH2Cl2 48 84 69 
7 10ad’ (10) NaH THF 48 86 70 
8 10ad’ (10) BSA/AcOK CH2Cl2 16 90 62 
9 10ae’ (10) NaH THF 24 85 76 
10 10ae’ (10) NaH CH2Cl2 18 89 86 
11 10ae’ (10) BSA/AcOK CH2Cl2 15 90 82 
12 10ae’ (10) BSA/AcOLi CH2Cl2 24 89 88 
13 10af’ (10) BSA/AcOK CH2Cl2 24 87 13 
 
The role of the solvent was then examined and it was found that the reaction takes place 
also in dichloromethane, despite the poor solubility of sodium dimethyl malonate and the 
consequent lower reaction rate, but a slightly lower e.e. was obtained (entry 3). The same 
trend was observed when the n-butyl substituted ligand 10ab’ was used in both solvents, 
but the e.e.’s (60-63%) were lower (entries 4, 5). Similar results were obtained with the t-
butyl substituted ligand 10ac’ (used as a 84:16 mixture of unseparable diastereomers) and 
the ligand 10ad’ (R2 = t-BuCH2CH2) in different experimental conditions. Finally, the phenyl 
substituted ligand 10ae’ provided high levels of enantioselectivity with e.e. up to 88% in 
entry 12.  
Again, we wanted to demonstrate the need of a substituent at the benzylic positions since 
this would induce the stereoselective formation of the N-aziridine stereocenter in the 
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cationic palladium complex. It should be observed that N-alkyl aziridines are not 
pyramidally stable at room temperature, and the bulkiness of the substituent decrease the 
barrier of inversion.[12] As demonstrated in the previous chapter, all the previously 
prepared η3-allylic palladium complexes carrying bidentate (N,N)*-ligands displayed a 
unique configuration of the aziridine nitrogen atoms, that is dictated by the configuration 
of the benzylic carbon stereocenters and minimises the steric interactions between the 
benzylic (R2) and aziridine (R1) substituents. To that purpose, we synthesized the ligand 
10af' by reduction of the diimine 8a to give the intermediate diaminediol 9a,f’, followed 
by the usual cyclization step (Scheme 1). The correctness of our hypothesis was 
demonstrated by the observation that the typical allylic alkylation of sodium dimethyl 
malonate with the allylic carbonate 14a in THF at 25 °C in the presence of 10 mol% of 
ligand 10af’ occurred with very low enantioselectivity (13% e.e., entry 13). 
The terdentate ligands 10b, derived from (S)-phenylglycinol and hence carrying phenyl 
substituents on the aziridine rings, were then examined in the same typical AAA reaction 
Table 3). (R)-15 was formed in all cases with e.e.’s definitely superior to those obtained 
with the corresponding (S)-valinol-derived ligands 10a. For example, using sodium hydride 
as the base in THF in the presence of allylpalladium chloride dimer (5 mol%) and the ligand 
10ba' (10 mol%) the product (R)-15 was obtained with 82% yield and 82% e.e. after 72 h 
(entry 14). Then, we observed that in dichloromethane, despite the very low solubility of 
sodium dimethyl malonate, the reaction with the ligand 10ba' was almost complete after 
only 3 h and the product was obtained with excellent yield and 98% e.e. (entry 15). The 
same level of enantioselectivity was obtained by performing the reaction with the same 
ligand and generating the nucleophile by the alternative protocol (BSA-AcOK in DCM, entry 
16), even with reduced amounts of ligand (3 mol%, entries 17 and 18).  
It was apparent that an increase in the bulkiness of the R2 substituents in the ligands 10b 
caused a decrease of the reaction rate. The n-butyl- and phenyl-substituted ligands 10bb', 
10bc' and 10be' were used as an unseparable mixture of diastereomers, with the (S,S) and 
(S,R) configurations of the two benzylic stereocenters (d.r. 91:9, 86:14 and 92:8, 
respectively); nevertheless high e.e.’s were obtained (e.e.’s 80, 81, 70 and 83% in entries 
19 to 22). Finally, we were surprised to find that the ligand 10bf’ (R2 = H, Scheme 1), in 
contrast to the analogous (S)-valinol-derived 10af' (13% e.e., entry 13), provided a 
moderate enantioselectivity (76% e.e., entry 23). 
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Ph Ph
OCO2Et
(allylPdCl)2 (5 mol%), 
L* , Solvent, Base
Ph Ph
MeO2C CO2MeCH2(CO2Me)2 N
NN
R2R2
PhPh
 
 
Entry Ligand (mol%) Base Solvent Time (h) Yield (%) E.e. (%) 
14 10ba’ (10) NaH THF 72 82 82 
15 10ba’ (10) NaH CH2Cl2 3 90 98 
16 10ba’ (10) BSA/AcOK CH2Cl2 2 92 98 
17 10ba’ (3) BSA/AcOK CH2Cl2 8 87 98 
18 10ba’ (3) BSA/AcOLi CH2Cl2 5 90 98 
19 10bb’ (10, d.r. 91:9) NaH THF 48 77 80 
20 10bb’ (10, d.r. 91:9) BSA/AcOK CH2Cl2 16 89 81 
21 10bc’ (10, d.r. 86:14) BSA/AcOK CH2Cl2 48 64 70 
22 10be’ (10, d.r. 92:8) BSA/AcOK CH2Cl2 16 88 83 
23 10bf’ (10) BSA/AcOK CH2Cl2 24 92 76 
 
The role of different palladium sources was briefly investigated carrying out the allylation 
of the malonate anion (BSA, AcOK) with the carbonate 14b in the presence of the ligand 
10ba’ in dichloromethane at 25 °C. In comparison with the reaction catalyzed by 
allylpalladium chloride dimer (entry 1), which was almost complete after only 3 h, the 
reactions catalyzed by palladium acetate, palladium chloride and the 
dibenzylideneacetonate complex required 24 h to give comparable yields and slightly lower 
e.e.s; up to 85% yield and 96% e.e. were obtained with the latter catalyst (entry 4). 
Ph Ph
OCO2Et
Pd-Source (5 mol%), L* , 
BSA (3 equiv.), AcOK (0.1 eq.)
Ph Ph
MeO2C CO2MeCH2(CO2Me)2 N
NN
PhPh
 
 
Entry Pd catalyst (3 mol%) Time (h) Yield (%) of (S)-15 E.e. (%) 
1 (allylPdCl)2 3 87 
[b] 98 
2 Pd(OAc)2 24 76 87 
3 PdCl2 24 81 94 
4 Pd(dba)2CHCl3 24 85 96 
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Then, to extend the scope of our catalytic system, we investigated the AAA reactions of 
other stabilized enolates as well as diversely substituted allylic carbonates (Scheme 3). The 
enolates derived from substituted malonates have been relatively less employed as 
nucleophiles, and chiral P,P, P,N and N,P,N ligands have been used.[13] We were pleased to 
find that the alkylations of the benzyl- and phenyl-substituted malonate esters 16a and 
16b, respectively, proceeded smoothly in the presence of the ligand 10ba’ to give the 
products 17a and 17b in high yields and with 97-99% e.e.’s. The S configuration of the 
stereocenter in 17a was assigned on the basis of the optical rotation (-)13e] Since the 
previously unknown compound 17b has the same sense of optical rotation of 17a, the same 
configuration is assumed.  
Ph Ph
OCO2Et
14b
RCH(CO2Me)2  16  (2.5 equiv.)
BSA (3 equiv.), AcOK (0.1 equiv.), 
(allylPdCl)2 (5 mol%), 
10ba' (10 mol%), 
CH2Cl2, 25 °C, 38 h
Ph Ph
                 17
MeO2C CO2Me
R
a: R = Bn, 88%, e.e. 97%
b: R = Ph ,89 %, e.e. 99%
 
 
The cyclohexenyl carbonate 18 was poorly reactive in the usual experimental conditions 
and the e.e. of the derived product 19[14] was low. For example, using ligand 10ba’, a 40% 
yield and 6% e.e. were achieved, whereas a 68% yield and 37% e.e. were obtained with the 
ligand 10ae’, in both cases after 3 days. The reaction rate could be slightly increased in 
the presence of silver tetrafluoroborate, and good yields of the cyclohexenyl-substituted 
malonate 19 were obtained after 2 days using either ligand 10ad’ or 10ae’, but the e.e. 
did not exceed 38%. Surprisingly, the use of ligand 10ba' resulted in a low yield of 19 (40%) 
and very low e.e. (6%).  
 
BSA (3 equiv.), AcOK (0.1 equiv.), 
(allylPdCl)2 (5 mol%),10 (10 mol%), 
AgBF4 (10 mol%), CH2Cl2, 25 °C,
24 h
18
OCO2Et CO2MeMeO2C
cat. 10ad': 74%, e.e. 38%
cat. 10ae': 85%, e.e. 37%
cat. 10ba': 40%, e.e. 6%
CH2(CO2Me)2
 
 
Similarly, the reaction of dimethyl malonate anion with ethyl 3-penten-2-yl carbonate 20 
in the presence of the ligands 10ae' and 10ba' afforded the substitution product 21 in good 
yields in the presence of AgBF4, but with low e.e.s (up to 28%).  
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Me Me
OCO2Et
20
CH2(CO2Me)2 (2.5 equiv.)
(allylPdCl)2 (5 mol%),
AgBF4 (10 mol%), 10 (3 mol%), 
BSA (3 equiv.), 
AcOK (0.1 equiv.), 25 °C, 24 h
Me Me
CO2MeMeO2C
21
10ae': 85%, e.e. 28%
10ba': 78%, e.e. 18%
 
 
Utilizing the unsymmetrically disubstituted allylic carbonate 22, a mixture of products 
(ratio 95:5) was obtained, as usually found with other ligands:[15] the prevalent product 23 
was formed by attack at the methyl-substituted allylic terminus with low enantioselectivity 
(e.e. 14%), whereas the minor regioisomer 24 was obtained with 95% e.e.  
 
Ph Me
OCO2Et
22
CH2(CO2Me)2 (2.5 equiv.)
(allylPdCl)2 (1.5 mol%), 10 (3 mol%),
BSA (3 equiv.), AcOK (0.1 equiv.),  
25 °C, 24 h
Ph Me
CO2MeMeO2C
23 24
PhMe
MeO2C CO2Me
+
10ba': 88%, 23/ 24 = 95:5, e.e. 23 14%, e.e. 24 95%
10ae': 89%, 23/ 24 = 85:15, e.e. 23 10%, e.e. 24 95% 
 
Finally, we turned our attention to the capability of our catalytic system to induce 
enantioselectivity in the formation of a quaternary stereogenic center at the nucleophilic 
carbon. This goal should be achieved by the discrimination of the two diastereotopic faces 
of a fully substituted planar enolate attacking the η3-allylic ligand. This is difficult to 
realise because the chiral N,N,N-ligand does not interfere in any way with the incoming 
nucleophile, and the newly formed stereocenter is more remote from the inducing 
stereocenter(s) than in previous experiments. Hence, we investigated the reaction of (E)-
cinnamyl ethyl carbonate 25 with the anion derived from 2-ethoxycarbonylcyclohexanone 
26 under the usual reaction conditions (BSA, AcOK, CH2Cl2). The reaction proceeded 
smoothly to give the linear alkylation product 27 with high yield but only 27% e.e.. This 
result can be compared with the reported Pd-catalyzed enantioselective synthesis of 27 
using a P-chirogenic diaminophosphine oxide as the ligand, where 92% e.e. was 
obtained[16b] We assigned the S configuration to the major enantiomer of 27 by comparison 
with the authentic enantiomer.[16b]  
 
Ph OCO2Et
25
10ba' (10 mol%), 
CH2Cl2, 25 °C, 38 h
O
CO2Et
O
Ph
CO2Et
26 (1.5 equiv.)
+
BSA (), AcOK, 
(allylPdCl)2 (5 mol%) 27, 83%, e.e. 27%
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6.3. Tentative explanation of mechanism and enantioselectivity 
 
Different (allyl)- and (1,3-diphenylallyl)Pd+ salts bearing the (S)-valinol- and (S)-
phenylglycinol-derived ligands, 10ae' and 10ba', with PF6, SbF6 or BF4 counterions, were 
prepared by standard methodology. These salts were generally obtained as white or 
yellowish powders, and some of them appeared impure by 1H NMR analysis. Up till now, we 
have succeeded to obtain crystals suitable for X-ray crystallographic structure 
determinations only in the case of the salt [(10ae')(allyl)Pd][PF6].  
 
 
 
The crystal structure is quite similar to those of the previously reported allylic palladium 
salts with pyridine-aziridine ligands,[8] featuring the bidentate coordination of the ligand to 
palladium cation and the η3 hapticity of the endo/exo allyl ligand. The palladium-aziridine 
bond is shorter than the palladium-pyridine bond (2.109(3) vs 2.158(3) Å), and the terminal 
allylic carbon anti to the aziridine form a bond with palladium (2.178(4) Å) longer than the 
allylic terminus anti to the pyridine ring (2.126(4) Å). This observation supports the 
hypothesis that the allylic terminus anti to the aziridine has a more electrophilic 
character. The 1H NMR spectra of the CD2Cl2 solutions of this salt and all the other [(allyl)- 
or (1,3-diphenylallyl)(10a or 10b)]Pd+ salts with PF6
-, SbF6
- and BF4- counterions were 
complex and showed broad absorptions, indicating the presence of several species, 
although the endo- and exo-(η3-allyl) (N,N)Pd+ species were predominant. Most 
importantly, in the case of the 1,3-diphenylallyl complexes, a higher ratio of rotamers 
(>3:1) was observed for the complex derived from the ligand 10ba', which afforded the 
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highest enantioselectivity. Moreover, the spectra were complicated by the lack of C2-
symmetry of the ligand complex, demonstrating that only one aziridine nitrogen was 
involved in Pd coordination. For example, for each rotamer, distinct absorptions were 
observed for the two benzylic protons.  
In the absence of information on the reactive intermediate involved in the enantioselective 
step, we can only speculate on the the origin of the enantioselectivity. We take into 
account the available structural information of the bidentate complex 13 and the 
mechanistic hypothesis that has been suggested to explain the sense of asymmetric 
induction provided by such ligands. [8] Moreover, several studies on the binding properties 
of potentially terdentate ligands towards (allyl)Pd(II) cations have been reported.[17]-[19] For 
example, the X-ray crystal structure of a (terpyridine)(allyl)palladium complex has been 
determined and its dynamic behaviour in solution has been studied by 1H- and 13C-NMR 
spectroscopy.[17] It was therein shown that terpyridine binds the (η1-allyl)Pd+ fragment in 
the terdentate fashion and η3-allyl)Pd+ as a bidentate ligand. In fact, the two species are 
present both in the crystal and in a CD2Cl2 solution in a dynamic equilibrium, which is 
strongly displaced towards the η3-allyl form at low temperature. On the other hand, the 
2,6-bis(diphenylphosphanylmethyl)pyridine (PNP) ligand in the complex 
[(PNP)(allyl)Pd][BF4] adopts the terdentate coordination mode both in the crystal and in 
solution, where the complex is fluxional through η1-η3 equilibrium processes.[18][19] This is 
in contrast to the behaviour of (N,P,N) ligands which act as (P,N)-bidentate ligands in (η3-
dimethylallyl)Pd+ complexes.[20] Similarly, the presence of the pyridine ring in a chiral 
(P,N,N) ligand was unnecessary for high selectivity in the AAA reaction, suggesting that the 
ligand acts in a (P,N)-bidentate fashion.[21]  
On the basis of the precedent studies, we believe that the prevalent rotamer of the 
reactive (η3-1,3-diphenylallyl)(N,N,N)Pd+ complex is 28, featuring the syn,syn-
configuration of the allylic ligand and reduced interactions of the allylic phenyl groups and 
the aziridine substituent. Moreover, in solution the chiral aziridinylalkyl substituent not 
involved in palladium chelation should take the same spatial arrangement as observed in 
the crystal structure, with the methine hydrogen oriented towards the allylic ligand in 
order to reduce the steric interactions. Obviously, owing to the C2-symmetry of the 
nitrogen ligand, identical η3-(N,N)-complexes are formed when one or the other aziridine 
nitrogen is involved in Pd coordination. 
If this assumption is correct, the sense of enantioselectivity is easily explained by the 
attack of the nucleophile on the more electrophilic allylic terminus anti to the aziridine 
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nitrogen of the intermediate 28 to give the (η2-alkene)Pd(0) complex η2-(N,N)-29. The 
regioselectivity of the nucleophilic attack is also favoured by the preferential clock-wise 
rotation of the hydrocarbon ligand occurring during the formation of the most stable (η2-
alkene)Pd complex 29, as the steric interactions between the alkene and the nitrogen 
ligand are reduced concurrently.  
 
28
Me
N
Pd
NR
Ph
N
PhPh
Ph
H
R
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Me Me
N
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Ph
N
Ph
H
R
R
S
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29
Ph
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6.4. Chiral ligands featuring two aziridine rings linked by a non-chelating 
aromatic spacer 
 
In the DIAZAP ligands studied before the linker between the two aziridine ring was “active” 
since the palladium was actually chelated by the nitrogen atom of the pyridine moiety. We 
wished to verify if the two aziridine rings alone could be able to chelate efficiently a metal 
center in a bidentate fashion, so we planned to synthesize ligands featuring two aziridines 
connected by different spacer: a ferrocenyl or a phenyl moiety.  
The synthetic route to these new ligands was very similar to the one for Diazap ligands. We 
started from 1,1’-ferrocenyldicarboxaldehyde, which was easily prepared by double 
metallation of ferrocene in dry hexane with n-BuLi-TMEDA and then quenching the dilitio 
species with DMF. Imines were prepared in almost quantitative yields by condensation of 
the dialdehyde with the proper aminoalcohol (2 equivalents of valinol or phenylglycinol) 
and silylation of the hydroxy groups; for the latter step, we obtained the best results 
employing hexamethyldisilazane in dichloromethane and iodine as a catalyst.  
 
Fe
N
R1
N
OTMS
OTMS
R1
Fe
H
H
O
O
Fe
1) BuLi-TMEDA
2) DMF
HO
NH2
R1
1)                      ,    MgSO4,
                              CH2Cl2, 20 °C2) HN(TMS)2/I2(cat.)
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These electron rich imines were poorly reactive and only the most reactive organolithium 
reagents gave smoothly the corresponding diamines with satisfactory yields and 
diastereoselectivities.  
Fe
N
R1
N
OTMS
OTMS
R1
Fe
N
H
R1
H
N
OH
OH
R1
R2
R2
1) R2Li, Et2O, 4h
-78 °C        0 °C
2) NH4F (aq.)
 
 
Imine R2Li d.r. Resa% 
R1 = iPr nBuLi 93:7 95 
R1 = iPr tBuLi 99:1 96 
R1 = Ph PhLi 85:15 94 
R1 = Ph nBuLi 90:10 91 
 
 
The construction of the aziridine ring from the β-aminoalcohol moiety was even more 
troublesome, and we were not able to find a procedure having a general applicability for 
every substrate. The desired aziridines were obtained only in moderate yields after 
considerable efforts in each case. 
Fe
N
H
R1
H
N
OH
OH
R1
R2
R2
Fe
N
N
R2
R2
R1
R1
Method
a or b or c
a: MsCl/TEA/DMAP, 
     DCM -78°C to rt 3hr
b: CDI, DCM/THF,H2O
c: PPh3/DEAD, THF, rt 2 hr
 
 
AminoAlcohol Method Yield% 
R1 = iPr, R2 = nBu b 68 
R1 = iPr, R2 = tBut c 50 
R1 = Ph, R2 = Ph a 47 
R1=Ph, R2 = nBu a 45 
 
With these new ligands in hand the next step was to test them in standard AAA reactions, 
but with our great disappointment we found that the reaction with dimethyl malonate did 
not proceed with all the ligands we prepared in the standard reaction conditions (BSA, 
allylpalladium chloride dimer, dichloromethane).  
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Ph Ph
OCO2Et
Ph Ph
MeO2C CO2MeCH2(CO2Me)2
Fe
N
N
R2
R2
R1
R1
L*=
(AllylPdCl)2, Base
X
 
 
R1 R2 Temp. Solvent Base t Yield e.e% 
Ph t-Bu 25 DCM BSA/AcOK 24 - - 
Ph Ph 25 DCM BSA/AcOK 24 - - 
i-Pr n-Bu 25 DCM BSA/AcOK 24 - - 
i-Pr t-Bu 25 DCM BSA/AcOK 24 - - 
 
 
A reasonable explanation for this negative results is that these ligands can not act as 
bidentate ligands because of the preferred anti-conformation of the two cyclopentadienyl 
substituents, or the eventually formed bidentate complex is too labile.  
Aiming to obtain a more rigid ligands, we prepared a ligand structurally similar to the 
previously described DIAZAP ligands, but presenting a non-chelating 1,3-disubstituted 
phenyl in substitution of the pyridine ring starting from isophtalaldehyde, following the 
usual synthetic scheme. 
 
HNNH
76%, 9
MeMe
NN
81%, 10
MeMe
DEAD, 
PPh3
THF, 
25 °C PhPh
NN
1) 3 MeLi, THF, -78 to 0 °C
2) HCl 3) NaOH
PhPh PhPh
Me3SiO OSiMe3 OHHO
 
 
This new ligand proved again to be completely uneffective in the standard palladium 
catalysed AAA reaction of 1,3 diphenylallylcarbonate with sodium dimethylmalonate, and 
no considerable conversion was observed after 5 days even with 10% mol/mol catalyst 
loading. 
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Ph Ph
OCO2Et
Ph Ph
MeO2C CO2MeCH2(CO2Me)2
L*=
(AllylPdCl)2, Base
X NN
MeMe
PhPh
 
 
These results confirm that the pyridine moiety is necessary for an efficient chelation of the 
metal center and, consequence to this, to achieve good conversions and 
enantioselectivities. 
 
Experimental Section: 
 
General Protocol for the Preparation of Imines: To a solution of (S)-valinol (6 mmol, 
0.618 g) or (S)-phenylglycinol (6 mmol, 0.823 g) in THF (50 mL) was added anhydrous MgS04 
(5 g), the aldehyde (3 mmol, 0.405 g) and the mixture was stirred overnight. The solid 
phase was filtered off on a pad of Celite and the organic solvent was evaporated under 
reduced pressure. The residue was dissolved in CH2Cl2 (20 mL) and triethylamine (7 mmol, 
0.708 g) and chlorotrimethylsilane (7 mmol, 0.97 mL. 0.760 g) were added at 0 °C. After 3 
h the solvent was removed under vacuum. A solution of cyclohexane/diethyl ether 1:1 was 
added and the solid phase was filtered off on a pad of Celite. The organic solvent was 
evaporated under reduced pressure to leave the imine in almost quantitative yield; this 
was used in the following step without further purification. 
  
Preparation of β-Aminoalcohols 9 by Addition of Organolithium Reagents to Imines 8: 
Organolithium reagent (9 mmol) was added to a magnetically stirred solution of the imine 
8 (3 mmol) in THF (10 mL) cooled to –78 °C. After 30 minutes, the reaction mixture was 
slowly warmed at 0 °C, and quenched after 3 h by adding 1 N HCl (10mL). After 2 h NaOH 
pellets were added until the solution reached pH 11, and the organic phase was extracted 
with diethyl ether (3 ×10 mL). The collected ethereal phases were dried over Na2SO4 and 
concentrated to leave the crude  products. The diastereomeric ratio was determined by 1H 
NMR analysis. Flash column chromatography (SiO2), eluting with cyclohexane/ethyl acetate 
mixtures, gave the product which was directly used in the subsequent step.  
 
  
 - 126 - 
Preparation of β-Aminoalcohols 9af’ and 9bf’ by Reduction of Imines 8a and 8b: To a 
solution of imine 8a or 8b (1 mmol) in methanol (5 mL), NaBH4 (2 mmol, 0.076 g) was 
added in one portion. After 1 h the reaction was quenched with 1 N HCl (5 mL) and further 
stirred for 2 h. Then NaOH pellets were added until the solution reached pH 11, and the 
organic phase was extracted with diethyl ether (3 × 10 mL). The collected ethereal phases 
were dried over Na2SO4 and concentrated to leave the crude product in quantitative yield. 
Pure compounds were obtained by column chromatography (SiO2) eluting with 
cyclohexane/ethyl acetate mixtures.  
 
Preparation of Aziridines 10:  To a solution of β-aminoalcohol 9 (2.8 mmol) in THF (20 
mL) was added PPh3 (6.2 mmol, 1.6 g). To this solution DEAD (6.2 mmol, 1.082 g) was 
added dropwise. After 4 h, a solution of 2 N  KOH (10 mL) was added to the mixture, which 
was stirred for 3 h. Diethyl ether was added (30 mL) and the organic phase was separated. 
The aqueous phase was extracted with Et2O (3 x 20 mL), and the collected organic phase 
was washed with 2 N KOH (3 x 10 mL), then with brine. The organic phase was dried over 
Na2SO4 and concentrated under reduced pressure. The residue was flash-chromatographed 
on a SiO2 column eluting with cyclohexane/ethyl acetate mixtures. In order to obtain 
analytically pure samples, further purification by chromatography or crystallization was 
carried out. 
 
N,N'-Bis((S)-1-trimethylsilyloxy-3-methyl-butan-2-yl)-2,6-bis(imino)pyridine (8a): 
Yellowish oil; [α]D
25 = -19.7 (c 0.7, CHCl3); 
1H NMR (CDCl3, 200 MHz): δ= 0.05 (s, 18 H), 0.92 
(d, J = 6.9 Hz, 6 H), 0.94 (d, J = 6.9 Hz, 6 H), 2.0 (sept, J = 6.9 Hz,  2 H), 3.1 (m, 2 H), 3.69 
(dd, J = 7.8 Hz,  J = 10.3 Hz, 2 H), 3.89 (dd ,  J = 4.3 Hz, J = 10.3 Hz , 2 H), 7.76 (t, J = 7.6 
Hz, 2 H), 8.07 (d, J = 7.6 Hz, 1 H), 8.36 (s, 2 H); 13C NMR (CDCl3, 50 MHz):  = 0.4, 18.5, 
20.0, 29.9, 64.3, 78.4, 121.9, 136.7, 154.5, 161.6; IR (neat): ν = 2958, 2872, 1648, 1585, 
1569, 1457, 1251, 1107,1077, 877, 841, 746 cm 1; GC-MS m/z: 73 (100), 171 (70), 346 (36), 
103 (27), 316 (11), 449 (10, M ). 
 
N,N'-Bis((S)-2-trimethylsilyloxy-1-phenylethyl)-2,6-bis(imino)pyridine (8b): white solid; 
m.p. = 117 °C; [α]D
25 = +25.1 (c 0.8, CHCl3); 
1H NMR (CDCl3, 200 MHz): δ= 0.02 (s, 18 H), 
3.89 (d, J = 1.7 Hz, 2 H), 3.91 (s, 2 H), 4.52 (dd, J = 5.6 Hz, J = 7.8 Hz, 2 H), 7.2-7.4 (m, 7 
H). 7.5-7.6 (m, 3 H), 7.81 (t, J = 7.6 Hz, 1 H), 8.20 (d, J = 7.6 Hz, 2 H), 8.49 (s, 2 H); 13C 
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NMR (CDCl3, 50 MHz): δ = 0.4, 67.6, 76.7, 122.2, 127.4, 128.4, 136.7, 140.7, 155.4; IR 
(Nujol):ν = 3067, 3029, 1647, 1364, 1251, 1118, 1081, 1054, 884, 841, 757, 699 cm 1. 
 
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-aminoethyl)pyridine (9aa'): 
White solid; m.p. = 86 °C; [α]D
25 = -74.6 (c 0.18, CHCl3);
 1H NMR (CDCl3, 200 MHz): δ= 0.81 
(d, J = 6.8 Hz, 6H), 0.86 (d , J = 6.8 Hz, 6 H), 1.37 (d, J = 6.7 Hz, 6 H), 1.65 (sept, J = 6.8 
Hz, 2 H), 2.19 (dd, J = 4.2 Hz, J = 4.8 Hz, 2 H), 2.70 (bs, 4 H), 3.38 (dd, J = 4.8 Hz, J = 10.8 
Hz, 2 H), 3.61 (dd, J = 4.2 Hz, J = 10.8 Hz, 2 H), 3.89 (q, J = 6.7 Hz, 2 H), 7.05 (d, J = 7.7 
Hz, 2 H), 7.57 (t, J = 7.7 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ= 18.8, 19.6, 23.5, 29.4, 56.2, 
60.0, 62.0, 119.8, 136.7, 163.7; IR (KBr): ν= 3404, 3968, 1572, 1449, 1361, 1172, 1074, 834 
cm 1; anal. calcd. for C19H35N3O2: C 67.62, H 10.45, N 12.45; found: C 67.37, H 10.48, N 
12.41.  
 
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-aminopentyl)pyridine (9ab’): 
Yellowish oil; [α]D
25 = - 48.5 (c 1.1, CH2Cl2); 
1H NMR (CDCl3, 200 MHz): δ= 0.77 (d, J = 6.8 
Hz, 6 H), 0.79 (d, J = 6.8 Hz, 6 H),  0.82 (t, J = 6.6 Hz, 6 H), 1.25 (m, 8 H), 1.63 (sept, J = 
6.8 Hz, 2 H), 1.72 (m, 4 H), 2.08 (dd, J = 3.8 Hz, J = 6.4 Hz, 2 H), 3.73 (bs, 4 H), 3.39 (dd, 
J = 3.8 Hz, J = 10.8 Hz, 2H), 3.61 (dd, J = 6.4 Hz, J = 10.8 Hz, 2 H), 3.62 (t, J = 6.9 Hz, 2 
H), 6.97 (d, J = 7.6 Hz, 2 H), 7.52 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ= 13.9, 
18.8, 19.6, 22.6, 28.7, 29.4, 37.5, 59.5, 61.3, 62.0, 120.9, 136.0, 163.2; IR (neat): ν = 3160, 
2957, 2926, 2858, 1590, 1464, 1260, 1089, 801 cm 1; ESI-MS m/z: 422.4 [M + 1], 423.3 [M + 
2]; anal. calcd. for C25H47N3O2: C 71.21, H 11.23, N 9.97; found: C 71.08, H 11.25, N 
9.93. 
 
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-amino-2,2-
dimethylpropyl)pyridine (9ac’): Colourless oil; [α]D
25 = -82.9 (c 1.4, CHCl3); 
1 H NMR 
(CDCl3, 200 MHz): δ = 0.75 (d, J = 6.6 Hz, 6 H), 0.8 (d , J = 6.6 Hz, 6 H),  0.93 (s, 18 H), 
1.62  (sept, J = 6.6 Hz, 2 H), 2.00 (dd, J = 3.4 Hz, J = 3.9 Hz, 2 H), 2.40 (bs, 4 H), 3.39 (dd, 
J = 3.4 Hz, J = 10.9 Hz, 2 H) 3.42 (s, 2 H), 3.62 (dd, J = 3.9 Hz, J = 10.9 Hz, 2 H), 7.00 (d, J 
= 7.6 Hz, 2 H), 7.50 (t, J = 7.6 Hz, 1 H); 13C NMR(CDCl3, 50 MHz): δ= 18.7, 19.9, 27.3, 29.6, 
35.4, 59.0, 62.4, 69.9, 121.8, 131.0, 161.3; IR (Nujol): ν= 3444, 1644, 1496, 1205, 1090, 
933 cm 1; ESI-MS m/z: 422.6 [M + 1], 423.2 [M + 2]; anal. calcd. for C25H47N3O2: C 71.21, H 
11.23, N 9.97; found: C 71.00, H 11.28, N 9.94.  
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N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-1-amino-4,4-
dimethylpentyl)pyridine (9ad’): Colourless oil; [α]D
25 = -47.7 (c 1.4, CHCl3); 
1H NMR 
(CDCl3, 300 MHz): δ= 0.80 (d, J = 6.9 Hz, 6 H), 0.82 (s, 18 H), 0.83 (d , J = 6.9 Hz, 6 H), 
1.00 (dt, J = 4.4 Hz, J = 13.1 Hz, 2H), 1.35 (dt, J = 4.4 Hz, J = 13.1 Hz, 2 H), 1.65 (m, 6 H), 
2.12 (dd, J = 3.9 Hz, J = 6.8 Hz, 2 H), 3.42 (dd, J = 3.9 Hz, J = 10.8 Hz, 2 H), 3.60 (dd, J = 
6.8 Hz, J = 10.8 Hz, 2 H), 3.63 (t, J = 3.9 Hz, 2 H), 7.00 (d, J = 7.8 Hz, 2 H), 7.55 (t, J = 7.8 
Hz, 1 H); 13C NMR(CDCl3, 50 MHz): δ= 18.9, 19.8, 29.3, 29.5, 30.1, 32.9, 40.7, 59.5, 62.0, 
62.1, 120.7, 136.2, 163.2; IR (neat): ν= 3420, 2925, 1646, 1591, 1376, 1278, 997 cm 1; anal. 
calcd. for C28H52N3O2: C 72.68, H 11.33, N 9.08; found: C 72.38, H 11.40, N 9.07. 
 
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis((S)-amino(phenyl)methyl)pyridine 
(9ae’): Yellowish oil; [α]D
25 = + 95.7 (c 1.6, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ = 0.91 (d, J 
= 6.9 Hz, 6 H), 0.95 (d , J = 6.9 Hz, 6 H),  1.92 (sept, J = 6.9 Hz, 2 H), 2.46 (ddd, J = 3.9 
Hz, J = 6.0 Hz, J = 10.2 Hz, 2 H), 2.92 (bs, 2 H), 3.42 (dd, J = 6.6 Hz, J = 10.8 Hz, 2 H), 
3.57 (dd, J = 4.2 Hz, J = 10.8 Hz, 2 H), 5.0 (s, 2 H), 6.92 (d, J = 7.8 Hz, 2 H), 7.27-7.42 (m, 
11 H); 13C NMR (CDCl3, 75 MHz): δ= 18.2, 19.5, 30.2, 60.5, 62.1, 35.0, 120.8, 127.4, 127.9, 
128.5, 136.9, 142.9, 161.2; IR (neat): ν= 3417, 3333, 3061, 3027, 2957, 2872, 1589, 1572, 
1448, 1045, 839, 736, 700 cm 1; ESI-MS m/z: 462.0 [M + 1]; anal. calcd. for C29H39N3O2: C 
75.45, H 8.52, N 9.10; found: C 75.24, H 8.65, N 9.04. 
 
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-aminoethyl)pyridine (9ba’): White 
solid; m.p. = 95 °C; [α]D
25 = +30.7 (c 1.5, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ= 1.40 (d, J = 
6.6 Hz, 6 H), 3.59 (dd, J = 7.8 Hz, J = 10.8 Hz, 2 H),  3.65-3.88 (m, 6 H), 7.03 (d , J = 7.8 
Hz, 2 H), 7.2-7.4 (m, 10 H), 7.81 (t, J = 7.8 Hz, 1 H); 13C NMR (CDCl3, 75 MHz): δ= 21.4, 
55.7, 61.8, 66.1, 119.3, 127.5, 127.3, 128.3, 136.8, 141.1, 162.7; IR (KBr):ν= 3383, 3065, 
3032, 2973, 2930, 2846, 1577, 1458, 1327, 1233, 1096, 751, 733, 699 cm 1; ESI-MS m/z: 
406.2 [M + 1], 428.3 [M + Na]; anal. calcd. for C25H31N3O2: C 74.04, H 7.70, N 10.36; found: 
C 73.98, H 7.75, N 10. 33.  
 
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-aminopentyl)pyridine (9bb’): 
Colourless oil; [α]D
25 = +110.3 (c 0.6, CHCl3);
 1H NMR (CDCl3, 300 MHz): δ= 0.88 (t, J = 6.7 
Hz, 6 H), 1.0-1.4 (m, 8 H), 1.6-1.8 (m, 4 H), 3.1 (bs, 4 H), 3.4-3.6 (m, 4 H), 3.6-3.8 (m, 4 
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H), 6.88 (d, J = 7.7 Hz, 2 H), 7.1-7.4 (m, 11 H); 13C NMR (CDCl3, 75 MHz): δ= 14.0, 22.7, 
28.3, 36.4, 61.4, 62.2, 65.3, 120.2, 127.0, 127.2, 128.2, 136.0, 141.6, 162.5; IR (neat): ν = 
3324, 2923, 2853, 1576, 1457, 1366, 1129, 1052, 701 cm 1; anal. calcd. for C31H43N3O2: C 
76.03, H 8.85, N 8.58; found: C 75.75, H 8.87, N 8.55. 
 
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-amino-2,2-dimethylpropyl)pyridine 
(9bc’): Colourless oil; [α]D
25 = +105.0 (c 1.5, CHCl3), 
1H NMR (CDCl3, 300 MHz): δ= 0.84 (s, 
18 H), 3.31 (s, 2 H), 3.43 (dd, J = 4.8 Hz, J = 5.1 Hz, 2 H), 3.51 (dd, J = 5.1 Hz, J = 10.6 Hz, 
2 H), 3.73 (dd, J = 4.8 Hz, J = 10.6 Hz, 2 H), 6.73 (d, J =7.5 Hz, 2 H), 7.00-7.10 (m, 5 H), 
7.15-7.55 (m, 5 H), 7.46 (t, J = 7.4 Hz, 2 H); 13C NMR (CDCl3, 75 MHz): δ= 27.1, 35.5, 63.3, 
64.9, 70.0, 122.4, 128.2, 134,3, 142.0, 160.9; IR (neat):ν= 3408, 3055, 2952, 2863, 1588, 
1576, 1469, 1453, 1395, 1361, 1031, 824, 757, 701 cm 1; ESI-MS m/z: 490.4 [M + 1], 512.3 
[M + Na]; anal. calcd. for C31H43N3O2: C 76.03, H 8.85, N 8.58; found: C 75.80, H 8.91, N 
8.52. 
 
N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis((S)-1-amino(phenyl)methyl)pyridine 
(9be’): Colourless oil; [α]D
25 = +123.2 (c 1.1, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ= 3.00 (bs, 
4 H), 3.72 (m, 6 H), 4.78 (s, 2 H), 6.72 (d, J = 7.6 Hz, 2 H), 7.30-7.40 (m, 23 H); 13C NMR 
(CDCl3, 75 MHz): δ= 61.2, 64.0, 67.0, 120.4, 127.1, 127.5, 127.7, 128.3, 128.6, 128.7, 
130.0, 131.5, 133.2, 136.9, 145.0, 141.7, 167.0; IR (neat):ν= 3411, 3060, 3026, 2925, 2850, 
1590, 1573, 1493, 1451, 1054, 1027, 700 cm 1; ESI-MS m/z: 530.4 [M + 1], 531.5 [M + 2], 
552.5 [M + Na]; anal. calcd. for C35H35N3O2: C 79.37, H 6.66, N 7.93; found: C 79.00, H 
6.71, N 7.90. 
 
N,N'-Bis((S)-1-hydroxy-3-methyl-butan-2-yl)-2,6-bis(aminomethyl)pyridine (9af’): 
Colourless oil; [α]D
25 = +41.6 (c 0.9, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ= 0.89 (d, J = 6.9 
Hz, 6 H), 0.95 (d, J = 6.9 Hz, 6 H), 1.89 (sept, J = 6.9 Hz, 2 H ), 2.43 (dd, J = 3.3 Hz, J = 
7.5 Hz, 2 H), 3.42 (dd , J = 7.5, J = 11.1 Hz, 2 H), 3.42 (dd , J = 3.3, J = 11.1 Hz, 2 H), 3.87 
(d, J = 14.7 Hz, 2 H), 3.97 (d, J = 14.7 Hz, 2 H), 7.11 (d, J = 7.5 Hz, 2 H), 7.58 (t, J = 7.5 
Hz, 1 H); 13C NMR (CDCl3, 75 MHz): δ= 18.6, 19.5, 29.5, 52.3, 61.4, 65.0, 120.6, 137.3, 
159.5; IR (neat):ν = 3322, 2957, 2866, 1594, 1576, 1455, 1386, 1367, 1155, 1047, 787 cm 1; 
anal. calcd. for C17H31N3O2: C 65.98, H 10.10, N 13.58; found: C 66.01, H 10.11, N 13.54. 
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N,N'-Bis((S)-2-hydroxy-1-phenylethyl)-2,6-bis(aminomethyl)pyridine (9bf’): Viscous oil; 
[α]D
25 = +106.2 (c 2.0, CHCl3); 
1H NMR (CDCl3, 200 MHz): δ= 3.67 (m, 4 H), 3.72 (d, J = 14.1 
Hz, 2 H), 3.80 (d, J = 14.1 Hz, 2 H), 3.86 (dd, J = 5.3 Hz, J = 9.6 Hz, 2 H), 4.1 (bs, 1 H), 7.0 
(d , J = 7.6 Hz, 2 H), 7.2-7.4 (m, 10 H), 7.52 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): 
δ= 51.9, 64.6, 67.0, 120.6, 127.4, 127.5, 128.4, 136.8, 140.4, 158.7; IR (Nujol):ν= 3310, 
3061, 3028, 2924, 2862, 1594, 1577, 1492, 1452, 1357, 1057, 1027, 759, 702 cm 1; ESI-MS 
m/z: 378.3 [M  + 1], 379.4 [M  + 2], 400.4 [M  + Na]; anal. calcd. for C23H27N3O2: C 73.18; H 
7.21, N 11.13; found: C 72.83, H 7.24, N 11.10. 
 
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)ethyl)pyridine (10aa’): Colourless oil; [α]D
25 =   
-119.6 (c 0.5, CHCl3); 
1 H NMR (CDCl3, 200 MHz): δ= 0.53 (d, J = 6.6 Hz, 6 H), 0.75 (d, J = 
6.6 Hz, 6 H),  1.10 (sept, J = 6.6 Hz, 2 H), 1.22 (m, 2 H), 1.33 (d, J = 6.3 Hz, 2 H), 1.38 (d, 
J = 6.6 Hz, 6 H), 1.63 (d, J = 3.3 Hz, 2 H), 2.53 (q, J = 6.6 Hz, 2 H), 7.37  (d , J = 7.6 Hz, 2 
H), 7.63 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ = 19.5, 20.4, 21.2, 31.4, 32.6, 
45.8, 71.6, 119.6, 136.7, 162.7; IR (neat): ν = 3041, 2962, 1591, 1576, 1460, 1327, 1176, 
822 cm 1; GC-MS m/z: 56 (100), 55 (87), 84 (63), 132 (35), 218 (18), 162 (9); anal. calcd. for 
C19H31N3: C 75.70, H 10.36, N 13.94; found: C 75.78, H 10.41, N 13.88.  
 
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)pentyl)pyridine (10ab’): Colourless oil; [α]D
25=  
-140.7 (c 0.5, CHCl3);  
1H NMR (CDCl3, 200 MHz): δ = 0.47 (d, J = 6.5 Hz, 6 H), 0.74 (d, J = 
6.5 Hz, 6 H), 0.78 (t, J = 7.0 Hz, 6 H), 0.86 (m, 2 H), 1.04 (m, 2 H), 1.21 (m, 8 H), 1.40 (d, 
J = 6.3 Hz, 2 H), 1.67 (d, J = 3.6 Hz, 2 H), 1.88 (q, J = 7.6 Hz, 2 H), 2.44 (t, J = 7.2 Hz, 2 
H), 7.31  (d , J = 7.6 Hz, 2 H), 7.63 (t, J = 7.6 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ = 14.1, 
19.9, 20.6, 22.0, 28.6, 31.9, 34.2, 35.9, 45.0, 77.3, 120.8, 136.7, 162.1; IR (neat): ν= 3040, 
2957, 2871, 1591, 1576, 1457, 1364, 1029 cm 1; GC-MS m/z: 84 (100), 302 (75), 259 (53), 
174 (35), 55 (30), 385 (1, M ); anal. calcd. for C25H43N3: C 77.86, H 11.24, N 10.90; found: 
C 77.58, H 11.26, N 10.85. 
 
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)-2,2-dimethylpropyl)pyridine (10ac’): White 
solid; m.p. = 84 °C; [α]D
25= -18.8 (c 1.0, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ= 0.53 (d, J = 
6.6 Hz, 6 H), 0.72 (d, J = 6.6 Hz, 6 H),  0.98 (m, 2 H), 0.99 (s, 18 H), 1.18 (sept, J = 6.6 Hz, 
2 H) 1.49 (d , J = 6.3 Hz, 2 H), 1.76 (d, J = 3.9 Hz, 2 H), 2.73 (s, 2 H), 7.33  (d , J = 7.5 Hz, 
2 H), 7.57 (t, J = 7.5 Hz, 1 H); 13C NMR (CDCl3, 75 MHz): δ= 19.6, 20.8, 27.8, 30.8, 36.3, 
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36.7, 42.8, 85.5, 122.4, 134.4, 160.2; IR (KBr): ν = 3064, 2873, 1588, 1571, 1497, 1449, 
1286, 1031, 872 cm 1; anal. calcd. for C25H43N3: C 77.86, H 11.24, N 10.90; found: C 77.91, 
H 11.28, N 10.86. 
 
2,6-Bis((S)-1-((S)-2-isopropylaziridin-1-yl)-4,4-dimethylpentyl)pyridine (10ad’): 
Colourless oil; [α]D
25 = -149.5 (c 1.1, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ = 0.50 (d, J = 6.6 
Hz, 6 H), 0.79 (d, J = 6.6 Hz, 6 H), 0.83 (s, 18 H), 1.10 (sept, J = 6.6 Hz, 2 H), 1.17-1.37 
(m, 6 H), 1.43 (d, J = 6.5 Hz, 2 H), 1.70 (d, J = 3.5 Hz, 2 H), 1.91 (dt, J = 7.1 Hz, J =9.8 Hz, 
4 H), 2.40 (t, J = 7.1 Hz, 2 H), 7.36  (d , J = 8.0 Hz, 2 H), 7.68 (t, J = 8.0 Hz, 1 H); 13C NMR 
(CDCl3, 50 MHz): δ= 19.7, 20.4, 29.2, 30.1, 31.1, 31.7, 34.0, 40.0, 44.7, 77.5, 120.6, 136.6, 
161.9; IR (neat): ν= 3060, 2879, 1591, 1568, 1490, 1450, 1281, 1038, 878 cm 1; GC-MS m/z: 
57 (100), 84 (92), 56 (71), 287 (28), 258 (22), 132 (16), 202 (12); anal. calcd. for C29H51N3: 
C 78.85, H 11.64, N 9.51; found: C 78.75, H 11.68, N 9.47. 
 
2,6-Bis((S)-((S)-2-isopropylaziridin-1-yl)(phenyl)methyl)pyridine (10ae’): Yellowish oil; 
[α]D
25 = -158.3 (c 0.6, CHCl3); 
1H NMR (CDCl3, 200 MHz): δ = 0.47 (d, J = 6.6 Hz, 6 H), 0.82 
(d, J = 6.6 Hz, 6 H), 1.23 (m, 2 H), 1.44 (d , J = 7.2 Hz, 2 H), 1.54 (dd, J = 3.6 Hz, J = 7.2 
Hz, 2 H), 3.78 (s, 2 H), 7.25-7.39 (m, 8 H), 7.54-7.62 (m, 5 H); 13C NMR (CDCl3, 50 MHz): δ= 
19.5, 20.2, 31.4, 46.4, 79.8, 120.9, 126.9, 127.4, 128.1, 137.9, 142.4, 151.0; IR (neat): ν= 
3071, 2933, 2862, 1589, 1573, 1455, 1306, 1258, 1029, 699 cm-1; ESI-MS m/z: 426.1 [M  + 1], 
427.2 [M  + 2]; anal. calcd. for C29H35N3: C 81.84, H 8.29, N 9.87; found: C 81.78, H 8.32, 
N 9.84. 
 
2,6-Bis(((S)-2-isopropylaziridin-1-yl)methyl)pyridine (10af’): Colourless oil; [α]D
25 = -97.5 
(c 1.1, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ= 0.89 (d, J = 6.6 Hz, 6 H), 0.91 (d, J = 6.6 Hz, 6 
H), 1.30 (m,  2 H), 1.37 (dd, J = 3.3 Hz, J = 6.3 Hz, 2 H), 1.41 (d, J = 6.3 Hz, 2 H), 1.69 (d, 
J = 3.3 Hz, 2 H), 3.48 (d, J = 14.0 Hz, 2H ), 3.59 (d, J = 14.0 Hz, 2 H), 7.44 (d, J = 7.7 Hz, 2 
H), 7.69 (t, J = 7.7 Hz, 1 H); 13C NMR (CDCl3, 75 MHz): δ= 19.6, 20.6, 31.6, 33.2, 46.7, 66.6, 
120.6, 136.9, 158.6; IR (neat): ν= 3044, 2958, 2872, 1592, 1578, 1458, 1363, 1340, 1287, 
1035, 896, 829, 783 cm 1; anal. calcd. for C17H27N3: C 74.68, H 9.95, N 15.37; found: C 
74.22, H 9.99, N 15.33. 
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2,6-Bis((S)-1-((S)-2-phenylaziridin-1-yl)ethyl)pyridine (10ba’): White solid; m.p. = 79 °C; 
[α]D
25 = +176.6 (c 0.4, CHCl3); 
1H NMR (CDCl3, 300 MHz): δ= 1.52 (d, J = 6.6 Hz, 6 H), 1.89 
(d, J = 6.6 Hz, 2 H), 2.06 (d, J = 3.3 Hz, 2 H), 2.50 (dd , J = 3.3 Hz, J = 6.6 Hz, 2 H), 2.84 
(q, J = 6.6 Hz, 2 H), 7.17-7.29 (m, 10H), 7.36 (d, J = 8.1 Hz, 2 H), 7.46 (t , J = 8.1 Hz, 1 H); 
13C NMR (CDCl3, 75 MHz): δ= 21.6, 37.3, 40.8, 71.7, 118.8, 126.1, 126.6, 128.1, 137.3, 
140.0, 162.5; IR (KBr): ν= 3032, 2972, 1576, 1580, 1459, 1326, 1207, 1095, 815, 698 cm 1; 
ESI-MS m/z: 370.4 [M + 1], 371.4 [M  + 2], 392.4 [M + Na]; anal. calcd. for C25H27N25: C 
81.26, H 7.37, N 11.37; found: C 81.01, H 7.39, N 11.34. 
2,6-Bis((S)-1-((S)-2-phenylaziridin-1-yl)pentyl)pyridine (10bb’): Yellowish oil; d.r. 91:9; 
[α]D
25 = +124.5 (c 0.9, CHCl3); 
1H NMR (CDCl3, 200 MHz): δmajor diastereomer) = 0.86 (t, J = 
6.6 Hz, 6 H), 1.2-1.4 (m, 8 H), 1.92 (d,  J = 6.2 Hz, 2 H), 1.94 (m, 2 H), 2.09 (d, J = 3.2 Hz, 
2 H), 2.45 (dd, J = 3.2 Hz, J = 6.2 Hz, 2 H), 2.77 (dd, J = 6.2 Hz, J = 7.0 Hz, 2 H), 7.07-7.27 
(m, 10 H), 7.29 (d, J = 7.9 Hz, 2 H), 7.47 (t, J = 7.9 Hz, 1 H); 13C NMR (CDCl3, 50 MHz): δ= 
14.0, 23.0, 26.9, 28.1, 36.1, 38.4, 39.4, 119.9, 126.3, 126.6, 128.1, 137.0, 146.2, 161.7; IR 
(neat):ν= 3031, 2978, 1574, 1588, 1454, 1329, 1198, 1092, 818, 701 cm 1; anal. calcd. for 
C31H39N3: C 82.07, H 8.66, N 9.26; found: C 82.23, H 8.80, N 9.22. 
 
2,6-Bis((S)-2,2-dimethyl-1-((S)-2-phenylaziridin-1-yl)propyl)pyridine (10bc’): Colourless 
oil; [α]D
25 = +132.6 (c 1.0, CHCl3); 
1H NMR (CDCl3, 200 MHz): δ = 1.06 (s, 18 H), 1.97 (d, J = 
6.4 Hz, 2 H), 2.07 (dd, J = 3.2 Hz, J = 6.4 Hz, 2 H), 2.14 (d, J = 3.2 Hz, 2 H), 2.67 (s, 2 H), 
7.07-7.40 (m, 13 H); 13C NMR (CDCl3, 50 MHz): δ= 27.5, 36.5, 37.6, 42.9, 85.4, 121.6, 126.1, 
126.3, 128.0, 141.0, 151.0, 159.4; IR (neat): ν= 3033, 2974, 1572, 1584, 1456, 1323, 1187, 
1097, 813, 705 cm 1; anal. calcd. for C31H39N3: C 82.07, H 8.66, N 9.26; found: C 82.12, H 
8.70, N 9.25. 
 
2,6-Bis((S)-phenyl((S)-2-phenylaziridin-1-yl)methyl)pyridine (10be’): Colourless oil; d.r. 
92:8; [α]D
25 = +104.5 (c 1.1, CHCl3); 
1H NMR (CDCl3, 200 MHz) δmajor diastereomer)= 2.00 
(d, J = 6.4 Hz, 2 H), 2.13 (d, J = 3.5 Hz, 2 H), 2.79 (dd, J = 3.5 Hz, J = 6.4 Hz, 2 H), 4.06 (s, 
2 H), 7.17-7.74 (m, 23 H); 13C NMR (CDCl3, 50 MHz): δ = 38.0, 41.2, 79.5, 120.0, 126.3, 
126.6, 126.8, 127.1, 127.7, 128.1, 128.2, 137.3, 140.0, 142.2, 161.3; IR (neat): ν= 3036, 
2974, 1575, 1586, 1453, 1324, 1203, 1096, 829, 679 cm 1; ESI-MS m/z: 494.5 [M  + 1], 495.5 
[M  + 2]; anal. calcd. for C35H31N3: C 85.16, H 6.33, N 8.51; found: C 84.92, H 6.35, N 8.48. 
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2,6-Bis(((S)-2-phenylaziridin-1-yl)methyl)pyridine (10bf’): Colourless oil; [α]D
25 = +124.3 
(c 1.5 CHCl3); 
1H NMR (CDCl3, 200 MHz): δ= 1.92 (d, J = 6.6 Hz, 2 H), 2.03 (d , J = 3.2 Hz, 2 
H),  7.03 (dd, J = 3.2 Hz, J = 6.6 Hz 2 H), 3.65 (d, J = 15.0 Hz 2 H), 3.91 (d, J = 15.0 Hz, 2 
H) 7.20-7.74 (m, 13 H); 13C NMR (CDCl3, 50 MHz): δ = 38.1, 41.6, 66.3, 120.1, 126.1, 126.9, 
128.3, 128.4, 128.6, 131.9, 132.0, 132.2, 137.3, 140.1, 158.3; IR (neat):ν = 3031, 2978, 
1570, 1586, 1461, 1321, 1204, 1095, 819, 694 cm 1; anal. calcd. for C23H23N3: C 80.90, H 
6.79, N 12.31; found: C 81.15, H 6.83, N 12.30. 
 
 
Preparation of allylic palladium complexes. Typical procedure: [10ae'(η3-allyl)Pd][PF6]. 
Allyl palladium chloride dimer (73 mg, 0.1 mmol) was added to a solution of ligand 10ae' 
(80 mg, 0.2 mmol) in CH2Cl2 (4 mL) in one portion. After one hour a solution of NH4PF6 (39 
mg, 0.24 mmol) in THF (1mL) was added. The solution was stirred overnight, then filtered 
through a HPLC filter (0.45 µm) and the solvent was removed under reduced pressure to 
give a white solid: 0.130 g, 91%. White crystals, suitable for X-ray diffraction analysis were 
obtained from a double-layer of CH2Cl2 and pentane: white crystals; m.p. 124-126 °C 
(dec.); []D
20 +21.1 (c 1.2, CHCl3); IR (KBr) 3052, 3030, 2882, 1605, 1567, 1496, 1452, 1265, 
1014, 840, 732, 701, 553 cm 1.  
The 1H NMR spectra of all the allyl and 1,3-diphenylallyl cationic Pd complexes synthesized 
showed the presence of different species, but the exo and endo rotamers were prevalent 
with variable ratios. Specifically, the spectrum of the complex 10ae'(1,3-
diphenylallyl)PdPF6 (600 MHz, CDCl3) showed a 55:45 ratio of two rotamers, with the 
following absorptions of the allylic protons: major rotamer,  δ = 5.98 (t, J =11.4  Hz, 1 H), 
4.75 (d, J =  11.4 Hz, 1H), 4.67 (d, J =  11.4 Hz, 1H) ppm; minor rotamer, δ= 6.13 (t, J = 
11.4 Hz, 1 H), 5.0 (d, J = 11.4 Hz, 1 H), 4.40 (d, J = 11.4 Hz, 1 H) ppm. On the other hand, 
the 1H NMR spectrum (300 MHz, CDCl3) of 10ba'(1,3-diphenylallyl)PdPF6 showed the 
presence of a prevalent species (ca 75%) with the syn,syn geometry of the allylic ligand, 
whose protons gave absorptions at δ= 6.16 (t, J = 11.4 Hz, 1 H), 4.43 (d, J = 11.4 Hz, 1 H) 
and 3.80 (d, J = 11.4 Hz, 1 H).  
[(10ae')(allyl)Pd][PF6]. X-Ray details: Bruker APEX II CCD diffractometer (Mo-Kα radiation 
λ = 0.71073 Å). Results: C32H40F6N3PPd, Mr = 718.04, monoclinic P21, a = 11.0990(13), b = 
13.3802(16), c = 11.9282(14)Å,  = 112.045(2), V = 1641.9(3)Å
3, Z = 2, ρx 1.452 Mgm
3, µ 
0.674 mm 1, F(000) = 736, T = 296(2) K, θmax = 28.51, 13905 reflections collected, 6099 
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I>2σ(I). Final R1 = 0.0347, wR2 = 0.0860, GOF = 0.997, absolute structure parameter = 
0.04(2).CCD 297723. Crystallographic data (excluding structure factors) for the structure 
reported in this paper have been deposited with the Cambridge Crystallographic Data 
Centre as supplementary publication no. CCDC 297723. Copies of the data can be obtained 
free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [Fax: int. 
code + 44(1223)336-033; E-mail: deposit@ccdc.cam.ac.uk]. 
Palladium-Catalyzed Allylic Alkylation: To a solution of DIAZAP 10ba' (0.03 mmol, 10 mg) 
in CH2Cl2 (2 mL) was added (allylPdCl)2 (0.014 mmol, 5 mg) and the solution was degassed 
and stirred for 1h. 1,3-diphenyl-2-propenyl ethyl carbonate (14b) (0.27 mmol, 76 mg) was 
then added followed by dimethyl malonate (0.67 mmol, 90 mg), BSA (0.81 mmol, 0.165 g) 
and KOAc (0.02 mmol, 2 mg) after 10 min. The reaction was monitored by TLC analysis 
and, when complete, quenched with 1 N HCl solution (1 mL) and the organic phase was 
extracted with diethyl ether (3 ×10 mL). The organic layer was dried over Na2SO4 and the 
solvents were evaporated to dryness. The crude product was purified by chromatography 
on a silica gel column (hexane/AcOEt, 75:5) affording methyl (R)-(E)-3,5-diphenyl-2-
methoxycarbonyl-4-pentenoate (15): 73 mg, 84%. An e.e. of 99% was determined by chiral 
HPLC (Chiralpak AD; 2-propanol/hexane1:9, 1.0 mL/min; 250 nm). retention times: 10.7 
min (major enantiomer), 14.9 min (minor enantiomer). 
17a: 88%, e.e. 97%; [α]D
25 -38.7 (c 2.0, CHCl3). The e.e. was determined by chiral HPLC 
(Chiralpak AD; 2-propanol/hexane 3:97; 1.0 mL/min, 250 nm); retention times: 16.6 min 
(major enantiomer), 17.1 min (minor enantiomer). The absolute configuration of the 
product was determined by comparison of its optical rotation with that of the known 
compound.[13e]  
17b: 89%, e.e. 99%; [α]D
25= -48.4 (c 1.5, CHCl3). The e.e. was determined by chiral HPLC 
(Chiralpak AD; 2-propanol/hexane 1:99, 0.8 mL/min, 250 nm); retention times: 8.3 min 
(minor enantiomer), 10.9 min (major enantiomer). The absolute configuration was assumed 
by analogy with compound 17a.  
19: 40%, e.e. 6%; [α]D
25 =  +5.0 (c 1.1, CHCl3). The e.e. was determined by chiral GC: 
Megadex Chiral column (25 m, flow rate: 15mL/min, 50 °C (2 min), then 3 °C/min up to 
190 °C, FID detection): retention times: 27.2 min (minor enantiomer), 27.3 min (major 
enantiomer). The absolute configuration of the product was determined by comparison of 
its optical rotation with that of the known compound.[14] 
21: 85%, e.e. 28%, [α]D
25 = +6.5 (c 1.2, CHCl3). The e.e. was determined by chiral GC 
(Megadex Chiral column (25 m, flow rate: 15mL/min, isotherm 65 °C, FID detection); 
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retention times: 49.5 min (minor enantiomer), 51.6 min (major enantiomer). The absolute 
configuration of the product was determined by comparison of its optical rotation with that 
of the known compound.[15] 
23-24: The ratio was determined by GC-MS analysis. The e.e.s of 23 and 24 were 
determined by chiral HPLC (Chiralpak OD, 2-propanol/hexane 1:99, 0.5 mL/min, 250 nm); 
retention times of 24: 14.2 min (major enantiomer), 15.1 min (minor enantiomer); 
retention times of 23: 17.9 (minor enantiomer), 18.8 (major enantiomer). 
27: 83%, e.e. 27%; [α]D
25 = -23.5 (c 1.6, CHCl3). The e.e. was determined by chiral HPLC 
(Chiralpak OD, 2-propanol/hexane 5:95, 0.4 mL/min, 250 nm); retention times: 13.7 min 
(minor enantiomer), 15.6 min (major enantiomer). The absolute configuration of the 
product was determined by comparison of its optical rotation with that of the known 
compound.[16b] 
 
References: 
 
[1] [1a] A. Togni, L. M. Venanzi, Angew. Chem., Int. Ed. Engl. 1994, 33, 497- 526. [1b] F. 
Fache, E. Schulz, M. Lorraine Tommasino, M. Lemaire, Chem. Rev. 2000, 100, 2159-2231. 
[1c] Chiral Diaza Ligands for Asymmetric Synthesis, Eds. M. Lemaire, P. Mangeney, Springer, 
Berlin, 2005.   
[2] G. Desimoni, G. Faita, P. Quadrelli, Chem. Rev. 2003, 103, 3119-3154. 
[3] M. K. Tse, C. Döbler, S. Bhor, M. Klawonn, W.  Mägerlein, H. Hugl, M. Beller, Angew. 
Chem. Int. Ed. 2004, 43, 5255-5260. 
[4] S. Bhor, G. Anilkumar, M. K. Tse, M. Klawonn, C. Döbler, B. Bitterlich, A. Grotevendte, 
M. Beller, Org. Lett. 2005, 7, 3393-3396. 
[5] [5a] S. De Martin, G. Zassinovich, G. Mestroni, Inorg. Chim. Acta 1990, 174, 9-11. [5b] G. 
Zassinovich, G. Mestroni, Chem. Rev. 1992, 92, 1051-1069. [5c] D. A. Laidler, D. J. Milner, 
J. Organometal. Chem. 1984, 270, 121-129. 
[6] [6a] K. Bernauer, R. Deschenaux, T. Taura, Helv. Chim. Acta 1983, 66, 2049-2057. For 
analogous ligands having N,N',N",O',O"-pentacoordinate capability, see: [6b] K. Bernauer, T. 
Chuard, H. Stoeckli-Rvans, Helv. Chim. Acta 1993, 76, 2263-2273. [6c] K. Bernauer, P. 
Pousaz, Helv. Chim. Acta 1984, 67, 797-803. [6d] Analogous ligands can be prepared by 
reductive amination of diacetylpyridine with amines: T. J. Lotz, T. A. Kaden, Helv. Chim. 
Acta 1978, 61, 1376-1387. 
  
 - 136 - 
[7] [7a] K. Bernauer, F. Gretillat, Helv. Chim. Acta 1989, 72, 477-481. [7b] K. Bernauer, F. 
Gretillat, H. Stoeckli-Evans, R. Wermuth, Helv. Chim. Acta 1993, 76, 545-556. [7c] K. 
Bernauer, A. Cabort, N. Guicher, H. Stoeckli-Evans, G. Suss-Fink, J. Chem. Soc., Dalton 
Trans. 2002, 2069-2071. 
[8] [8a] K. Fiore, G. Martelli, M. Monari, D. Savoia, Tetrahedron: Asymmetry 1999, 10, 4803-
4810. [8b] F. Ferioli, C. Fiorelli, G. Martelli, M. Monari, D. Savoia, P. Tobaldin, Eur. J. Org. 
Chem 2005, 1016-1026. 
 [9] [9a] G. Alvaro, G. Martelli, D. Savoia, J. Chem. Soc., Perkin Trans 1 1998, 775-783. [9b] G. 
Alvaro, D. Savoia, Synlett 2002, 651-673. 
[10] [10a] P. D. Bartlett, M. Stiles, J. Am. Chem. Soc. 1955, 77, 2806-2814. [10b] S. Panev, 
V. Dimitrov, Tetrahedron: Asymmetry 2000, 11, 1517-1528.  
[11] R. R. Rülke, V. E. Kaasjager, P. Wehman, C. J. Elsevier, P. V. N. M. van Leeuwen, K. 
Vrieze, J. Fraanje, K. Goubitz, A. L. Spek, Organometallics 1996, 15, 3022-3031.  
[12] A. Rauk, L. C. Allen, K. Mislow, Angew. Chem. Int. Ed. 1970, 400-414. 
[13] [13a] S. Vyskočil, M. Smrčina, V. Hanuš, M. Polášek, P. Kočovský, J. Org. Chem. 1998, 63, 
7738-7748. [13b] T. Mino, Y. Tanaka, M. Sakamoto, T. Fujita, Tetrahedron: Asymmetry 
2001, 12, 2435-2440. [13c] Y. Matsushima, K. Onitsuka, T. Kondo, T. Mitsudo, S. Takahashi, 
J. Am. Chem. Soc. 2001, 123, 10405-10406. [13d] T. Yamagishi, M. Ohnuki, T. Kiyooka, D. 
Masui, K. Sato, M. Yamaguchi, Tetrahedron: Asymmetry 2003, 14, 3275-3279. [13e] X. Chen, 
R. Guo, Y. Li, G. Chen, C.-H. Yeung, A. S. C. Chan, Tetrahedron: Asymmetry 2004, 15, 
213-217. [13f] Y. Tanaka, T. Mino, K. Akita, M. Sakamoto, T. Fujita, J. Org. Chem. 2004, 69, 
6679-6687. [13g] G. A. Molander, J. P. Burke, P. J. Carroll, J. Org. Chem. 2004, 69, 8062-
8069. 
[14] [14a] P. Sennhenn, B. Gabler, G. Helmchen, Tetrahedron Letters 1994, 35, 8595-8598. 
[14b] E. J. Bergner, G. Helmchen, Eur. J. Org. Chem. 2000, 419-423. 
[15] [15a] A. Togni, Tetrahedron: Asymmetry 1991, 2, 683-690. [15b] E. Peña-Cabrera, P.-O. 
Norrby, M. Sjögren, A. Vitagliano, V. De Felice, J. Oslob, S. Ishii, D. O’Neill, B. Åkermark, 
P. Helquist, J. Am. Chem. Soc. 1996, 118, 4299-4313. [15c] D. Liu, Q. Dai, X. Zhang, 
Tetrahedron 2005, 61, 6460-6471. 
[16]  [16a] P. Gamez, B. Dunjic, F. Fache, M. Lemaire, Tetrahedron: Asymmetry 1995, 6, 
1109-1116. [16b] T. Namoto, T. Matsumoto, T. Masuda, T. Hitomi, K. Datano, Y. Hamada, J. 
Am. Chem. Soc. 2004, 126, 3690-3691. 
 
 
